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Abstract 
 
Gestational diabetes mellitus (GDM) is an increasingly prevalent form of diabetes that 
first appears during pregnancy, and reverses after parturition in most cases. Nonetheless, 
GDM is associated with adverse maternal and fetal health outcomes. There is currently 
no reliable method of intervention for GDM and a limited understanding of the 
mechanisms of impaired endocrine adaptability in GDM. In this thesis, I aimed to address 
these knowledge gaps by establishing a mouse model for the study of suboptimal 
endocrine adaptations during pregnancy. This was accomplished using a dietary low 
protein (LP) insult during fetal and neonatal development, which programs for 
suboptimal pancreas development in the offspring, and performing histomorphometric 
analyses on fixed pancreas tissues. Female offspring displayed glucose intolerance during 
their own pregnancy that was apparent by gestational day (GD) 18.5 and characterized by 
reduced β-cell mass (BCM) and α-cell mass (ACM) relative to control-fed animals. Using 
this model, I provided evidence that pancreatic maladaptations at GD18.5 persisted at 
postpartum day 7.5, contributing to glucose intolerance until 1 month after parturition. To 
provide mechanistic insights of reduced BCM expansion in GDM, I investigated the 
contribution of α- to β-cell transdifferentiation via immunofluorescence cell counting 
analysis of fixed pancreas tissues. I identified maladaptations of α-cell plasticity in 
glucose-intolerant mice, as demonstrated by reduced α-cell proliferation, leading to 
reduced ACM expansion relative to controls. Additionally, these animals presented with 
hyperglucagonemia. These findings demonstrated that, in addition to β-cells, insufficient 
pancreatic α-cell adaptations can also contribute to GDM pathogenesis. Although there 
were differences in the percentages of bihormonal (Insulin+Glucagon+) cells in LP vs. 
control pregnancy, genetic lineage tracing in control pregnancy using Glucagon-
Cre/Rosa26-eYFP mice revealed a negligible amount of α- to β-cell transdifferentiation 
contributing to BCM expansion. Finally, I used the animal model to test a therapeutic 
intervention for GDM through the attempted manipulation of BCM using the artemisinin, 
artesunate. Artesunate-treated animals had improved glucose tolerance, although the 
glucose-lowering effect was attributed to the acetone vehicle. Collectively, this thesis has 
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identified mechanisms of impaired endocrine pancreas adaptability in GDM and has 
established a mouse model that can be used to explore novel therapeutics.  
                                    Keywords 
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Summary for Lay Audience 
 
Diabetes occurs when there is a loss or dysfunction of insulin-producing β-cells in the 
pancreas, leading to elevated blood sugar levels. Diabetes is often classified as either 
being type 1 or type 2. However, gestational diabetes mellitus (GDM) is another type of 
diabetes that first presents during pregnancy and is becoming increasingly prevalent. 
Although human pancreas samples during GDM are scarce, it is believed that β-cell 
dysfunction is a major driver of GDM pathogenesis. In this thesis, I sought to develop a 
mouse model that can be used to better understand the reasons for suboptimal pancreas 
adaptations in GDM. First, I established the mouse model using a dietary insult (low 
protein) during early life, which results in suboptimal pancreas development in the 
offspring. As is diagnosed in humans, these animals presented with GDM identified 
during late gestation (which in mice is around gestational day 18.5) due to impairments in 
β-cell number and the capacity for insulin release. Since many women go on to develop 
type 2 diabetes mellitus after delivery, I also presented evidence that these impairments in 
the pancreas are still present following birth and contribute to high blood sugar levels 
until at least one month postpartum. Using our mouse model, I demonstrated that diabetes 
develops not only due to impairments in β-cells, but also due to abnormalities in 
pancreatic α-cells, which work antagonistically with β-cells to secrete glucagon. Finally, I 
identified a therapeutic effect in GDM where there was a reversal of diabetes in animals 
treated with a chemical that likely damages the gut equivalent to transient fasting. This 
thesis characterized a novel mouse model of GDM and provides new information about 
mechanisms of suboptimal pancreas adaptations that can be used to explore methods of 
treatment. 
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Sections of this chapter have been published: 
 
S.K. Szlapinski, D. Hill. Metabolic Adaptations To Pregnancy In Healthy And 
Gestational Diabetic Pregnancies: The Pancreas – Placenta Axis, Curr. Vasc. Pharmacol. 
18 (2020). https://doi.org/10.2174/1570161118666200320111209. 
 
 
2 
1  Introduction  
The disease report conducted by the World Health Organization from 2000 to 2015 lists 
diabetes mellitus (DM), which was not on the report previously, as the top 6th leading 
cause of death in 2015 killing 1.6 million people worldwide [1]. DM is a metabolic 
disorder characterized by increased levels of glucose in the blood (hyperglycemia). When 
left uncontrolled, DM can result in multiple adverse health complications such as damage 
to the nerves and blood vessels increasing the risk of cardiovascular disease [2], 
nephropathy [3] and retinopathy [4]. 
 
1.1  Diabetes  
There are two main types of diabetes, Type I diabetes mellitus (T1DM) and Type II 
diabetes mellitus (T2DM). T1DM is characterized by insufficient insulin production 
while T2DM occurs when the body is unable to effectively use insulin. Insulin is a 
hormone produced by pancreatic beta (β)-cells, which are cells located in the endocrine 
portion of the pancreas called the islets of Langerhans. Insulin binds the insulin receptor, 
a tyrosine kinase, on target tissues (liver, adipose, muscle) resulting in 
autophosphorylation and subsequent phosphorylation of downstream targets [5]. This 
ultimately leads to translocation of vesicles containing glucose transporters (i.e. Glut1, 
Glut4) to the cell membrane and regulates glucose uptake in target tissues [5]. 
Insulin was first isolated by Sir Frederick Banting and colleagues Charles Best, James 
Collip and John Macleod in 1922 which revolutionized treatment for individuals with 
T1DM [6]. This life-saving treatment is now given via exogenous insulin therapy. The 
protein, insulin, was isolated from pancreas extract samples and injected into dogs with 
pancreatectomy-induced diabetes, which resulted in lowering of blood glucose levels. 
In individuals with T1DM, insulin deficiency occurs due to autoimmune destruction of 
insulin producing β-cells [5]. Autoimmune destruction of β-cells is mediated by T-cell 
activation through direct cell toxicity and β-cell specific autoantibodies [7]. T1DM is the 
less common form of diabetes as it accounts for only 5-10% of all cases of diabetes. 
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Symptoms include fatigue, weight loss, polyuria and dehydration. Individuals with 
T1DM require exogenous insulin therapy to maintain euglycemia. Transplantation of 
cadaveric human islets or whole pancreas as a strategy for diabetes reversal has also been 
undertaken but is limited by the shortage of organ supply from deceased donors which 
does not meet the demand for islet transplantations [8]. A combination of predispositions 
for T1DM have been suggested including viral exposure and genetic susceptibility [9]. 
T2DM is the more common form of diabetes (>90% of patients with diabetes) and occurs 
when insulin secretion is suboptimal [10]. T2DM often includes peripheral insulin 
resistance, meaning that target tissues are unable to respond to insulin resulting in 
hyperglycemia. However, the major driver of T2DM is suggested to be β-cell dysfunction 
with particularly a marked reduction of first-phase insulin secretion [11]. Individuals with 
T2DM can manage blood glucose levels with lifestyle changes including diet and 
exercise. Antihyperglycemic therapeutics can also be used, such as glucagon-like peptide 
1 (GLP-1) receptor agonists, metformin and sodium-glucose cotransporter 2 (SGLT2) 
inhibitors. Each therapeutic works to either decrease blood glucose levels or increase 
insulin secretion in effort to attain euglycemia. Metformin reduces gluconeogenesis in the 
liver, GLP-1 receptor agonists enhance glucose-stimulated insulin secretion (GSIS), and 
SGLT2 inhibitors block the reabsorption of filtered glucose in the kidney [12]. The 
prevalence of T2DM is drastically increasing as the susceptibility is influenced by 
lifestyle factors such as obesity, age and a sedentary lifestyle [13]. This is concerning due 
to the various health risks associated with T2DM including cardiovascular disease, 
neuropathy and nephropathy [12]. 
Both T1DM and T2DM show the vital role that pancreatic β-cells play in maintaining 
euglycemia which demonstrates the important role of the pancreas in the physiology of 
regulating glucose homeostasis. 
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1.2  Pancreas Anatomy and Development  
The pancreas is an organ located in the abdominal cavity. In humans, the head of the 
pancreas is attached at the initial curve of the duodenum of the small intestine, while the 
tail is attached to the spleen (Fig. 1.1). The body of the pancreas is found between the tail 
and head. This organization differs from that observed in mice, where 3 less defined 
lobes (duodenal, gastric and splenic) are present. The pancreas has both endocrine and 
exocrine functions, with only ~1-2% of the pancreas being endocrine despite its critical 
role in glucose homeostasis. Endocrine cells of the pancreas are congregated in the islets 
of Langerhans and secrete various hormones. Exocrine cells comprise the remaining 
~98% of the pancreas including acinar and duct cells which secrete pancreatic fluids 
containing digestive enzymes into the small intestine.  
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Figure 1.1. Anatomical location of the pancreas 
The pancreas is located behind the stomach in the upper left abdomen. The endocrine 
portion, the islets of Langerhans, are found dispersed throughout the head and tail of the 
pancreas and function to regulate glucose metabolism. The exocrine portion is 
characterized as a highly branched ductal system, which secretes digestive enzymes into 
the small intestine through the pancreatic duct. Reproduced from Human Anatomy and 
Physiology, an OpenStax College resource [14]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
All pancreatic progenitor cells express the transcription factor pancreatic duodenal 
homeobox-1 (Pdx1) [15], which is a key regulator of pancreas development, β-cell 
differentiation and maintenance of β-cell function in mature β-cells [16]. In mice, 
development of pancreatic tissue begins at embryonic day (E) 8.5 when expression of 
Pdx1 is induced in the endodermal epithelium of the foregut [17]. This is followed by 
formation of the dorsal and ventral pancreatic buds from the foregut endoderm at E9.5. 
Expression of pancreas associated transcription factor 1a (Ptf1), the key transcriptional 
regulator promoting exocrine cell specification [18], is initiated at E9.5, with Pdx1 co-
expression from E9.5-12.5 [19]. Both Pdx1 and Ptf1a are essential for appropriate 
endocrine and exocrine pancreas lineage specification, as animal models lacking these 
transcription factors demonstrate pancreatic defects such as incomplete branching, 
expansion and differentiation [18,20]. Each pancreatic bud develops into a highly 
branched ductal-tree structure of undifferentiated ductal epithelium [21]. By E14.5, both 
pancreatic buds rotate and fuse into a single organ [21]. Contained within the dorsal and 
ventral pancreatic buds are multipotent progenitor cells (MPC) forming a multilayered 
epithelium. The MPCs are able to give rise to endocrine, acinar and duct cells. From 
E12.5-15.5, the MPCs in the dorsal bud proliferate causing pancreatic bud expansion. 
Endocrine cells are present from the beginning of pancreatic development arising from 
MPCs in the gut endoderm by E9.5, while acinar cell clusters differentiate from ductal 
epithelium and are visible by E14.5 [22,23]. The differentiation of MPCs into either 
endocrine/ductal or acinar exocrine lineages occurs as MPCs are segregated into either 
the trunk or tip domains, respectively. The allocation of MPCs to either domain is 
regulated by the balance of the transcription factors Ptf1a, which favors tip formation, 
and homeobox protein Nkx6.1, which induces trunk formation [23,24]. Thus, both 
endocrine and exocrine compartments in the mouse and human fetus arise from 
endodermal pancreatic epithelium during development. However, the expression of the 
transcription factor neurogenin3 (Ngn3) plays a major role in the lineage switch that is 
required for development of all endocrine cell types [25,26].  
Expression of the pancreatic hormone, glucagon, occurs as early as E9.5 and is followed 
by insulin co-expression by E10.5 [21]. Studies have demonstrated an increase in 
messenger ribonucleic acid (mRNA) encoding endocrine hormones between E14.5-
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E20.5, indicating endocrine cell morphological development [27]. On E16.5 the 
endocrine cells that were previously organized as single cells within the ductal 
epithelium, become organized as clusters [21]. By E19.5, the endocrine clusters, termed 
the islets of Langerhans, become regulated by specific transcription factors to produce 
either alpha (α), β, epsilon (), delta () or pancreatic polypeptide/gamma (γ) cells. In 
both mice and humans, the majority of the islet is composed of α- and β-cells, while the 
remaining minority of composition of the islet contain , γ and -cells. Nonetheless, islet 
composition and architecture vary between these species. In mice, β-cells are localized to 
the core of the islet, encompassing 60-80% of the islet, while α-cells are contained within 
the mantle and compose only 10-20%. In contrast, human islets do not display this core-
mantle arrangement, with most islet cell types being dispersed throughout the islet. 
Additionally, in humans, 50-70% of the islet is composed of β-cells while α-cells account 
for 20-40% [28]. These two endocrine cell types play a critical role in maintaining 
glucose homeostasis by functioning in an antagonistic manner, whereby the intra-islet 
hypothesis states that insulin inhibits glucagon secretion [29]. β-cells secrete insulin in 
response to high blood glucose levels (i.e. fed state), resulting in glycolysis or glucose 
uptake in peripheral organs and initiating a decrease in blood glucose levels. On the other 
hand, α-cells secrete glucagon in response to fasting conditions to increase blood glucose 
levels via glycogenolysis in the liver and muscle. In order to maintain glucose 
homeostasis, islet cells receive information about neighbouring cells through paracrine 
interactions [29,30]. For example, studies have shown that paracrine intra-islet glucagon 
signaling is essential for maintaining appropriate secretion of insulin from β-cells [29]. 
An additional study showed that the pancreatic islet establishes the ‘glycemic set-point’ 
in the body [30]. This process relies on paracrine input of neighbouring α-cells in the islet 
to regulate insulin secretion from β-cells. The transcriptional balance of α- and β-cells is 
regulated by changes in the expression of V-maf musculoaponeurotic fibrosarcoma 
oncogene homolog A (MafA) and MafB transcription factors. MafA levels increase in 
mature β-cells while MafB expression becomes restricted to α-cells [31]. In addition to 
MafA, mature β-cells express multiple transcription factors including neurogenic 
differentiation 1 (NeuroD), paired box gene4 (Pax4), Homeobox protein Nkx2.2 
(Nkx2.2), and Nkx6.1 [19,32]. A transcriptional network listing some of the key 
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transcription factors involved in endocrine cell lineage development is shown in Figure 
1.2. Together with α- and β-cells, islets also contain hormone-producing -, γ- and -
cells. -cells produce somatostatin which acts as an important regulator of paracrine 
inhibition of insulin and glucagon secretion while also controlling gastric emptying [33]. 
Novel studies have started to explore the mechanisms involved in -cell secretion in 
regulating blood glucose levels in more detail [34–36]. -cells have filopodia that enable 
interaction with many islet cell types despite their low prevalence (~5% of islet cell 
types) [36]. Somatostatin is released via adenosine triphosphate (ATP)-sensitive 
potassium channels (K+ATP channels) but can also be released in response to glucose 
stimulation via K+ATP channel-independent mechanisms [35]. It is postulated that 
defective somatostatin secretion can occur in diabetes, warranting continued research 
efforts to understanding the integrative communication between the multiple islet cell 
types [35]. Lastly, -cells release ghrelin, stimulating appetite and γ-cells produce 
pancreatic polypeptide in response to food intake proportional to calorie intake, inhibiting 
pancreas secretions [37,38]. 
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Figure 1.2. Transcriptional pathways involved in endocrine cell specification 
Progenitor cells expressing Ngn3 give rise to all islet cell types. A simplified list of some 
of the key transcription factors involved in endocrine islet subtype specification are 
depicted. The expression of different transcription factors ultimately delineates the 
differentiation of the distinct endocrine cell types. Figure was created in Biorender. 
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In addition to differences in islet architecture between humans and mice, differences also 
exist in islet development. While in humans islet development is complete at birth, this 
process continues in mice from E15.5 to postnatally at the end of lactation [39,40]. Islet 
maturation occurs via increased β-cell replication and neogenesis, both of which slow 
extensively by adulthood [41]. Pancreatic β-cells are considered to be a slowly renewed 
cell with low turnover in healthy adults. The steady state β-cell replication rate in an adult 
rat is just over 2% per day [42–44] and this rate is even lower in humans [45]. However, 
rates of β-cell apoptosis are also low in adulthood, around 0.5% in the rat, allowing for 
gradual replacement of β-cells and maintenance of β-cell mass (BCM) in adulthood [46]. 
Thus, BCM is considered to be fairly stable after birth. Nevertheless, the pancreas 
undergoes extensive remodeling postnatally, which in the rat is characterized by a wave 
of β-cell apoptosis peaking around postnatal day 14 [41]. This is immediately followed 
by an additional wave of neogenesis which allows for replacement of β-cells and 
maintenance of BCM (Fig. 1.3).  
 
 
 
11 
 
 
Figure 1.3. Schematic diagram of the dynamic changes in BCM with age 
The various determinants of β-cell growth in mice are shown as they change with age.  
Reproduced from Bonner-Weir et al. Ups. J. Med. Sci. 2016;121:155-158, with minor 
revisions.  
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1.3  Mechanisms and Dynamics of Insulin Secretion  
The first step in the cascade that initiates insulin secretion from pancreatic β-cells 
involves a glucose molecule entering the β-cell. This occurs via glucose-transporter-2, 
Glut2, which is a transmembrane protein on the β-cell that permits for uptake of glucose 
across the β-cell membrane, amongst other tissues, in response to high glucose 
concentrations [47]. An important difference between glucose uptake mechanisms 
between mice and humans is that human β-cells are able to use both Glut1 and Glut2 to 
uptake glucose [48]. Nonetheless, Glut1 is considered to be the primary source of glucose 
uptake in the β-cell in humans [49]. This is in contrast to mice where only Glut2 is used 
[48]. Once glucose enters the cell, it is phosphorylated by glucokinase (Gck) and 
converted into ATP via multiple steps in glucose metabolism (Fig. 1.4) [50]. The rising 
ATP:adenosine diphosphate (ADP) ratio triggers the closure of ATP-sensitive K+ 
channels, resulting in β-cell membrane depolarization [51]. Depolarization of the β-cell 
membrane triggers opening of voltage-dependent Ca2+ channels and a rapid influx of 
Ca2+ into the cell, triggering exocytosis of insulin-containing granules [11]. To be more 
effective at reducing blood glucose levels, insulin is secreted in pulses which is 
postulated to be modulated by oscillations in [Ca2+] [52,53]. Insulin secretion occurs in a 
biphasic pattern with first phase insulin secretion occurring rapidly within minutes of 
stimulation and lasting only approximately 2 min [11]. This is followed by second phase 
insulin secretion, which is considered to be a slow release, but sustained, phase. It is well-
established that a loss of first phase insulin secretion and a blunted second phase is 
characteristic of T2DM [54]. Once insulin is released into the circulation, it can interact 
with the insulin receptor on peripheral tissues to stimulate glucose uptake via the insulin 
receptor signaling pathway that results in trafficking of Glut4 transport vesicles to the 
plasma membrane (Fig. 1.4) [55].  
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Figure 1.4. Overview of insulin release and action 
In mice, glucose enters the β-cell via Glut2 and is metabolized via glycolysis, generating 
ATP. The accumulation of ATP in the cytoplasm leads to closure of ATP-sensitive K+ 
channels, and depolarization of the plasma membrane. Depolarization of the plasma 
membrane results in opening of voltage-dependent Ca2+ channels. The influx of Ca2+ into 
the cell leads to release of insulin granules, which are carried in the bloodstream to cells 
throughout the body (i.e. liver, skeletal muscle, adipose) to bind the insulin receptor. 
Upon binding, autophosphorylation of tyrosine residues occurs in addition to 
phosphorylation of other cellular proteins, including recruitment of insulin receptor 
substrates (INSR1/2). This results in recruitment of other proteins, activating various 
signaling pathways (dashed lines). Ultimately, translocation of Glut4 vesicles to the 
plasma membrane occurs permitting uptake of glucose into the cell, in addition to 
activation of pathways that regulate metabolism, transcriptional changes and cell growth. 
Reproduced from Abner Louis Notkins J. Biol. Chem. 2002;277:43545-43548, with minor 
revisions. 
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1.4  β-cell Plasticity  
As mentioned in section 1.2, β-cell number is considered to remain stable after birth and 
variations in BCM are minimal in adulthood [56]. Nonetheless, there are many studies 
that have reported that β-cells display plasticity in injury models and certain 
physiological situations (i.e. obesity and pregnancy). These findings have drawn interest 
to understanding the mechanisms of β-cell plasticity and the stimuli for β-cell 
regeneration in these models. Once elucidated, these mechanisms could be appealing 
strategies for endogenous pancreatic β-cell replacement for diabetes reversal.  
 
1.4.1  Models to Study β-cell Regeneration  
Numerous animal models have been developed where an insult initiates β-cell 
regeneration and have been pivotal for β-cell plasticity research. Some of these β-cell 
stresses can be induced by surgical damage (partial pancreatectomy, pancreatic duct 
ligation), and β-cell destruction (genetic or pharmacological) which will be briefly 
described below. 
Partial pancreatectomy    
Partial pancreatectomy involves the removal of 90% of the pancreas resulting in diabetes 
[57]. In this model, regeneration of both endocrine and exocrine pancreas, in addition to 
generation of new lobes, was demonstrated in rats [57–59]. These studies were followed 
by mechanistic lineage tracing experiments that showed that β-cell regeneration occurred 
mainly through proliferation of pre-existing cells [60], although other studies report that 
α- to β-cell transdifferentiation could also be occurring [61]. Similar mechanisms might 
be operating in humans as there is evidence of pancreas regeneration in patients with 
pancreatectomy [62].   
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Pancreatic duct ligation 
Pancreatic duct ligation (PDL) involves the surgical ligation of the pancreatic duct at the 
pylorus, resulting in accumulation of exocrine secretions in the body and tail of the 
pancreas. Studies of pancreas remodelling following PDL in rat have shown the 
formation of new β-cells from progenitors in ductal epithelium [63] by activation of Ngn3 
which gives rise to all islet cell types [64]. That being said, the origin of these progenitor 
cells remains controversial (discussed below in section 1.4.3.2) as some experiments 
suggest that pancreatic ductal cells are not pancreatic progenitors [65–67]. 
β-cell damage: genetic ablation   
Islet cell plasticity has also been demonstrated in transgenic mouse models using in vivo 
cell lineage tracing tools that allow for inducible (doxycycline (DOX) or tamoxifen 
(TAM) administration) β-cell ablation and tracing of islet cells. In one model, upon DOX 
administration to transgenic mice (Insulin-rtTA;TET-DTA), targeted ablation of 
pancreatic β-cells occurred based on driving of insulin promoter and conditional ablation 
of β-cells in specific transgenic strains. Upon DOX administration in this model, a 
targeted β-cell loss of 70-80% was observed [68]. In this model, experiments concluded 
that β-cell regeneration occurred due to replication of pre-existing β-cells. An additional 
study using TAM administration to investigate β-cell regeneration showed that β-cell 
proliferation was the driver of regeneration in this model [69]. 
β-cell damage: pharmacological  
The two most commonly used pharmacological agents to induce β-cell ablation for study 
of β-cell plasticity and regeneration are streptozotocin (STZ) and alloxan. Both drugs 
enter the β-cell through Glut2 and trigger β-cell death [70]. STZ is a cytotoxic product 
produced by Streptomycetes achromogenes that causes damage to β-cells by entering the 
β-cell [71]. STZ causes deoxyribonucleic acid (DNA) alkylation and damage ultimately 
resulting in β-cell death. Alloxan triggers β-cell death by inducing production of reactive 
oxygen species (ROS). Both models have been widely used to study β-cell regeneration 
in various animal models [72–77].  
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1.4.2  β-cell Plasticity with Age  
Although there is clear evidence of β-cell regeneration in the many discussed studies 
above, it is important to note that the capacity for β-cell regeneration varies with age. It 
has been well-established that β-cell replication declines drastically after birth in both 
humans and rodents implicating a long lifespan and low turnover rate for β-cells 
[42,43,56,78–80]. The impairment of this replicative process correlates with the induction 
of processes preventing the β-cell from re-entering the cell cycle [81,82]. Furthermore, 
aged islets have been shown to exhibit inflammatory markers, including nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-kB), which has been shown to 
upregulate socs2, a gene that inhibits β-cell proliferation [83]. In addition to reduced 
replicative capacity, some studies in humans show that β-cell function is also impaired 
with age [84]. The reduced capacity for β-cell regeneration in the adult could also be due 
to the reduction of multipotent precursor cells, expressing insulin but low levels of 
glucose-transporter 2, Glut2 (Ins+Glut2LO),  which have been previously shown to 
decrease with age in both humans and mice [85].  
Regeneration of β-cells following β-cell loss has been shown to occur in young mice 
[68,86] although studies with aged mice have shown a limited capacity for regeneration 
[87,88]. Similarly, regeneration might be restricted in non-human primates as a study 
using STZ-mediated β-cell ablation in middle-aged velvet monkeys did not find a 
compensatory increase in β-cell replication [89]. Another example in humans showed that 
young children (between 2 and 9 years old) had complete pancreas regeneration 
following a pancreatectomy [62]. However, pancreatectomy in adults (39-72 years) did 
not yield an increase in pancreatic volume [90]. Studies in mice treated with STZ 
demonstrated that neonates treated with STZ were able to partially regenerate their 
pancreas. In contrast, mice treated with STZ in adulthood showed reduced regeneration 
[87]. Elegant studies by Herrera’s group investigated the influence of age on islet cell 
plasticity in β-cell ablated mice and demonstrated β-cell regeneration via reprogramming 
of -cells in juvenile mice. Interestingly, this process involved the dedifferentiation of -
cells, subsequent proliferation and redifferentiation into β-cells which differed from 
mechanisms that occurred in adults [91]. Taken together, these studies suggest that β-cell 
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regeneration declines with age in mammals. The reduced replicative capacity of β-cells 
and reduced β-cell function in aged islets are important considerations to address for 
regenerative therapies or islet replacement protocols. 
 
1.4.3  Sources of New β-cells From Within the Pancreas  
It is important to elucidate the sources of new β-cells in order to be able to better 
manipulate these populations to increase BCM as a strategy for diabetes reversal. In this 
section, 5 topics will be discussed including replication from pre-existing β-cells, 
conversion from ductal progenitors, pancreatic progenitors within the endocrine pancreas, 
α- to β-cell transdifferentiation, and acinar to β-cell transdifferentiation (Fig. 1.5).  
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Figure 1.5. Schematic diagram of sources of new β-cells from within the pancreas 
Overview of some of the sources of new β-cells from within the pancreas discussed in 
this thesis. Sources include the differentiation of pancreatic progenitor cells (A), 
reprogramming of cells from within the exocrine and endocrine pancreas (B), and self-
replication of pre-existing β-cells (C). Figure was created in Biorender. 
 
 
 
 
 
 
 
19 
1.4.3.1  Replication from Pre-Existing β-cells  
As previously mentioned β-cells have a slow cellular turnover. Nonetheless, in stressful 
situations, such as the injury models described in section 1.4.1, evidence of increased 
replication from pre-existing β-cells has been documented [60,68]. Additionally, in some 
physiological situations, such as in pregnancy, increased β-cell replication has also been 
demonstrated [92]. A milestone study that lineage traced β-cells in young adult mice 
demonstrated that most β-cells arise by self-replication rather than from a progenitor 
source [60]. In this study, a pulse-chase experiment was performed using transgenic mice 
that tagged existing mature insulin-expressing β-cells with human placental alkaline 
phosphatase following tamoxifen injection. After following the mice for up to a year the 
authors concluded that the new β-cells were products of self-renewal. Important 
limitations of this study however arise due to only 30% of β-cells undergoing tamoxifen-
induced recombination [93]. Furthermore, tamoxifen-independent recombinase activity 
poses a technical limitation for mice in these experiments [93,94]. However, additional 
studies re-affirmed these findings by also detecting no evidence of β-cell neogenesis 
arising from progenitors to contribute to β-cell regeneration using an innovative DNA 
double-labelling experiment [95]. In this study the authors also concluded that replication 
occurred from pre-existing β-cells. In humans, fewer studies have investigated the 
contribution of β-cell replication, therefore less is known regarding the contribution of 
this mechanism to β-cell renewal [80,96]. However, there is evidence from pancreas 
samples that suggests mature human β-cells can proliferate in vivo [97]. Thus, 
manipulation of existing β-cells presents as an attractive strategy to β-cell deficiency 
reversal.  
β-cells possess cell cycle regulators although they are sequestered in the cytoplasm of 
mature β-cells [98,99]. Transfection of cell cycle regulators into β-cell lines in vitro have 
successfully led to an increase in replicative rate [100]. However, overexpression of 
oncogenes could increase the risk of carcinogenesis hindering the safety of such 
therapeutics. Application of growth factors and mitogens, such as growth hormone and 
placental lactogen, has been shown to increase β-cell replication in mice in vivo and in 
vitro [101,102]. Nonetheless, some of these agents have failed to produce a replicative 
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response in human β-cells. Furthermore, this was accomplished by inducing targeted 
expression via transgene which could result in off-target consequences if administered 
systemically. Recently, dual-specificity tyrosine-regulated kinase 1A (DYRK1A) was 
identified and shown to stimulate proliferation of human β-cells in vitro and transplanted 
human β-cells in vivo [103–105]. Combined pharmacologic inhibition of DYRK1A and 
transforming growth factor β superfamily signaling resulted in a synergistic increase in 
human β-cell proliferation [105]. This occurred due to activation of cyclins and 
reductions of cell cycle inhibitors. In conclusion, the identification of molecules that 
stimulate β-cell replication which have reversible effects and are β-cell-specific are 
needed to optimize strategies of stimulating endogenous β-cell replication as a 
therapeutic for diabetes reversal. 
 
1.4.3.2  Exocrine Conversion: Differentiation from Ductal 
Progenitors  
An additional endogenous source of β-cell reversal for diabetes would be an existing 
progenitor population in the pancreas. There are many studies that have implicated 
pancreatic ductal cells as the source of progenitor cells in the pancreas, dating back to 
1911 when it was observed that small endocrine cell clusters were budding from ducts 
[106]. This was a convincing hypothesis considering endocrine cells and pancreatic 
ductal cells stem from a common developmental ductal lineage, prior to endocrine 
lineage delineation by Ngn3. An initial study by Xu et al. reported evidence of β-cell 
neogenesis in a PDL model via formation of β-cells from Ngn3+ cells resulting in an 
increased BCM [64]. Proliferation increased in ductal cells and importantly the Ngn3+ 
cells were shown to migrate away from the duct into islet structures. Further evidence of 
this contribution stems from a study that tagged ductal cells with the Cre-Lox system 
using carbonic anhydrase II promoter. In this study, new islets were traced back to 
carbonic anhydrase II-expressing cells as progenitors after PDL [63,107]. These findings 
were supported by additional pancreas-injury models where β-cell regeneration occurred 
from pancreatic ducts [23,108,109]. A more recent study importantly showed via lineage 
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tracing that under certain conditions (mild hyperglycemia, gastrin or epidermal growth 
factor treatment) pancreatic ductal cells can be induced to differentiate into β-cells and 
reverse diabetes [110]. On the contrary, there are studies that have failed to observe the 
contribution of ductal cells to β-cell regeneration [65–67,111], which is postulated to be 
due to potential differences in lineage tracing tools, markers for ductal cells or injury 
models used. An additional argument is that embryonic-specific transcription factors 
(Ngn3/Pax4) are not expressed during postnatal life, suggesting that postnatal β-cells 
should arise from an additional source. Nonetheless, convincing data suggesting the 
therapeutic potential of a ductal progenitor pool has been demonstrated in STZ-treated 
mice where β-cell regeneration was successful using isolated ductal cells [112,113]. This 
has also been extrapolated to non-rodents as a recent study showed that β-cell 
differentiation can occur from ductal progenitor cells in zebrafish [114]. Importantly, 
human pancreatic ductal cells have been grown in vitro and induced to differentiate into 
glucose-responsive, insulin-producing cells [115]. The authors concluded that the 
pancreatic ductal epithelium thus serves as a pool of pancreatic progenitor cells [116].  
 
1.4.3.3  Pancreatic Progenitors Within the Endocrine 
Pancreas  
The existence of β-cell progenitors remains one of the most controversial concepts in β-
cell biology. Dor’s initial landmark study suggested that new β-cells are predominantly 
generated by self-replication of pre-existing β-cells rather than from new islets arising 
from a progenitor [60]. Nonetheless, this conclusion remains open-ended as the study 
does not consider mechanisms of regeneration that can occur in injury models such as the 
convincing evidence discussed in section 1.4.3.2 and below. In this section, evidence for 
pancreatic progenitors will be discussed. 
A study by Liu et al. opposed the work done by Dor, where the same transgenic mouse 
model was used to track β-cells with age, in addition to STZ-mediated β-cell ablation 
[77]. In this study, β-cell progenitors were identified that had an immature β-cell 
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phenotype (lack of Nkx6.1 and Glut2). Importantly, these cells proliferated in STZ-
ablated pancreas and were concluded to be a group of progenitor cells with substantial 
endocrine lineage plasticity. Additional studies have identified putative adult pancreatic 
stem/progenitor cells in mouse pancreas [117,118]. Suzuki et al. isolated progenitor cells 
with flow cytometry from neonatal pancreas, while Seaberg’s study also identified rare 
single clonal cells from adult mouse pancreas [117,118]. Importantly, these cells were 
shown to have the capacity to differentiate into functional β-cells and were thus 
concluded to be a source of multipotent precursors cells in mouse pancreas [118]. 
Follow-up studies from this group validated Liu’s findings that these progenitor cells 
represent “immature” β-cells, characterized by decreased levels of Nkx6.1 and Pdx1, and 
lacked Glut2 [119]. These cells were also found to be capable of proliferation, renewal, 
and differentiation into multiple endocrine lineages in both isolated mouse and human 
islet tissues [119]. Importantly, after transplantation into mice with diabetes, both mouse 
and human pancreatic progenitor cells decreased hyperglycemia in the rodents, 
demonstrating the therapeutic potential of these progenitors. As discussed in section 
1.4.3.2, additional proof for the existence of pancreatic progenitors was shown by lineage 
tracing studies where one of the origins of the progenitors was suggested to be in ductal 
cells, as shown by reactivated Ngn3 expression in endocrine cells [63,64]. 
Since these landmark studies, additional studies have supported the hypothesis of 
multipotent pancreatic precursor cells including a progenitor pool expressing insulin but 
low levels of glucose-transporter 2, Glut2 (Ins+Glut2LO). These progenitors have been 
identified in mouse in addition to human pancreas and have been shown to have the 
ability to differentiate into mature β-cells under metabolic stress [118,119]. Ins+Glut2LO 
cells have been shown to decrease with advancing age in both human and mouse 
pancreas, however they retain a progenitor-type plasticity as they have a higher 
proliferation rate compared to mature Ins+Glut2HI cells [120]. Thus, these cells may 
represent a progenitor pool capable of differentiating into new β-cells. An additional 
recent publication used a marker to identify immature β-cells in a “neogenic niche” at the 
islet periphery, that are importantly present throughout life [121]. These immature β-cells 
express insulin, but represent an immature β-cell as they lack key markers (i.e. Glut2) 
including the maturation marker, Urocortin3 [122]. The authors suggested that the 
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Urocortin-Insulin+ cells represent an intermediate stage in transdifferentiation of α-cells 
into β-cells (discussed below in section 1.4.3.4). Importantly, Urocortin-Insulin+cells 
were also identified in human pancreas of varying ages, including donors with T1DM. 
Although there are inherently going to be challenges in using these populations as a 
therapeutic, such as the findings that many of these progenitor populations are extremely 
small, the therapeutic potential of the research has been convincing thus far and could be 
important for diabetes reversal should the methods be optimized. 
 
1.4.3.4  Endocrine Conversion: α- to β-cell 
Transdifferentiation  
An alternative source for β-cell regeneration for diabetes reversal could be from re-
programming of the closely-related glucagon-producing α-cells. After β-cells, α-cells are 
the most abundant cell type in islets. Importantly, α-cells remain viable in diabetes, and 
both mice and humans are able to survive without α-cells should existing α-cells be used 
as a therapeutic [123,124]. As was discussed in section 1.2, the pancreas arises from a 
common Pdx1-expressing progenitor. Upon expression of Ngn3 in ductal cells, islet 
lineages develop. Perhaps most interesting in the transcriptional changes in development 
of specific endocrine cell lineages is the overlap of transcription factors common to both 
mature α- and β-cells. It was once thought that the development of mature α- and β-cells 
was static and a definitive lineage. However, studies have discovered that both α- and β-
cells are able to interconvert between one another. Remarkable pioneer studies 
demonstrated that the misexpression of α-cell specific transcription factors, such as Arx, 
in β-cells can result in conversion to α-cells [125]. Conversely, expression of β-cell 
specific transcription factors, such as Pax4, can cause conversion of α-cells into β-cells 
[126]. Moreover, these new β-cells displayed most characteristics of mature β-cells. On 
the contrary, β-cells have also been shown to undergo de-differentiation into α-cells, 
which contributed to loss of BCM in T2DM [127]. The epigenetic chromatin signature of 
α-cells, resembling stem cells, likely attributes to this remarkable plasticity [128]. 
Nonetheless, this process has also been shown without genetic manipulation of 
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transcription factors. One of the first studies demonstrating interconversion between α- 
and β-cells was reported in 2007 in a β-cell ablated model of diabetes using zebrafish 
[129]. In this study, the authors lineage traced the regenerated β-cells and found that they 
arose from a non-β-cell origin located at the periphery of the islet. These studies were 
followed by lineage tracing experiments to show that α- to β-cell conversion was the 
main contributor of β-cell regeneration. Interestingly the location of these cells at the 
periphery of the islet supports the more novel findings of the Urocortin3 study that 
proposes a neogenic niche where α-cells can convert to β-cells in order to facilitate β-cell 
regeneration [121]. Additional compelling evidence for this process exists in many 
models of β-cell regeneration. Studies using a model of extreme β-cell ablation 
demonstrated β-cell regeneration via conversion from α-cells, or -cells, depending on 
the age of the mice [86,91]. The regeneration has been shown to occur even after multiple 
insults of β-cell ablation and is postulated to arise from a pancreatic ductal cell origin 
[108]. To compensate for the shortage of α-cells, α-cell neogenesis was stimulated via re-
activation of Ngn3 in ductal cells, which enabled subsequent conversion into β-cells upon 
Pax4 expression or Arx inhibition resulting in a continuous cycle of neogenesis and 
conversion [108,126,130].  
As exciting as these studies are they do have practical limitations as these processes are 
only observed in extreme and acute models of β-cell ablation, which do not have clinical 
equivalents. The amount of β-cell loss and injury model used will also determine whether 
α- to β-cell transdifferentiation occurs and this will further influence the degree of re-
programming. Thorel and colleagues showed that β-cell loss must be near total for 
triggering the re-programming process as in situations of milder β-cell ablation (less than 
95%), less α-cell reprogramming occurred and the mechanism of β-cell regeneration was 
self-replication of existing β-cells [86]. Importantly, an even milder form of β-cell 
ablation showed no evidence of reprogramming at all. Furthermore, although some 
studies suggest that this process can occur in humans [131,132], without lineage tracing 
studies direct evidence is lacking. 
Despite these limitations, an endogenous source of β-cell replacement for diabetes, such 
as the closely related, and increasingly proven to be plastic, α-cell, is appealing if shown 
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to be feasible. Some molecules have been suggested to promote α- to β-cell conversion 
including γ-aminobutyric acid (GABA) [132], GLP-1 [133]  and artemisinins [134]. 
Nonetheless, some of these findings remain controversial as a study rebutted the 
suggestion that artemisinins cause α- to β-cell conversion [135]. Thus, the detailed 
mechanisms and reasons for differences in these studies should be further addressed. 
However, continued research efforts to identify stimulators for α- to β-cell conversion are 
warranted.  
 
1.4.3.5  Exocrine Conversion: Acinar to β-cell 
Transdifferentiation  
As was discussed in section 1.2, the pancreas has both an endocrine and an exocrine 
portion. In addition to the findings of exocrine ductal cells as a source of progenitor cells 
discussed in section 1.4.3.2, there is data to support the reprogramming of exocrine acinar 
cells into insulin-producing β-cells as well [136–139]. Similar to the studies involved in 
α- to β-cell conversion involving transcriptional manipulation, studies using mouse acinar 
cells have shown that by expressing β-cell transcription factors (Pdx1, Ngn3 and MafA) 
via adenoviral vectors injected into pancreatic parenchyma, new β-cells arose in vivo. 
Furthermore, when these cells were transplanted into rodents with diabetes, 
hyperglycemia was reduced and importantly recurred upon removal of the graft 
[138,139]. The new β-cells also resembled a mature β-cell phenotype and have been 
confirmed to persist for up to 1 year in vivo [140]. These results were confirmed in vitro 
using primary human pancreatic exocrine cells cultured in specific conditions 
(transforming growth factor-B1, Rho-associated kinase inhibitors) that generated cells 
amongst which 18% were mature, glucose responsive β-cells in vitro and in vivo [141]. 
Upon transplantation, these cells were able to prevent diabetes in STZ-β-cell ablated 
mice. More recently, the same group demonstrated that by suppressing the α-cell specific 
transcription factor, Arx, while simultaneously overexpressing the β-cell specific 
transcription factor, Pax4, there was an enhanced production of functional insulin-
producing β-cells from exocrine tissue [142]. When transplanted into mice with diabetes, 
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there was an immediate and prolonged effect of reduced blood glucose levels. As with 
previous transdifferentiation studies, some of these studies are nonetheless limited in 
terms of clinical applications due to the use of viral vectors. Furthermore, the results are 
still controversial as one publication used in vivo lineage tracing after partial 
pancreatectomy and demonstrated no evidence of acinar to β-cell conversion; rather the 
authors concluded that new exocrine cells arose from replication of pre-existing acinar 
cells [143]. 
In summary, although the topic remains controversial, many studies do provide evidence 
for multiple alternate endogenous sources of β-cell replacement for diabetes reversal. 
Most data suggest that β-cells replicate from pre-existing β-cells, although some more 
severe injury models demonstrate convincing evidence for alternate sources of β-cell re-
programming from the other pancreatic cell types discussed above. Importantly, these 
alternate mechanisms could still be contributing to β-cell replacement, even if the 
contribution is minor. These mechanisms should be studied further in order to allow for 
the implementation of targeted therapeutics which increase BCM during pathological 
conditions characterized by β-cell insufficiency. Translational applications will be limited 
by the need to produce stable, and functional β-cells. This will be complicated by the 
need to evaluate the safety of molecules to induce in vivo programming of β-cells. Thus, 
there are many remaining questions, nevertheless the results have tremendous potential to 
have an influential impact on diabetes research and treatment. 
 
1.5  Metabolic Situations of β-cell Adaptability  
In contrast to the models of regeneration discussed in section 1.4.1 that are used to study 
the sources of new β-cells, in this section, real physiological situations of β-cell 
adaptability in response to metabolic stress will be discussed. As mentioned in section 
1.2, β-cells are considered to be a slowly renewing cell type with low levels of apoptosis 
and replication enabling for gradual replacement of β-cells to maintain BCM. In contrast, 
there are compensatory mechanisms that occur in certain physiological situations to 
rapidly increase BCM. Two such situations where β-cell compensation must occur in 
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order to maintain euglycemia are the insulin-resistant states of obesity and pregnancy 
[144].  
 
1.5.1  Obesity  
Obesity is described as a pathological condition that involves excess deposition of 
adipose tissue. It is diagnosed by body mass index (BMI) and fat distribution through the 
waist-hip ratio. In the context of β-cell biology, obese patients show increased BCM 
expansion compared to lean individuals [80,145,146] with the increase being from 50-
90% [147,148]. Interestingly, one study found a lack of β-cell replication in human 
samples and the authors suggested that BCM increased via neogenesis through 
differentiation of ductal cells [80]. Two subsequent studies supported this hypothesis, 
demonstrating a lack of β-cell replication in obese human patients, rather the authors 
found an increased number of cells coexpressing insulin and a ductal marker, cytokeratin 
19, in patients with insulin resistance [80,149]. Interestingly, one study found an increase 
in the number of bihormonal (Insulin+Glucagon+) cells in insulin resistant patients, which 
could implicate α- to β-cell conversion as a compensatory mechanism for increased 
insulin demand [149]. Although most reports implicate neogenesis rather than β-cell 
proliferation to increased BCM expansion in obesity, most authors warrant that the 
conclusion should be taken with caution. One cannot exclude the possibility that β-cell 
proliferation was simply too small to be detected, or importantly could occur prior to the 
insulin resistance manifestation in obesity. Other studies have indeed found evidence of 
β-cell proliferation contributing to BCM expansion in obesity [150,151]. Thus, it is clear 
that the exact mechanisms of β-cell expansion in obesity have yet to be delineated. 
Several downstream effectors of the insulin signaling pathway have been implicated in 
BCM expansion in animal models of insulin resistance. For example, FoxM1 activation 
in islets was shown to increase compensatory β-cell proliferation in obese mice via 
neuronal input [152]. Nevertheless, further elucidation of these mechanisms is warranted.  
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1.5.2  Pregnancy 
An additional metabolic situation requiring successful, and a remarkably reversible, 
adaptation of pancreatic β-cells is during the insulin-resistant state of pregnancy. There 
are numerous physiological changes that occur during pregnancy. In humans, one of 
these changes is driven by the release of placental growth hormone from the placental 
syncytiotrophoblast, which contributes to a state of peripheral maternal insulin resistance 
[153]. These changes are also modulated by release of placental lactogen, estrogen, 
progesterone and other pregnancy hormones [153]. The state of maternal insulin 
resistance occurs in order to maintain trans-placental transport of glucose to the fetus to 
ensure optimal fetal development. Nonetheless, in order to compensate for the state of 
insulin resistance, the maternal pancreas must respond by increasing BCM to maintain 
euglycemia. As previously mentioned, the steady state β-cell replication rate in adult 
mammals is low. Remarkably, the rise in levels of the hormones placental lactogen and 
prolactin during mouse pregnancy have been shown to initiate proliferation of insulin 
producing β-cells in early pregnancy in order to prepare for adaptation of BCM 
[101,154]. The insulin resistance is thus countered by an increase in BCM and enhanced 
insulin secretion which maintains euglycemia in a healthy pregnancy [155,156]. Similar 
changes in BCM are believed to occur in humans however fewer studies have been 
performed.   
 
1.5.2.1  Pancreatic Compensation in Mouse vs. Human 
Pregnancy  
Pancreatic adaptation in mouse pregnancy has been extensively studied. It is well 
understood that there is a substantial increase in BCM during gestation in order to 
compensate for the increased metabolic demand [155,157,158]. In mice, successful 
adaptation of BCM during pregnancy occurs, in part, due to increased β-cell hypertrophy 
and proliferation which peak at mid-gestation and are mediated by increased levels of 
lactogenic hormones [92,155,159]. In mice, placental lactogen-1 is synthesized at early 
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gestation and peaks on gestational day (GD) 10.5. Mouse placental lactogen-1 is then 
replaced by mouse placental lactogen 2 which peaks at GD14.5 and remains high 
throughout the remainder of pregnancy [160]. This is in contrast to humans which only 
have one placental lactogen (human placental lactogen or human chorionic 
somatomammotropin) which gradually increases throughout pregnancy. Furthermore, 
estrogen levels increase during pregnancy which are associated with decreased β-cell 
apoptosis, suggesting a protective role for β-cells [161]. Collectively, these changes 
enable for expansion of BCM which peaks towards the latter portion of gestation 
(GD18.5, in mouse comparable to late gestation in human) [159,162]. Increased GSIS, in 
part due to a decrease in threshold for glucose stimulation, from β-cells further 
contributes to the maintenance of euglycemia during the insulin resistant state of 
pregnancy [155,163,164]. The adaptive increase in BCM is reversible and returns to pre-
pregnancy levels after birth through progesterone-mediated increases in β-cell apoptosis 
[165], concomitant with decreased levels of placental lactogen reducing β-cell 
proliferation. The mechanisms and timing of these changes in mouse pregnancy are well-
established. In contrast, due to a scarcity of pancreas samples from pregnant humans, 
these adaptive mechanisms in human pregnancy remain unclear. 
There have only been two studies exploring changes in endocrine pancreas in human 
pregnancy. Importantly, both studies found an increase in endocrine pancreas mass in 
pregnancy thus implicating endocrine adaptation to the metabolic changes of pregnancy 
in both humans and mice. The first study conducted by Van Assche et al. [166] reported a 
2.4-fold increase in β-cell fractional area in pregnant women compared to non-pregnant 
controls. More recently, Butler et al. [96] found a 1.4-fold increase in β-cell fractional 
area during pregnancy. Differences in the extent of endocrine pancreas adaptation have 
been postulated to occur due to varying factors between the two studies (such as women 
who died in car accidents, women with inflammatory diseases, varying pre-pregnancy 
BMI, wide ranges of gestational ages). Nonetheless, the studies collectively confirm that 
β-cell expansion occurs in human pregnancy.  
The most controversial studied difference between human and mouse compensatory β-
cell mechanisms in pregnancy is in regard to β-cell proliferation and neogenesis. In 
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addition to differences in distribution and composition of islets between mice and humans 
[28], adult human β-cells are thought to be very stable and rarely divide [167]. The Butler 
study found that the increased β-cell fractional area was not due to β-cell proliferation, 
rather there was an increased number of small islets implicating islet neogenesis as the 
driver of endocrine pancreas adaptation. In contrast, β-cell proliferation has been shown 
to peak at mid-gestation in mice driving the compensatory adaptations in endocrine 
pancreas. Nonetheless, prior to concluding islet neogenesis as the sole contributor to 
BCM expansion in human pregnancy based on the findings of the Butler study it is 
important to consider that samples were pooled across all gestational ages. Thus, it is 
plausible that pooling the samples could have diluted an increase in β-cell proliferation if 
proliferation occurs in a timing-specific manner such as in mice. Furthermore, it is 
possible that a much lower rate of β-cell proliferation is sufficient to achieve BCM 
expansion in humans over 9 months of pregnancy vs. 3 weeks in mice which requires a 
higher rate of proliferation to achieve maximal BCM expansion in a shorter time [154]. 
Further contributing to the potential difference of β-cell replication as a driver of 
endocrine pancreas adaptation between humans and mice is the role of lactogenic 
hormones. In mice, placental lactogen has been shown to drive β-cell replication via 
signaling through the prolactin receptor (PRLR) in pancreatic β-cells [168]. Signaling via 
PRLR increases serotonin receptor expression, which upon ligand binding further 
regulates β-cell proliferation and insulin secretion [169]. Studies of lactogen treatment in 
human β-cells have reported conflicting results, with some studies suggesting that 
treatment with lactogens increases GSIS and β-cell proliferation [170] in contrast to 
others which showed a lack of a mitogenic response to lactogens [171]. Differences in 
humans could be due to lower expression of PRLR on human β-cells than in mice [172]. 
Evidently there are differences between the behaviour of mouse and human β-cells during 
pregnancy which require careful consideration when translating animal data to humans. 
Nonetheless, the scarcity of human pancreas samples in pregnancy poses a challenge to 
studies in this field. 
Although there is evidence to suggest adaptive increases in BCM in pregnancy in both 
humans and mice, based on current evidence it is likely that the mechanisms leading to 
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this adaptation differ between mice and humans. Nonetheless, current studies provide 
clear evidence that both mice and humans rely on compensatory adaptation of β-cells to 
successfully counter insulin resistance in pregnancy. 
 
1.5.2.2  Mechanisms of Endocrine Compensation During 
Pregnancy  
Since human pancreas samples during pregnancy are sparse, the cellular mechanisms for 
maternal β-cell expansion during pregnancy have only been possible to decipher in mice. 
Expansion of maternal BCM in mouse pregnancy is predominantly due to β-cell 
replication. Adaptation to metabolic demands of pregnancy also involves lowering the 
threshold for GSIS, β-cell hypertrophy and increased insulin biosynthesis [92,158]. 
Whether increased GSIS and β-cell proliferation contribute to expansion in humans 
remains controversial. In this section, the contribution of β-cell progenitors to BCM 
expansion in pregnancy will be discussed, in addition to unveiling a potential 
contribution of other islet cell types (Fig. 1.6). 
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Figure 1.6. Endocrine pancreas adaptations in pregnancy 
Beta- and α-cell mass expansion occur in response to increased insulin demand during 
the insulin resistant state of pregnancy. Endocrine mass expansion occurs due to 
increased replication, increased hypertrophy of individual cells, and neogenesis from 
resident progenitor cells. Transdifferentiation of α- to β-cells is also possible. These 
adaptations maintain euglycemia together with enhanced glucose-stimulated insulin 
secretion. Reproduced from Szlapinski et al. Curr. Vasc. Pharmacol. 2020;18.  
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β-cell neogenesis  
Expansion of maternal BCM in mouse pregnancy is predominantly due to β-cell 
replication mediated through PRLR signaling, although the source of these cells remains 
to be determined. Some studies suggest that the majority of BCM expansion occurs 
through replication of pre-existing β-cells [173–176]. However, there is also evidence via 
lineage tracing that up to 25% of β-cells could arise from non-β-cell progenitors 
[173,175]. We and others have found an increase in the number of islets during mouse 
pregnancy which further contributes evidence to this hypothesis [159,177]. Additional 
studies from our laboratory have shown that the proportion of proliferating multipotent 
precursor cells (Ins+Glut2LO) significantly increased at GD9, which preceded β-cell 
proliferation at GD12 and facilitated BCM expansion at GD18.  The increase in 
proliferating progenitor cells at GD9 occurred at the same time as an increase in Pdx1 
mRNA expression which is a transcriptional marker for endocrine progenitor and mature 
β-cells. Thus, these cells may represent a progenitor pool capable of differentiating into 
new β-cells and in the context of pregnancy are present to facilitate BCM expansion. 
Islet cell transdifferentiation  
An alternative source of β-cells during pregnancy could be from re-programming of 
pancreatic glucagon-producing α-cells. The majority of the endocrine islet of Langerhans 
is composed of α- and β-cells, with the balance being regulated by changes in expression 
of the MafA and MafB transcription factors. MafA levels increase in mature β-cells while 
MafB expression becomes restricted to α-cells [31]. As discussed in section 1.4.3.5, 
studies have discovered that both α- and β-cells are able to convert between one another. 
Thus, an appealing method for regenerating β-cells in situations of β-cell deficiency 
would be through transdifferentiation of the closely related α-cells.  
The lineage-tracing methods used in the studies that failed to detect neogenesis in 
pregnant mouse models cannot exclude transdifferentiation from other islet types. Thus, 
it is possible that this process could contribute to a portion of the 25% increase in β-cells 
from non-β-cell progenitors during pregnancy. Although there was a lack of literature 
about other islet cell types in gestation in mice, a study was published in 2019 that 
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investigated the pancreatic α-cell in pregnancy. The study reported that, similar to BCM 
expansion, ACM expansion occurred in a healthy pregnancy and was maximal at GD18.5 
[178]. The authors further concluded that this was due to increased α-cell proliferation 
which followed a similar mechanism to pancreatic β-cells which proliferate during 
pregnancy to facilitate BCM expansion. Hypertrophy of α-cells was also observed at 
GD18.5. Additionally, the study investigated the role of gestational hormones in α-cell 
adaptations during pregnancy. It was found that in α-tc1.9 cells, placental lactogen and 
prolactin stimulated α-cell proliferation in vitro. This study also claimed that there was a 
negligible amount of α- to β-cell transdifferentiation occurring in mouse pregnancy, as 
was postulated to occur in an additional study in 2010 investigating this phenomenon in a 
healthy pregnancy [173]. However, one must acknowledge that the amount of β-cell loss 
will determine whether α- to β-cell transdifferentiation occurs and this will further 
influence the degree of re-programming. Thorel and colleagues showed that β-cell loss 
must be near total for triggering the re-programming process as in situations of milder β-
cell ablation, less α-cell reprogramming occurred [86]. Importantly, an even milder form 
of β-cell ablation showed no evidence of reprogramming at all. In the case of the healthy 
animals, there is no loss of β-cells rather an adaptive increase in BCM expansion occurs 
successfully in pregnancy. Therefore, it is likely that the metabolic stress of pregnancy is 
insufficient to trigger reprogramming of α-cells and without the stressor of β-cell loss, α- 
to β-cell transdifferentiation will not occur. In contrast, it is plausible that in a situation of 
higher metabolic stress in pregnancy, such as in gestational diabetes mellitus (GDM) or 
in obese pregnancies, α- to β-cell transdifferentiation could occur. In conclusion, this 
study implicated the importance of other islet cell types in pregnancy that were 
previously overlooked. 
In summary, evidence suggests that the majority of BCM expansion during pregnancy 
likely occurs due to replication of pre-existing β-cells which is mediated by PRLR 
signaling of placental hormones. Nonetheless, there is evidence for alternate sources of β-
cells. These mechanisms should be studied further in order to allow for the 
implementation of targeted therapeutics which increase BCM during pathological 
pregnancies which are characterized by β-cell insufficiency (such as GDM, discussed 
below in section 1.6). 
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1.5.2.3  PRLR Signaling-Mediated JAK2/STAT5 Cascade  
It is important to understand and identify the mediators influencing adaptive β-cell 
expansion during pregnancy in order to permit for implementation of targeted 
therapeutics to reverse this deficiency in pathological pregnancies such as GDM. In this 
section, some intracellular mechanisms involved in adaptive BCM expansion in 
pregnancy will be discussed, with many genes being primarily downstream of the 
lactogens. 
PRLR signaling  
As previously mentioned, β-cell replication from pre-existing β-cells is the predominant 
source of BCM expansion in mouse pregnancy. β-cell proliferation is mediated by 
lactogenic (prolactin and placental lactogen) signaling through the PRLR receptor which 
is expressed specifically in β-cells in mice [179]. Upon binding of ligand, JAK2 
phosphorylates the receptor and allows recruitment and phosphorylation of STAT5 to the 
nucleus where regulated expression of target genes occurs. The requirement of PRLR 
signaling in gestational BCM expansion and maintenance of euglycemia was 
demonstrated in pregnant female mice heterozygous for the PRLR null mutation. These 
animals were glucose intolerant and had a reduced BCM during pregnancy due to 
reduced β-cell proliferation [168]. Conversely, overexpression of placental lactogen 
caused increased β-cell proliferation, and increased BCM leading to hypoglycemia [180]. 
Signals for adaptive maternal β-cell expansion 
The influence of lactogens on adaptive maternal BCM expansion has been well studied 
and additional studies are discovering various important intracellular signals that mediate 
these effects. PRLR signaling has been shown to activate multiple signaling pathways in 
addition to the canonical JAK2/STAT5 pathway, including: mitogen-activated protein 
kinase (MAPK), phosphatidylinositol 3-kinase (PI3k) and insulin receptor substrate (IRS) 
1/2 pathways in order to initiate adaptive BCM expansion [181–185]. Some of these 
signaling pathways activate cell-cycle proteins and ultimately increase β-cell 
proliferation. For example, one pathway involves increased expression of tryptophan 
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hydroxylase (Tph1) which is involved in the rate limiting step of serotonin synthesis. 
Initial studies on the effects of serotonin in islets postulated an inhibitory effect on GSIS. 
However, recent studies show that serotonin was upregulated in pregnant rat islets and 
upon inhibition of serotonin synthesis there was decreased gestational β-cell proliferation 
and BCM expansion resulting in glucose intolerance [169]. Serotonin was also shown to 
play a role in GSIS [186]. The authors of this study further concluded that serotonin acts 
downstream of PRLR signaling to drive β-cell proliferation [169]. Another mechanistic 
pathway involved in mediating an adaptive response in β-cells is via suppression of 
menin by JAK2/STAT5 signaling. In a non-pregnant state menin, a tumor suppressor 
protein, regulates expression of cyclin dependent kinase inhibitors p27 and p18 which 
inhibit β-cell proliferation by blocking the cell-cycle protein cyclin-D2 (CCND2). 
However, signaling through PRLR during pregnancy decreases levels of menin, which 
subsequently decreases p27 and p18, enabling CCND2 to increase β-cell replication and 
facilitate an adaptive increase in BCM [187,188].  The regulation of menin has been 
shown to occur due to increased expression of Bcl6, a transcriptional repressor of the 
Men1 gene [188]. Proof of principle studies showed that when expression of Men1 was 
increased in pregnant mice, BCM expansion was impaired due to blocked β-cell 
proliferation resulting in impaired glucose tolerance during pregnancy. 
A second intracellular pathway that signals downstream of JAK2/STAT5 in the PRLR 
pathway is the PI3k/Akt1 pathway. PRLR signaling acts through this pathway to increase 
mTOR (mechanistic target of rapamycin) signaling which increases β-cell proliferation 
[185]. The mTOR signaling pathway regulates β-cell proliferation and BCM [189]. Thus, 
unsurprisingly when this pathway was inhibited by rapamycin in pregnant mice, there 
were impairments in β-cell proliferation and BCM [190]. 
 
1.5.2.4  Transcriptional Regulation of Endocrine Adaptations  
The mitogenic response of β-cells in response to pregnancy in mice has been shown to be 
mediated by changes in expression of transcription factors in the islet. These transcription 
 
 
37 
factors initiate the processes leading to adaptive β-cell proliferation and BCM expansion 
in pregnancy. Some of these transcription factors include the orphan nuclear receptor 
hepatocyte nuclear factor-4 (HNF-4) [191], Foxm1 [192] and MafB [179]. 
HNF-4 
Mutations in the human ortholog of HNF-4 have been shown to cause maturity onset 
diabetes of the young type 1 (MODY1) [193]. As could be expected, studies in non-
pregnant mice lacking HNF-4 demonstrated β-cell impairments [194]. It was then 
shown in pregnant mice that HNF-4  is required for expansion of BCM since upon 
elimination of HNF-4 from β-cells, proliferation and BCM were reduced leading to 
glucose intolerance [191]. 
Foxm1  
Mice lacking Foxm1 have been shown to have a reduced BCM since the transcription 
factor plays a role in cell proliferation [195]. Unsurprisingly, pregnant mice with 
pancreatic deletion of FoxM1 had decreased β-cell replication and BCM contributing to 
glucose intolerance at late gestation [192]. Inactivation of FoxM1 prevented lactogen-
mediated β-cell proliferation and thus was implicated to be a downstream regulator of 
lactogens. 
MafB 
The transcription factor MafB is normally restricted to -cells. Interestingly, during 
pregnancy in mice, MafB  expression was induced in a subset of β-cells [196]. 
Subsequent studies showed that the loss of MafB in β-cells decreased gestational 
proliferation, implicating the transcription factor in gestational β-cell proliferation [179]. 
 
Collectively, multiple components discussed in this section are part of the same signaling 
pathways and are mediated by signaling via PRLR. The increase in β-cell proliferation 
leading to increased BCM and GSIS permit successful endocrine adaptation to counter 
hormone-mediated insulin resistance that progressively increases during pregnancy. The 
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importance of mediating an adaptive increase in BCM can be seen in situations of 
pathology where BCM expansion is suboptimal and can precipitate GDM. 
 
1.6  Gestational Diabetes as a Consequence of Inadequate 
β-cell Compensation  
Although there have been advances in understanding the mechanisms leading to β-cell 
adaptation during pregnancy there is still much that is unknown about β-cell dysfunction 
in GDM. However, it appears that a suboptimal increase in BCM is equally as important 
as a failure to adaptively increase GSIS. 
GDM is described as diabetes that first appears during pregnancy with diagnosis 
occurring around 24-28 weeks of gestation by oral-glucose tolerance test [197]. GDM 
can develop as a result of severe insulin resistance, insufficient compensation of β-cells 
and insufficient insulin secretion, leading to maternal hyperglycemia [198]. Thus, GDM 
occurs due to insufficient β-cell adaptation to compensate for insulin resistance in 
pregnancy. The incidence of GDM worldwide is around 17% of all pregnancies [197] 
although a true estimate is difficult to conclude as the incidence will vary depending on 
the population characteristics and diagnostic criteria. The incidence will only continue to 
rise as more women enter pregnancy obese or at an older age, both of which are risk 
factors for GDM [199]. Although obesity increases the risk of developing GDM, many of 
the women who develop GDM are not obese implicating dysfunction at the level of the β-
cell to GDM pathophysiology [199–201]. While GDM reverts after pregnancy in most 
situations, growing evidence unfortunately associates GDM with adverse maternal and 
fetal outcomes. In terms of maternal health, GDM can result in pregnancy complications 
during labour and delivery, and increase the risk of T2DM postpartum [202]. The rates of 
these manifestations vary ranging between 3% and 90%, nonetheless there is up to a 7-
fold increase in risk compared to normoglycemic pregnancies [203]. In terms of the 
health of the offspring, exposure to GDM in utero has been linked to an increased risk of 
pre-term birth, respiratory distress syndrome, obesity and developing T2DM [204–206]. 
The increase in incidence of obesity and T2DM observed in children today may be partly 
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due to the increased cases of GDM. These pathologies in the current generation of youth 
may lead to further increases in GDM occurrences as they mature, continuing the cycle 
and implicating the urgent need for a therapeutic to prevent GDM. Currently in Canada, 
management strategies for GDM involve strict lifestyle management (dietary regulation 
and exercise) to manage blood glucose levels [197]. If blood glucose targets are not met 
within 2 weeks, the patient is given insulin or metformin as a treatment to accommodate 
pancreatic β-cell insufficiency. Thus, dysfunction at the level of the pancreatic β-cell is 
hypothesized to be the key determinant of GDM pathogenesis. 
β-cell defects in GDM 
GDM, like most human diseases, is multi-factorial which makes it difficult to determine a 
specific mechanistic origin. Nonetheless, clinical studies have implicated β-cell failure as 
a major driver to development of GDM [207] which has been confirmed in animal 
models of GDM where diabetes occurred when β-cell expansion and β-cell dysfunction 
failed to compensate for insulin resistance during pregnancy [92,157,168,188,192]. Some 
factors that contribute to inadequate β-cell compensation and β-cell dysfunction include 
signaling via PRLR, adipokines, inflammation, and oxidative stress. Studies found that 
the targeted loss of signaling through the PRLR in β-cells of mice resulted in reduced β-
cell proliferation and BCM expansion, leading to GDM (Fig. 1.7) [179].  
 
 
 
 
 
40 
 
 
Figure 1.7. Adverse pancreatic β-cell stress during pregnancy can impair adaptation 
to pregnancy 
Reproduced from Szlapinski et al. Curr. Vasc. Pharmacol. 2020;18. 
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Role of inflammation and oxidative stress in β-cell dysfunction in GDM 
Cytokines released from adipose tissue influence metabolism during pregnancy; leptin 
and adiponectin representing two main adipokines that have been shown to be 
dysregulated in GDM. Changes in adipose-derived adipokines and pro-inflammatory 
cytokines associated with maternal obesity are likely to exacerbate the risk of β-cell 
dysfunction during pregnancy, leading to GDM. Circulating leptin, which increases 
insulin sensitivity, is 2-3 fold higher in pregnancy due to placental as well as adipose 
expression [208]. Compared to healthy pregnant women, placental leptin expression was 
increased in patients with GDM and women with high levels of leptin preconception had 
a 20 times higher incidence of developing GDM [209]. In the context of pancreatic β-cell 
biology, it has been well-documented that inflammation can contribute to β-cell 
dysfunction [210]. Inflammation leads to endoplasmic reticulum stress which directly 
influences β-cell dysfunction in addition to causing decreased insulin sensitivity, as has 
been documented in GDM patients [211]. Women with GDM have been shown to have 
increased circulating levels of the proinflammatory cytokines tumor necrosis factor 
(TNF-α), Interleukin (IL) -1β, and IL-6 which are also associated with β-cell dysfunction 
[199,212,213]. In one study, human and mouse islets treated in vitro with IL-1β showed a 
reduction in GSIS in addition to β-cell de-differentiation, implicating inflammation to β-
cell dysfunction [214]. TNF-α has been shown to contribute to insulin resistance by 
impairing insulin receptor signaling [104] and observations in women with GDM support 
the role of TNF-α in the development of insulin resistance [211]. Since leptin increases 
production of TNF-α, increased levels of leptin in GDM are additive to the pre-existing 
inflammatory state in late pregnancy that normally contributes to insulin resistance. This 
increases the metabolic pressure on β-cells to adapt during pregnancy and thus can 
contribute to the pathophysiology of β-cell dysfunction in GDM. This has also been 
shown in obesity where both hyper-leptinemia and leptin resistance can impair GSIS and 
β-cell proliferation [215,216].  In contrast to leptin, adiponectin has been shown to 
increase β-cell proliferation in mouse islets [217] and was thus, unsurprisingly, shown to 
influence adaptive BCM expansion in pregnancy. Qiao et al. found that pregnant mice 
with an adiponectin gene knockout had reduced BCM and developed glucose intolerance 
in pregnancy [218]. Interestingly, the deficiencies were reversed with adiponectin 
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reconstitution and may be mediated by protection of β-cells against lipotoxic damage 
[219]. Importantly, hypoadiponectinemia was found and associated with β-cell 
dysfunction in women with GDM [220]. Collectively these studies implicate 
inflammation to play a role in dysfunctional β-cell properties in GDM. 
Pancreatic β-cell dysfunction can also occur due to oxidative stress, which can be induced 
in part by chronic hyperglycemia [221]. GDM is also characterized by hyperlipidemia 
[222] and in the context of β-cell biology, pancreatic β-cells are susceptible to 
lipotoxicity-induced β-cell dysfunction. Thus, both lipotoxicity and glucotoxicity are 
contributors to β-cell dysfunction in GDM by causing a buildup of oxidative stress which 
impairs insulin production and can result in β-cell apoptosis [223]. 
In conclusion, β-cell dysfunction is one of the key determinants of GDM pathogenesis. 
Although two studies have looked at β-cells in pregnant humans [96,166], no studies 
have examined pancreas histology in GDM pregnancies due to lack of human samples 
and imaging modalities available for in vivo examination [224]. Thus, we highly rely on 
animal models of diabetes in pregnancy to advance our understanding of mechanisms of 
reduced β-cell adaptability.  
1.7  Animal Models of Diabetes in Pregnancy  
There are many risk factors for the development of GDM such as being 35 years of age 
or older or from a high-risk group (Asian, Indigenous, African, Hispanic), in addition to 
having obesity and GDM in a previous pregnancy [197]. These many factors make it 
difficult to accurately reproduce the heterogenous pathogenesis of GDM. Nonetheless, 
many attempts have been made using various approaches that have been reviewed 
elsewhere [224,225] but will be briefly introduced here. These include: pharmacological, 
surgical, genetic, and nutritional manipulations. 
Pharmacological 
One example of a pharmacologically-induced approach for modeling diabetes in 
pregnancy is via STZ-mediated β-cell ablation which can be utilized to portray mild or 
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severe hyperglycemia depending on the dosage/timing of administration [225]. An 
advantage of this model is that β-cell destruction can occur rapidly. However, many of 
these models show severe hyperglycemia which is rarely seen in humans as GDM usually 
presents as a mild glucose intolerance [224]. Furthermore, the rapid insult does not 
present true GDM pathogenesis which occurs gradually. An additional limitation is that 
permanent β-cell destruction and diabetes often remain after pregnancy, which usually 
does not occur in GDM as symptoms tend to reverse in most women after delivery. 
Importantly, the β-cell destruction in this model better resembles insulin deficiency and 
can be described as being more similar to T1DM rather than the progressive insulin 
resistance and β-cell deficiency that develops during GDM. 
Surgical 
As discussed in section 1.4.1, one type of surgical manipulation that results in removal of 
β-cells and has been used to model GDM is partial pancreatectomy. Nonetheless, results 
in these studies have produced inconsistent findings [224]. Furthermore, this complex 
technique can result in diabetes onset that can take long to manifest. Importantly, GDM 
does not occur due to a sudden insult and similarly to the pharmacological manipulation, 
the GDM phenotype described here better resembles T1DM. 
Genetic 
The db/db mouse is characterized by a mutation in the leptin receptor gene and is used for 
studying obesity [226]. Although homozygous females (db/db) are sterile, heterozygotes 
are fertile and importantly non-pregnant females do not show glucose intolerance 
[227,228]. During pregnancy, females display increased adiposity contributing to insulin 
resistance and mild glucose intolerance [228,229]. Thus, this model accurately mimics 
many features of human GDM. Although obesity is a major driver of GDM, some 
features of this model better resemble the increased adiposity that is observed in some 
cases with T2DM. It is important to consider that non-obese individuals develop GDM as 
well, thus implicating dysfunction at the level of the β-cell rather than due to obesity 
alone. Furthermore, the use of genetic models is limited for translational use in larger 
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animal models and simplifies the human condition as GDM is influenced by many genes 
and environmental factors [224]. 
Nutritional 
Animal models using high-fat diet (HFD) feeding have been used to mimic GDM 
symptoms where HFD feeding before and during pregnancy results in a GDM phenotype 
by late gestation in rats [230]. Experiments in mice have reproduced these findings 
showing that HFD feeding prior to and throughout gestation results in elevated blood 
glucose and insulin levels during pregnancy [231]. However, the phenotype was present 
prior to pregnancy in these experiments and thus does not accurately represent the human 
phenotype. This method has several advantages to modeling the disease, since obesity is 
a major driver of GDM in humans, and permits for study in larger animals where genetic 
manipulation is unfeasible [224]. Nonetheless, similarly to the db/db mice, this phenotype 
better resembles the T2DM condition as the animals show increased adiposity and insulin 
resistance. Therefore, existing pre-gestational diabetes/obesity is more likely driving the 
disease in this model which does not take into consideration that lean women also 
develop GDM. 
 
Although each model presents both advantages and limitations, an important concept of 
GDM pathogenesis that each model lacks is the progressive development of transient 
hyperglycemia during pregnancy that is restricted to late gestation and reverts after 
pregnancy. Thus, continued efforts to produce an accurate model of GDM characterized 
by defects in β-cell adaptability with restricted hyperglycemia to late pregnancy are 
needed in order to be able to implement novel methods of intervention. One animal 
model that has been well-characterized and shown to impact β-cell plasticity is the low 
protein model of fetal programming. 
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1.8  Low Protein Model  
The hypothesis of fetal programming of adult diseases first formulated by Professor Sir 
David Barker proposes that the intrauterine environment during development can 
influence the risk of metabolic diseases later in life in the offspring [232]. More 
specifically, nutrient availability during fetal and early postnatal life plays an important 
role in determining adult health. Metabolic disturbances during these critical 
developmental timepoints, such as dietary restriction, contribute to the development of 
adult chronic diseases such as T2DM, obesity, and cardiovascular disease [233]. After the 
hypothesis was formulated, Snoeck and colleagues demonstrated that a low protein (LP) 
diet during gestation in rats (in comparison to a control, C, diet) resulted in reduced birth 
weight (intra-uterine growth restricted, IUGR) offspring [234]. The LP diet was made 
isocaloric to the C diet via increased carbohydrate. IUGR is described as the failure of a 
fetus to achieve its genetic potential for size which in clinical terms would be below the 
10th percentile for gestational age [235]. When the dams were maintained on a LP diet 
during lactation, body weight of offspring was reduced until weaning [236]. IUGR affects 
the development of multiple organs, including the pancreas [236,237]. Using the 
established model of dietary protein restriction during pregnancy and lactation, it has 
been extensively published that dietary insufficiency in early life alters normal pancreatic 
development in the offspring, which ultimately contributes to impaired glucose 
homeostasis in adulthood. We found that maternal protein restriction altered cell-cycle 
kinetics in offspring by increasing the incidence of β-cell apoptosis and decreasing the 
proliferative rate of β-cells, ultimately resulting in a reduced BCM [236,238,239]. 
Although offspring of LP-fed dams displayed impaired GSIS, glucose intolerance did not 
manifest until 130 days of age in female rats [240,241]. In females, glucose intolerance 
was attributed to decreased BCM. Interestingly, the males in this study displayed insulin 
resistance in adipose and skeletal muscle in contrast to the reduced BCM observed in 
females. These findings have also been supported in additional larger animal IUGR 
models, as in sheep decreased β-cell replication was also shown to result in reduced 
BCM, in addition to β-cell dysfunction, leading to decreased GSIS [242–244]. 
Furthermore, IUGR human fetuses have also been shown to have decreased BCM [245]. 
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More recently, β-cell plasticity was examined in mice treated with LP and STZ [246]. 
The results showed that control fed offspring had largely regenerated their β-cells and 
replaced BCM after STZ, since young mice normally show a regenerative capability 
following β-cell loss. Nonetheless, LP exposure limited the capacity for recovery of BCM 
in both males and females after STZ treatment. In the same study, there was a delayed 
ability to increase α-cell mass (ACM) implying that mechanisms involved might be 
common to multiple endocrine cell types. In addition to histological and functional 
differences in endocrine cells, pancreatic vascularity and signaling between β-cells and 
endothelial cells has been shown to play a role in β-cell dysfunction of IUGR fetuses. 
Lower pancreatic islet vascularity has been observed in IUGR humans [245] and animal 
models of IUGR [247,248]. Importantly, islet size and GSIS was limited by vascular 
supply [248,249]. Furthermore, expression of angiogenic factor vascular endothelial 
growth factor A (VEGFA) was decreased in LP rats [234,236]. VEGFA is important in 
islet development and β-cell function. Proof of concept studies showed that gestational 
taurine supplementation in the LP rat prevented the decrease in fetal islet vascularity and 
VEGFA expression [237]. β-cell apoptosis was also attenuated in taurine-supplemented 
LP rats compared to non-supplemented, resulting in higher BCM [250].  
 
Collectively these studies demonstrate strong evidence for impaired β-cell development 
and plasticity after exposure to the LP diet during development, which is potentially 
reversible.  
 
1.8.1.  Relevance to Humans  
One model that represents the effects of famine on fetal development is the calorie 
restriction model. However, the effects of famine on fetal development are of lesser 
concern in North America. In contrast, the LP model shares common features to human 
placental insufficiency. Placental insufficiency is a major cause of IUGR in North 
America and complicates 4-8% of pregnancies [251]. Similar to the LP diet model, 
placental insufficiency in humans can produce a protein deficiency in the fetus [252]. 
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Since placental insufficiency results in both decreased oxygen and nutrient delivery, the 
LP model permits for differentiation of the specific effects of amino acid deficiency 
[252]. Importantly, the LP diet has no major effects on maternal physiology (including 
maternal food intake and weight gain) and no effect on offspring food intake [253]. These 
findings are important as altered food intake in the mother could add confounding 
variables to the model and is in contrast to the caloric restriction model which adversely 
affects both maternal and fetal physiology. 
 
 
1.9  Rationale, Objectives, Hypothesis  
Rationale 
GDM seriously impacts the short and long-term health of both the mother and her child. 
Unfortunately, there is a lack of effective methods for prevention/treatment to reverse β-
cell insufficiency in GDM. Given that rates of GDM are increasing, and the in utero 
environment is an important determinant of adult health, it is important to investigate the 
underlying mechanisms of GDM. The mechanisms leading to GDM are poorly 
understood and β-cells of pregnant humans with GDM have yet to be analysed. 
Furthermore, changes in endocrine pancreas of humans with GDM cannot be viewed in 
vivo due to lack of imaging modalities available at present for pregnant humans. 
However, the reliance on animal models is hindered as models that accurately represent 
symptoms of GDM are currently lacking. These models present multiple limitations such 
as demonstrating pre-gestational glucose intolerance and obesity which is not a true 
diagnosis of clinical GDM, while others better resemble T1DM or T2DM pathogenesis as 
opposed to the characteristics of insulin resistance seen in conditions such as GDM. 
Furthermore, these models importantly lack the transient hyperglycemia that is diagnosed 
at late gestation. Given that β-cell dysfunction is a key determinant to GDM 
pathogenesis, a better model characterized by impairments of reduced β-cell adaptability 
is needed so that targeted methods of intervention can be implemented. The LP model 
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has been well-characterized, and much evidence supports altered pancreatic β-cell 
development. However, no studies have investigated the plasticity of β-cells during a 
subsequent time of increased metabolic stress, such as pregnancy. Thus, we sought to use 
this model in an attempt to produce an animal model of reduced β-cell adaptability in 
pregnancy that can be used to better understand β-cell insufficiency in GDM. 
Hypothesis 
It is hypothesized that exposure to LP diet during fetal and neonatal development will 
impair β-cell adaptability in pregnant F1 females. This will result in glucose intolerance 
during pregnancy, which can be reversed with treatment. 
Objectives 
1. Establish a mouse model of impaired glucose tolerance during pregnancy  
2. Determine the long-term effects of GDM on glucose tolerance and pancreas 
histology after pregnancy 
3. Investigate the contribution of α- to β-cell transdifferentiation to gestational BCM 
expansion 
4. Test strategies to improve glucose tolerance in pregnancy through the 
manipulation of BCM 
 
 
 
 
 
 
 
 
 
 
49 
1.10  References  
 
[1] WHO | The top 10 causes of death, WHO. (2017). 
[2] The Emerging Risk Factors Collaboration, N. Sarwar, P. Gao, S.R.K. Seshasai, R. 
Gobin, S. Kaptoge, E. Di Angelantonio, E. Ingelsson, D.A. Lawlor, E. Selvin, M. 
Stampfer, C.D.A. Stehouwer, S. Lewington, L. Pennells, A. Thompson, N. Sattar, 
I.R. White, K.K. Ray, J. Danesh, Diabetes mellitus, fasting blood glucose 
concentration, and risk of vascular disease: a collaborative meta-analysis of 102 
prospective studies, Lancet. 375 (2010) 2215–2222. 
https://doi.org/10.1016/S0140-6736(10)60484-9. 
[3] R. Saran, Y. Li, B. Robinson, J. Ayanian, R. Balkrishnan, J. Bragg-Gresham, 
J.T.L. Chen, E. Cope, D. Gipson, K. He, W. Herman, M. Heung, R.A. Hirth, S.S. 
Jacobsen, K. Kalantar-Zadeh, C.P. Kovesdy, A.B. Leichtman, Y. Lu, M.Z. Molnar, 
H. Morgenstern, B. Nallamothu, A.M. O’Hare, R. Pisoni, B. Plattner, F.K. Port, P. 
Rao, C.M. Rhee, D.E. Schaubel, D.T. Selewski, V. Shahinian, J.J. Sim, P. Song, E. 
Streja, M. Kurella Tamura, F. Tentori, P.W. Eggers, L.Y.C. Agodoa, K.C. Abbott, 
US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney 
Disease in the United States, Am. J. Kidney Dis. 66 (2015) A7. 
https://doi.org/10.1053/j.ajkd.2015.05.001. 
[4] R.R.A. Bourne, G.A. Stevens, R.A. White, J.L. Smith, S.R. Flaxman, H. Price, J.B. 
Jonas, J. Keeffe, J. Leasher, K. Naidoo, K. Pesudovs, S. Resnikoff, H.R. Taylor, 
Vision Loss Expert Group, Causes of vision loss worldwide, 1990–2010: a 
systematic analysis, Lancet Glob. Heal. 1 (2013) e339–e349. 
https://doi.org/10.1016/S2214-109X(13)70113-X. 
[5] P. Rorsman, M. Braun, Regulation of Insulin Secretion in Human Pancreatic Islets, 
Annu. Rev. Physiol. 75 (2013) 155–179. https://doi.org/10.1146/annurev-physiol-
030212-183754. 
[6] F.G. Banting, C.H. Best, J.B. Collip, W.R. Campbell, A.A. Fletcher, Pancreatic 
Extracts in the Treatment of Diabetes Mellitus., Can. Med. Assoc. J. 12 (1922) 
141–146. 
[7] L. Szablewski, Role of immune system in type 1 diabetes mellitus pathogenesis, 
 
 
50 
Int. Immunopharmacol. 22 (2014) 182–191. 
https://doi.org/10.1016/j.intimp.2014.06.033. 
[8] A.M.J. Shapiro, C. Ricordi, B.J. Hering, H. Auchincloss, R. Lindblad, R.P. 
Robertson, A. Secchi, M.D. Brendel, T. Berney, D.C. Brennan, E. Cagliero, R. 
Alejandro, E.A. Ryan, B. DiMercurio, P. Morel, K.S. Polonsky, J.-A. Reems, R.G. 
Bretzel, F. Bertuzzi, T. Froud, R. Kandaswamy, D.E.R. Sutherland, G. Eisenbarth, 
M. Segal, J. Preiksaitis, G.S. Korbutt, F.B. Barton, L. Viviano, V. Seyfert-
Margolis, J. Bluestone, J.R.T. Lakey, International Trial of the Edmonton Protocol 
for Islet Transplantation, N. Engl. J. Med. 355 (2006) 1318–1330. 
https://doi.org/10.1056/NEJMoa061267. 
[9] M.A. Atkinson, G.S. Eisenbarth, A.W. Michels, Type 1 diabetes., Lancet (London, 
England). 383 (2014) 69–82. https://doi.org/10.1016/S0140-6736(13)60591-7. 
[10] C.J. Nolan, P. Damm, M. Prentki, Type 2 diabetes across generations: from 
pathophysiology to prevention and management, Lancet. 378 (2011) 169–181. 
https://doi.org/10.1016/S0140-6736(11)60614-4. 
[11] S. Seino, T. Shibasaki, K. Minami, Dynamics of insulin secretion and the clinical 
implications for obesity and diabetes., J. Clin. Invest. 121 (2011) 2118–2125. 
https://doi.org/10.1172/JCI45680. 
[12] E.T. Kato, S.R. Das, D.K. McGuire, Antihyperglycemic therapies and 
cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art 
and future directions, Trends Cardiovasc. Med. (2020). 
https://doi.org/10.1016/j.tcm.2019.12.010. 
[13] K. Ogurtsova, J.D. da Rocha Fernandes, Y. Huang, U. Linnenkamp, L. Guariguata, 
N.H. Cho, D. Cavan, J.E. Shaw, L.E. Makaroff, IDF Diabetes Atlas: Global 
estimates for the prevalence of diabetes for 2015 and 2040, Diabetes Res. Clin. 
Pract. 128 (2017) 40–50. https://doi.org/10.1016/j.diabres.2017.03.024. 
[14] Betts GJ, Desaix P, Johnson E, Korol O, Kruse D, Poe B et al. Human Anatomy 
and Physiology. OpenStax College: Houston, TX, USA, 2013. 
[15] H. Ohlsson, K. Karlsson, T. Edlund, IPF1, a homeodomain-containing 
transactivator of the insulin gene., EMBO J. 12 (1993) 4251–4259. 
[16] H. Kaneto, T. Miyatsuka, D. Kawamori, K. Yamamoto, K. Kato, T. Shiraiwa, N. 
 
 
51 
Katakami, Y. Yamasaki, M. Matsuhisa, T.-A. Matsuoka, PDX-1 and MafA play a 
crucial role in pancreatic beta-cell differentiation and maintenance of mature beta-
cell function., Endocr. J. 55 (2008) 235–252. 
[17] D.A. Stoffers, R.S. Heller, C.P. Miller, J.F. Habener, Developmental expression of 
the homeodomain protein IDX-1 in mice transgenic for an IDX-1 promoter/lacZ 
transcriptional reporter., Endocrinology. 140 (1999) 5374–5381. 
https://doi.org/10.1210/endo.140.11.7122. 
[18] A. Krapp, M. Knofler, B. Ledermann, K. Burki, C. Berney, N. Zoerkler, O. 
Hagenbuchle, P.K. Wellauer, The bHLH protein PTF1-p48 is essential for the 
formation of the exocrine and the correct spatial organization of the endocrine 
pancreas, Genes Dev. 12 (1998) 3752–3763. 
https://doi.org/10.1101/gad.12.23.3752. 
[19] A. Bastidas-Ponce, K. Scheibner, H. Lickert, M. Bakhti, Cellular and molecular 
mechanisms coordinating pancreas development, Development. 144 (2017) 2873–
2888. https://doi.org/10.1242/dev.140756. 
[20] M.F. Offield, T.L. Jetton, P.A. Labosky, M. Ray, R.W. Stein, M.A. Magnuson, 
B.L. Hogan, C. V Wright, PDX-1 is required for pancreatic outgrowth and 
differentiation of the rostral duodenum., Development. 122 (1996) 983–995. 
[21] J.F. Habener, D.M. Kemp, M.K. Thomas, Minireview: Transcriptional Regulation 
in Pancreatic Development, Endocrinology. 146 (2005) 1025–1034. 
https://doi.org/10.1210/en.2004-1576. 
[22] M. Sander, M.S. German, The β cell transcription factors and development of the 
pancreas, J. Mol. Med. 75 (1997) 327–340. 
https://doi.org/10.1007/s001090050118. 
[23] F.C. Pan, E.D. Bankaitis, D. Boyer, X. Xu, M. Van de Casteele, M.A. Magnuson, 
H. Heimberg, C.V.E. Wright, Spatiotemporal patterns of multipotentiality in Ptf1a-
expressing cells during pancreas organogenesis and injury-induced facultative 
restoration, Development. 140 (2013) 751–764. 
https://doi.org/10.1242/dev.090159. 
[24] A.E. Schaffer, K.K. Freude, S.B. Nelson, M. Sander, Nkx6 transcription factors 
and Ptf1a function as antagonistic lineage determinants in multipotent pancreatic 
 
 
52 
progenitors., Dev. Cell. 18 (2010) 1022–1029. 
https://doi.org/10.1016/j.devcel.2010.05.015. 
[25] A. Grapin-Botton, A.R. Majithia, D.A. Melton, Key events of pancreas formation 
are triggered in gut endoderm by ectopic expression of pancreatic regulatory 
genes., Genes Dev. 15 (2001) 444–454. https://doi.org/10.1101/gad.846001. 
[26] G. Gradwohl, A. Dierich, M. LeMeur, F. Guillemot, neurogenin3 is required for 
the development of the four endocrine cell lineages of the pancreas, Proc. Natl. 
Acad. Sci. 97 (2000) 1607–1611. https://doi.org/10.1073/pnas.97.4.1607. 
[27] T.G. Sanders, W.J. Rutter, The developmental regulation of amylolytic and 
proteolytic enzymes in the embryonic rat pancreas., J. Biol. Chem. 249 (1974) 
3500–3509. 
[28] J. Dolenšek, M.S. Rupnik, A. Stožer, Structural similarities and differences 
between the human and the mouse pancreas, Islets. 7 (2015) e1024405. 
https://doi.org/10.1080/19382014.2015.1024405. 
[29] B. Svendsen, O. Larsen, M.B.N. Gabe, C.B. Christiansen, M.M. Rosenkilde, D.J. 
Drucker, J.J. Holst, Insulin Secretion Depends on Intra-islet Glucagon Signaling, 
Cell Rep. 25 (2018) 1127-1134.e2. https://doi.org/10.1016/j.celrep.2018.10.018. 
[30] R. Rodriguez-Diaz, R.D. Molano, J.R. Weitz, M.H. Abdulreda, D.M. Berman, B. 
Leibiger, I.B. Leibiger, N.S. Kenyon, C. Ricordi, A. Pileggi, A. Caicedo, P.-O. 
Berggren, Paracrine Interactions within the Pancreatic Islet Determine the 
Glycemic Set Point, Cell Metab. 27 (2018) 549-558.e4. 
https://doi.org/10.1016/J.CMET.2018.01.015. 
[31] I. Artner, Y. Hang, M. Mazur, T. Yamamoto, M. Guo, J. Lindner, M.A. 
Magnuson, R. Stein, MafA and MafB regulate genes critical to beta-cells in a 
unique temporal manner., Diabetes. 59 (2010) 2530–2539. 
https://doi.org/10.2337/db10-0190. 
[32] L.C. Murtaugh, Pancreas and beta-cell development: from the actual to the 
possible, Development. 134 (2006) 427–438. https://doi.org/10.1242/dev.02770. 
[33] M.D. Gahete, J. Cordoba-Chacón, M. Duran-Prado, M.M. Malagón, A.J. 
Martinez-Fuentes, F. Gracia-Navarro, R.M. Luque, J.P. Castaño, Somatostatin and 
its receptors from fish to mammals, Ann. N. Y. Acad. Sci. 1200 (2010) 43–52. 
 
 
53 
https://doi.org/10.1111/j.1749-6632.2010.05511.x. 
[34] M.R. DiGruccio, A.M. Mawla, C.J. Donaldson, G.M. Noguchi, J. Vaughan, C. 
Cowing-Zitron, T. van der Meulen, M.O. Huising, Comprehensive alpha, beta and 
delta cell transcriptomes reveal that ghrelin selectively activates delta cells and 
promotes somatostatin release from pancreatic islets., Mol. Metab. 5 (2016) 449–
458. https://doi.org/10.1016/j.molmet.2016.04.007. 
[35] P. Rorsman, M.O. Huising, The somatostatin-secreting pancreatic δ-cell in health 
and disease., Nat. Rev. Endocrinol. 14 (2018) 404–414. 
https://doi.org/10.1038/s41574-018-0020-6. 
[36] R. Arrojo e Drigo, S. Jacob, C.F. García-Prieto, X. Zheng, M. Fukuda, H.T.T. 
Nhu, O. Stelmashenko, F.L.M. Peçanha, R. Rodriguez-Diaz, E. Bushong, T. 
Deerinck, S. Phan, Y. Ali, I. Leibiger, M. Chua, T. Boudier, S.-H. Song, M. Graf, 
G.J. Augustine, M.H. Ellisman, P.-O. Berggren, Structural basis for delta cell 
paracrine regulation in pancreatic islets, Nat. Commun. 10 (2019) 3700. 
https://doi.org/10.1038/s41467-019-11517-x. 
[37] R.A. Liddle, Regulation of Pancreatic Secretion, Physiol. Gastrointest. Tract. 
(2018) 895–929. https://doi.org/10.1016/B978-0-12-809954-4.00040-2. 
[38] A. Kastin, Handbook of Biologically Active Peptides, 2013. 
https://doi.org/10.1016/C2010-0-66490-X. 
[39] L. Scaglia, C.J. Cahill, D.T. Finegood, S. Bonner-Weir, Apoptosis participates in 
the remodeling of the endocrine pancreas in the neonatal rat., Endocrinology. 138 
(1997) 1736–1741. https://doi.org/10.1210/endo.138.4.5069. 
[40] J. Petrik, E. Arany, T.J. McDonald, D.J. Hill, Apoptosis in the pancreatic islet cells 
of the neonatal rat is associated with a reduced expression of insulin-like growth 
factor II that may act as a survival factor., Endocrinology. 139 (1998) 2994–3004. 
https://doi.org/10.1210/endo.139.6.6042. 
[41] S. Bonner-Weir, C. Aguayo-Mazzucato, G.C. Weir, Dynamic development of the 
pancreas from birth to adulthood., Ups. J. Med. Sci. 121 (2016) 155–158. 
https://doi.org/10.3109/03009734.2016.1154906. 
[42] D.T. Finegood, L. Scaglia, S. Bonner-Weir, Dynamics of beta-cell mass in the 
growing rat pancreas. Estimation with a simple mathematical model., Diabetes. 44 
 
 
54 
(1995) 249–256. 
[43] S. Perl, J.A. Kushner, B.A. Buchholz, A.K. Meeker, G.M. Stein, M. Hsieh, M. 
Kirby, S. Pechhold, E.H. Liu, D.M. Harlan, J.F. Tisdale, Significant human beta-
cell turnover is limited to the first three decades of life as determined by in vivo 
thymidine analog incorporation and radiocarbon dating., J. Clin. Endocrinol. 
Metab. 95 (2010) E234-9. https://doi.org/10.1210/jc.2010-0932. 
[44] J.J. Meier, A.E. Butler, Y. Saisho, T. Monchamp, R. Galasso, A. Bhushan, R.A. 
Rizza, P.C. Butler, Beta-cell replication is the primary mechanism subserving the 
postnatal expansion of beta-cell mass in humans., Diabetes. 57 (2008) 1584–1594. 
https://doi.org/10.2337/db07-1369. 
[45] L. Bouwens, D.G. Pipeleers, Extra-insular beta cells associated with ductules are 
frequent in adult human pancreas., Diabetologia. 41 (1998) 629–633. 
https://doi.org/10.1007/s001250050960. 
[46] S. Bonner-Weir, beta-cell turnover: its assessment and implications., Diabetes. 50 
Suppl 1 (2001) S20-24. 
[47] B. Thorens, GLUT2, glucose sensing and glucose homeostasis, Diabetologia. 58 
(2015) 221–232. https://doi.org/10.1007/s00125-014-3451-1. 
[48] A. De Vos, H. Heimberg, E. Quartier, P. Huypens, L. Bouwens, D. Pipeleers, F. 
Schuit, Human and rat beta cells differ in glucose transporter but not in 
glucokinase gene expression., J. Clin. Invest. 96 (1995) 2489–2495. 
https://doi.org/10.1172/JCI118308. 
[49] L.J. McCulloch, M. van de Bunt, M. Braun, K.N. Frayn, A. Clark, A.L. Gloyn, 
GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic 
beta cells: Implications for understanding genetic association signals at this locus, 
Mol. Genet. Metab. 104 (2011) 648–653. 
https://doi.org/10.1016/j.ymgme.2011.08.026. 
[50] F.W. Pagliuca, D.A. Melton, S. Kato, J.P. Thiery, P. Czernichow, S. Bellusci, R. 
Scharfmann, How to make a functional β-cell., Development. 140 (2013) 2472–
2483. https://doi.org/10.1242/dev.093187. 
[51] F.M. Ashcroft, ATP-sensitive potassium channelopathies: focus on insulin 
secretion, J. Clin. Invest. 115 (2005) 2047–2058. 
 
 
55 
https://doi.org/10.1172/JCI25495. 
[52] D.R. Matthews, B.A. Naylor, R.G. Jones, G.M. Ward, R.C. Turner, Pulsatile 
Insulin Has Greater Hypoglycemic Effect Than Continuous Delivery, Diabetes. 32 
(1983) 617–621. https://doi.org/10.2337/diab.32.7.617. 
[53] P. Gilon, M.A. Ravier, J.-C. Jonas, J.-C. Henquin, Control Mechanisms of the 
Oscillations of Insulin Secretion In Vitro and In Vivo, Diabetes. 51 (2002) S144–
S151. https://doi.org/10.2337/diabetes.51.2007.S144. 
[54] S.N. Davis, P.M. Piatti, L. Monti, M.D. Brown, W. Branch, C.N. Hales, K.G.M.M. 
Alberti, Proinsulin and insulin concentrations following intravenous glucose 
challenges in normal, obese, and non-insulin-dependent diabetic subjects, 
Metabolism. 42 (1993) 30–35. https://doi.org/10.1016/0026-0495(93)90168-N. 
[55] R.A. Haeusler, T.E. McGraw, D. Accili, Biochemical and cellular properties of 
insulin receptor signalling, Nat. Rev. Mol. Cell Biol. 19 (2018) 31–44. 
https://doi.org/10.1038/nrm.2017.89. 
[56] M. Teta, S.Y. Long, L.M. Wartschow, M.M. Rankin, J.A. Kushner, Very Slow 
Turnover of Beta-Cells in Aged Adult Mice, Diabetes. 54 (2005) 2557–2567. 
https://doi.org/10.2337/diabetes.54.9.2557. 
[57] J.S. Brockenbrough, G.C. Weir, S. Bonner-Weir, Discordance of Exocrine and 
Endocrine Growth After 90% Pancreatectomy in Rats, Diabetes. 37 (1988) 232–
236. https://doi.org/10.2337/diab.37.2.232. 
[58] H.C. Lee, S. Bonner-Weir, G.C. Weir, J.L. Leahy, Compensatory Adaption to 
Partial Pancreatectomy in the Rat, Endocrinology. 124 (1989) 1571–1575. 
https://doi.org/10.1210/endo-124-3-1571. 
[59] S. Bonner-Weir, D.F. Trent, G.C. Weir, Partial pancreatectomy in the rat and 
subsequent defect in glucose-induced insulin release., J. Clin. Invest. 71 (1983) 
1544–1553. https://doi.org/10.1172/JCI110910. 
[60] Y. Dor, J. Brown, O.I. Martinez, D.A. Melton, Adult pancreatic beta-cells are 
formed by self-duplication rather than stem-cell differentiation., Nature. 429 
(2004) 41–46. https://doi.org/10.1038/nature02520. 
[61] K.Y. Hayashi, H. Tamaki, K. Handa, T. Takahashi, A. Kakita, S. Yamashina, 
Differentiation and proliferation of endocrine cells in the regenerating rat pancreas 
 
 
56 
after 90% pancreatectomy, Arch. Histol. Cytol. 66 (2003) 163–174. 
https://doi.org/10.1679/aohc.66.163. 
[62] T. Berrocal, A.Á. Luque, I. Pinilla, L. Lassaletta, Pancreatic regeneration after 
near-total pancreatectomy in children with nesidioblastosis, Pediatr. Radiol. 35 
(2005) 1066–1070. https://doi.org/10.1007/s00247-005-1537-0. 
[63] A. Inada, C. Nienaber, H. Katsuta, Y. Fujitani, J. Levine, R. Morita, A. Sharma, S. 
Bonner-Weir, Carbonic anhydrase II-positive pancreatic cells are progenitors for 
both endocrine and exocrine pancreas after birth., Proc. Natl. Acad. Sci. U. S. A. 
105 (2008) 19915–19919. https://doi.org/10.1073/pnas.0805803105. 
[64] X. Xu, J. D’Hoker, G. Stangé, S. Bonné, N. De Leu, X. Xiao, M. Van De Casteele, 
G. Mellitzer, Z. Ling, D. Pipeleers, L. Bouwens, R. Scharfmann, G. Gradwohl, H. 
Heimberg, β Cells Can Be Generated from Endogenous Progenitors in Injured 
Adult Mouse Pancreas, Cell. 132 (2008) 197–207. 
https://doi.org/10.1016/j.cell.2007.12.015. 
[65] K. Furuyama, Y. Kawaguchi, H. Akiyama, M. Horiguchi, S. Kodama, T. Kuhara, 
S. Hosokawa, A. Elbahrawy, T. Soeda, M. Koizumi, T. Masui, M. Kawaguchi, K. 
Takaori, R. Doi, E. Nishi, R. Kakinoki, J.M. Deng, R.R. Behringer, T. Nakamura, 
S. Uemoto, Continuous cell supply from a Sox9-expressing progenitor zone in 
adult liver, exocrine pancreas and intestine, Nat. Genet. 43 (2011) 34–41. 
https://doi.org/10.1038/ng.722. 
[66] M. Solar, C. Cardalda, I. Houbracken, M. Martín, M.A. Maestro, N. De Medts, X. 
Xu, V. Grau, H. Heimberg, L. Bouwens, J. Ferrer, Pancreatic Exocrine Duct Cells 
Give Rise to Insulin-Producing β Cells during Embryogenesis but Not after Birth, 
Dev. Cell. 17 (2009) 849–860. https://doi.org/10.1016/j.devcel.2009.11.003. 
[67] J.L. Kopp, C.L. Dubois, A.E. Schaffer, E. Hao, H.P. Shih, P.A. Seymour, J. Ma, 
M. Sander, Sox9+ ductal cells are multipotent progenitors throughout development 
but do not produce new endocrine cells in the normal or injured adult pancreas, 
Development. 138 (2011) 653–665. https://doi.org/10.1242/dev.056499. 
[68] T. Nir, D.A. Melton, Y. Dor, Recovery from diabetes in mice by β cell 
regeneration, J. Clin. Invest. 117 (2007) 2553–2561. 
https://doi.org/10.1172/JCI32959. 
 
 
57 
[69] F. Shamsi, R. Parlato, P. Collombat, A. Mansouri, A genetic mouse model for 
progressive ablation and regeneration of insulin producing beta-cells, Cell Cycle. 
13 (2014) 3948–3957. https://doi.org/10.4161/15384101.2014.952176. 
[70] V. Cigliola, F. Thorel, S. Chera, P.L. Herrera, Stress-induced adaptive islet cell 
identity changes, Diabetes, Obes. Metab. 18 (2016) 87–96. 
https://doi.org/10.1111/dom.12726. 
[71] F. Zhong, Y. Jiang, Endogenous Pancreatic β Cell Regeneration: A Potential 
Strategy for the Recovery of β Cell Deficiency in Diabetes., Front. Endocrinol. 
(Lausanne). 10 (2019) 101. https://doi.org/10.3389/fendo.2019.00101. 
[72] M. Kataoka, Y. Kawamuro, N. Shiraki, R. Miki, D. Sakano, T. Yoshida, T. 
Yasukawa, K. Kume, S. Kume, Recovery from diabetes in neonatal mice after a 
low-dose streptozotocin treatment, Biochem. Biophys. Res. Commun. 430 (2013) 
1103–1108. https://doi.org/10.1016/j.bbrc.2012.12.030. 
[73] R.N. Wang, L. Bouwens, G. Klöppel, Beta-cell proliferation in normal and 
streptozotocin-treated newborn rats: site, dynamics and capacity., Diabetologia. 37 
(1994) 1088–1096. https://doi.org/10.1007/bf00418372. 
[74] R. De Haro-Hernández, L. Cabrera-Muñoz, J.D. Méndez, Regeneration of beta-
cells and neogenesis from small ducts or acinar cells promote recovery of 
endocrine pancreatic function in alloxan-treated rats., Arch. Med. Res. 35 (2004) 
114–120. https://doi.org/10.1016/j.arcmed.2003.10.001. 
[75] S. Thyssen, E. Arany, D.J. Hill, Ontogeny of Regeneration of β-Cells in the 
Neonatal Rat after Treatment with Streptozotocin, Endocrinology. 147 (2006) 
2346–2356. https://doi.org/10.1210/en.2005-0396. 
[76] R. V Intine, A.S. Olsen, M.P. Sarras, Jr., A zebrafish model of diabetes mellitus 
and metabolic memory., J. Vis. Exp. (2013) e50232. 
https://doi.org/10.3791/50232. 
[77] H. Liu, Y. Guz, M.H. Kedees, J. Winkler, G. Teitelman, Precursor cells in mouse 
islets generate new beta-cells in vivo during aging and after islet injury., 
Endocrinology. 151 (2010) 520–528. https://doi.org/10.1210/en.2009-0992. 
[78] M. Cnop, M. Igoillo-Esteve, S.J. Hughes, J.N. Walker, I. Cnop, A. Clark, 
Longevity of human islet α- and β-cells, Diabetes, Obes. Metab. 13 (2011) 39–46. 
 
 
58 
https://doi.org/10.1111/j.1463-1326.2011.01443.x. 
[79] M. Cnop, S.J. Hughes, M. Igoillo-Esteve, M.B. Hoppa, F. Sayyed, L. van de Laar, 
J.H. Gunter, E.J.P. de Koning, G. V. Walls, D.W.G. Gray, P.R. V. Johnson, B.C. 
Hansen, J.F. Morris, M. Pipeleers-Marichal, I. Cnop, A. Clark, The long lifespan 
and low turnover of human islet beta cells estimated by mathematical modelling of 
lipofuscin accumulation, Diabetologia. 53 (2010) 321–330. 
https://doi.org/10.1007/s00125-009-1562-x. 
[80] Y. Saisho, A.E. Butler, E. Manesso, D. Elashoff, R.A. Rizza, P.C. Butler, β-cell 
mass and turnover in humans: effects of obesity and aging., Diabetes Care. 36 
(2013) 111–117. https://doi.org/10.2337/dc12-0421. 
[81] J. Krishnamurthy, M.R. Ramsey, K.L. Ligon, C. Torrice, A. Koh, S. Bonner-Weir, 
N.E. Sharpless, p16INK4a induces an age-dependent decline in islet regenerative 
potential, Nature. 443 (2006) 453–457. https://doi.org/10.1038/nature05092. 
[82] H. Chen, X. Gu, I. Su, R. Bottino, J.L. Contreras, A. Tarakhovsky, S.K. Kim, 
Polycomb protein Ezh2 regulates pancreatic Beta-cell Ink4a/Arf expression and 
regeneration in diabetes mellitus, Genes Dev. 23 (2009) 975–985. 
https://doi.org/10.1101/gad.1742509. 
[83] S. Janjuha, S.P. Singh, A. Tsakmaki, S.N. Mousavy Gharavy, P. Murawala, J. 
Konantz, S. Birke, D.J. Hodson, G.A. Rutter, G.A. Bewick, N. Ninov, Age-related 
islet inflammation marks the proliferative decline of pancreatic beta-cells in 
zebrafish, Elife. 7 (2018). https://doi.org/10.7554/eLife.32965. 
[84] A.M. Chang, J.B. Halter, Aging and insulin secretion, Am. J. Physiol. Metab. 284 
(2003) E7–E12. https://doi.org/10.1152/ajpendo.00366.2002. 
[85] C.A. Beamish, S. Mehta, B.J. Strutt, S. Chakrabarti, M. Hara, D.J. Hill, Decrease 
in Ins+Glut2LO β-cells with advancing age in mouse and human pancreas., J. 
Endocrinol. 233 (2017) 229–241. https://doi.org/10.1530/JOE-16-0475. 
[86] F. Thorel, V. Népote, I. Avril, K. Kohno, R. Desgraz, S. Chera, P.L. Herrera, 
Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell 
loss., Nature. 464 (2010) 1149–1154. https://doi.org/10.1038/nature08894. 
[87] S.-I. Tschen, S. Dhawan, T. Gurlo, A. Bhushan, Age-Dependent Decline in Beta-
Cell Proliferation Restricts the Capacity of Beta-Cell Regeneration in Mice, 
 
 
59 
Diabetes. 58 (2009) 1312–1320. https://doi.org/10.2337/db08-1651. 
[88] M.M. Rankin, J.A. Kushner, Adaptive β-cell proliferation is severely restricted 
with advanced age, Diabetes. 58 (2009) 1365–1372. https://doi.org/10.2337/db08-
1198. 
[89] Y. Saisho, E. Manesso, A.E. Butler, R. Galasso, K. Kavanagh, M. Flynn, L. 
Zhang, P. Clark, T. Gurlo, G.M. Toffolo, C. Cobelli, J.D. Wagner, P.C. Butler, 
Ongoing β-Cell Turnover in Adult Nonhuman Primates Is Not Adaptively 
Increased in Streptozotocin-Induced Diabetes, Diabetes. 60 (2011) 848–856. 
https://doi.org/10.2337/db09-1368. 
[90] B.A. Menge, A. Tannapfel, O. Belyaev, R. Drescher, C. Muller, W. Uhl, W.E. 
Schmidt, J.J. Meier, Partial Pancreatectomy in Adult Humans Does Not Provoke 
Beta-Cell Regeneration, Diabetes. 57 (2008) 142–149. 
https://doi.org/10.2337/db07-1294. 
[91] S. Chera, D. Baronnier, L. Ghila, V. Cigliola, J.N. Jensen, G. Gu, K. Furuyama, F. 
Thorel, F.M. Gribble, F. Reimann, P.L. Herrera, Diabetes recovery by age-
dependent conversion of pancreatic δ-cells into insulin producers., Nature. 514 
(2014) 503–507. https://doi.org/10.1038/nature13633. 
[92] S. Rieck, K.H. Kaestner, Expansion of β-cell mass in response to pregnancy, 
Trends Endocrinol. Metab. 21 (2010) 151–158. 
https://doi.org/10.1016/j.tem.2009.11.001. 
[93] R.J. Nichols, C. New, J.P. Annes, Adult tissue sources for new β cells., Transl. 
Res. 163 (2014) 418–431. https://doi.org/10.1016/j.trsl.2013.11.012. 
[94] Y. Liu, J. Suckale, J. Masjkur, M.G. Magro, A. Steffen, K. Anastassiadis, M. 
Solimena, Tamoxifen-Independent Recombination in the RIP-CreER Mouse, 
PLoS One. 5 (2010) e13533. https://doi.org/10.1371/journal.pone.0013533. 
[95] M. Teta, M.M. Rankin, S.Y. Long, G.M. Stein, J.A. Kushner, Growth and 
Regeneration of Adult β Cells Does Not Involve Specialized Progenitors, Dev. 
Cell. 12 (2007) 817–826. https://doi.org/10.1016/j.devcel.2007.04.011. 
[96] A.E. Butler, L. Cao-Minh, R. Galasso, R.A. Rizza, A. Corradin, C. Cobelli, P.C. 
Butler, Adaptive changes in pancreatic beta cell fractional area and beta cell 
turnover in human pregnancy., Diabetologia. 53 (2010) 2167–2176. 
 
 
60 
https://doi.org/10.1007/s00125-010-1809-6. 
[97] J.J. Meier, A. Bhushan, A.E. Butler, R.A. Rizza, P.C. Butler, Sustained beta cell 
apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet 
regeneration?, Diabetologia. 48 (2005) 2221–2228. 
https://doi.org/10.1007/s00125-005-1949-2. 
[98] N.M. Fiaschi-Taesch, J.W. Kleinberger, F.G. Salim, R. Troxell, R. Wills, M. 
Tanwir, G. Casinelli, A.E. Cox, K.K. Takane, H. Srinivas, D.K. Scott, A.F. 
Stewart, Cytoplasmic-Nuclear Trafficking of G1/S Cell Cycle Molecules and 
Adult Human Beta-Cell Replication: A Revised Model of Human Beta-Cell G1/S 
Control, Diabetes. 62 (2013) 2460–2470. https://doi.org/10.2337/db12-0778. 
[99] N.M. Fiaschi-Taesch, J.W. Kleinberger, F.G. Salim, R. Troxell, R. Wills, M. 
Tanwir, G. Casinelli, A.E. Cox, K.K. Takane, D.K. Scott, A.F. Stewart, Human 
Pancreatic Beta-Cell G1/S Molecule Cell Cycle Atlas, Diabetes. 62 (2013) 2450–
2459. https://doi.org/10.2337/db12-0777. 
[100] I. Cozar-Castellano, K.K. Takane, R. Bottino, A.N. Balamurugan, A.F. Stewart, 
Induction of beta-cell proliferation and retinoblastoma protein phosphorylation in 
rat and human islets using adenovirus-mediated transfer of cyclin-dependent 
kinase-4 and cyclin D1., Diabetes. 53 (2004) 149–159. 
https://doi.org/10.2337/diabetes.53.1.149. 
[101] R.C. Vasavada, A. Garcia-Ocaña, W.S. Zawalich, R.L. Sorenson, P. Dann, M. 
Syed, L. Ogren, F. Talamantes, A.F. Stewart, Targeted Expression of Placental 
Lactogen in the Beta Cells of Transgenic Mice Results in Beta Cell Proliferation, 
Islet Mass Augmentation, and Hypoglycemia, J. Biol. Chem. 275 (2000) 15399–
15406. https://doi.org/10.1074/jbc.275.20.15399. 
[102] A. Garcia-Ocaña, K.K. Takane, M.A. Syed, W.M. Philbrick, R.C. Vasavada, A.F. 
Stewart, Hepatocyte growth factor overexpression in the islet of transgenic mice 
increases beta cell proliferation, enhances islet mass, and induces mild 
hypoglycemia., J. Biol. Chem. 275 (2000) 1226–1232. 
https://doi.org/10.1074/jbc.275.2.1226. 
[103] K.I. Aamodt, R. Aramandla, J.J. Brown, N. Fiaschi-Taesch, P. Wang, A.F. 
Stewart, M. Brissova, A.C. Powers, Development of a reliable automated 
 
 
61 
screening system to identify small molecules and biologics that promote human β-
cell regeneration, Am. J. Physiol. Metab. 311 (2016) E859–E868. 
https://doi.org/10.1152/ajpendo.00515.2015. 
[104] P. Wang, J.-C. Alvarez-Perez, D.P. Felsenfeld, H. Liu, S. Sivendran, A. Bender, A. 
Kumar, R. Sanchez, D.K. Scott, A. Garcia-Ocaña, A.F. Stewart, A high-
throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A 
increases human pancreatic beta cell replication., Nat. Med. 21 (2015) 383–388. 
https://doi.org/10.1038/nm.3820. 
[105] W. Shen, B. Taylor, Q. Jin, V. Nguyen-Tran, S. Meeusen, Y.-Q. Zhang, A. 
Kamireddy, A. Swafford, A.F. Powers, J. Walker, J. Lamb, B. Bursalaya, M. 
DiDonato, G. Harb, M. Qiu, C.M. Filippi, L. Deaton, C.N. Turk, W.L. Suarez-
Pinzon, Y. Liu, X. Hao, T. Mo, S. Yan, J. Li, A.E. Herman, B.J. Hering, T. Wu, H. 
Martin Seidel, P. McNamara, R. Glynne, B. Laffitte, Inhibition of DYRK1A and 
GSK3B induces human β-cell proliferation, Nat. Commun. 6 (2015) 8372. 
https://doi.org/10.1038/ncomms9372. 
[106] R.R. Bensley, Studies on the pancreas of the guinea pig, Am. J. Anat. 12 (1911) 
297–388. https://doi.org/10.1002/aja.1000120304. 
[107] S. Bonner-Weir, A. Inada, S. Yatoh, W.-C. Li, T. Aye, E. Toschi, A. Sharma, 
Transdifferentiation of pancreatic ductal cells to endocrine β-cells, Biochem. Soc. 
Trans. 36 (2008) 353–356. https://doi.org/10.1042/BST0360353. 
[108] K. Al-Hasani, A. Pfeifer, M. Courtney, N. Ben-Othman, E. Gjernes, A. Vieira, N. 
Druelle, F. Avolio, P. Ravassard, G. Leuckx, S. Lacas-Gervais, D. Ambrosetti, E. 
Benizri, J. Hecksher-Sorensen, P. Gounon, J. Ferrer, G. Gradwohl, H. Heimberg, 
A. Mansouri, P. Collombat, Adult Duct-Lining Cells Can Reprogram into β-like 
Cells Able to Counter Repeated Cycles of Toxin-Induced Diabetes, Dev. Cell. 26 
(2013) 86–100. https://doi.org/10.1016/j.devcel.2013.05.018. 
[109] A. Criscimanna, J.A. Speicher, G. Houshmand, C. Shiota, K. Prasadan, B. Ji, C.D. 
Logsdon, G.K. Gittes, F. Esni, Duct Cells Contribute to Regeneration of Endocrine 
and Acinar Cells Following Pancreatic Damage in Adult Mice, Gastroenterology. 
141 (2011) 1451-1462.e6. https://doi.org/10.1053/J.GASTRO.2011.07.003. 
[110] M. Zhang, Q. Lin, T. Qi, T. Wang, C.-C. Chen, A.D. Riggs, D. Zeng, Growth 
 
 
62 
factors and medium hyperglycemia induce Sox9+ ductal cell differentiation into β 
cells in mice with reversal of diabetes, Proc. Natl. Acad. Sci. 113 (2016) 650–655. 
https://doi.org/10.1073/PNAS.1524200113. 
[111] D. Kopinke, M. Brailsford, J.E. Shea, R. Leavitt, C.L. Scaife, L.C. Murtaugh, 
Lineage tracing reveals the dynamic contribution of Hes1+ cells to the developing 
and adult pancreas., Development. 138 (2011) 431–441. 
https://doi.org/10.1242/dev.053843. 
[112] M.R. Katdare, R.R. Bhonde, P.B. Parab, Analysis of morphological and functional 
maturation of neoislets generated in vitro from pancreatic ductal cells and their 
suitability for islet banking and transplantation., J. Endocrinol. 182 (2004) 105–
112. https://doi.org/10.1677/joe.0.1820105. 
[113] R.N. Wang, L. Bouwens, G. Kloppel, Beta-cell growth in adolescent and adult rats 
treated with streptozotocin during the neonatal period, Diabetologia. 39 (1996) 
548–557. https://doi.org/10.1007/BF00403301. 
[114] K.-C. Liu, G. Leuckx, D. Sakano, P.A. Seymour, C.L. Mattsson, L. Rautio, W. 
Staels, Y. Verdonck, P. Serup, S. Kume, H. Heimberg, O. Andersson, Inhibition of 
Cdk5 Promotes β-Cell Differentiation From Ductal Progenitors, Diabetes. 67 
(2018) 58–70. https://doi.org/10.2337/db16-1587. 
[115] S. Bonner-Weir, M. Taneja, G.C. Weir, K. Tatarkiewicz, K.-H. Song, A. Sharma, 
J.J. O’Neil, In vitro cultivation of human islets from expanded ductal tissue, Proc. 
Natl. Acad. Sci. 97 (2000) 7999–8004. https://doi.org/10.1073/pnas.97.14.7999. 
[116] S. Bonner-Weir, E. Toschi, A. Inada, P. Reitz, S.Y. Fonseca, T. Aye, A. Sharma, 
The pancreatic ductal epithelium serves as a potential pool of progenitor cells., 
Pediatr. Diabetes. 5 Suppl 2 (2004) 16–22. https://doi.org/10.1111/j.1399-
543X.2004.00075.x. 
[117] A. Suzuki, H. Nakauchi, H. Taniguchi, Prospective isolation of multipotent 
pancreatic progenitors using flow-cytometric cell sorting., Diabetes. 53 (2004) 
2143–2152. https://doi.org/10.2337/diabetes.53.8.2143. 
[118] R.M. Seaberg, S.R. Smukler, T.J. Kieffer, G. Enikolopov, Z. Asghar, M.B. 
Wheeler, G. Korbutt, D. van der Kooy, Clonal identification of multipotent 
precursors from adult mouse pancreas that generate neural and pancreatic 
 
 
63 
lineages., Nat. Biotechnol. 22 (2004) 1115–1124. https://doi.org/10.1038/nbt1004. 
[119] S.R. Smukler, M.E. Arntfield, R. Razavi, G. Bikopoulos, P. Karpowicz, R. 
Seaberg, F. Dai, S. Lee, R. Ahrens, P.E. Fraser, M.B. Wheeler, D. van der Kooy, 
The adult mouse and human pancreas contain rare multipotent stem cells that 
express insulin., Cell Stem Cell. 8 (2011) 281–293. 
https://doi.org/10.1016/j.stem.2011.01.015. 
[120] C.A. Beamish, B.J. Strutt, E.J. Arany, D.J. Hill, Insulin-positive, Glut2-low cells 
present within mouse pancreas exhibit lineage plasticity and are enriched within 
extra-islet endocrine cell clusters., Islets. 8 (2016) 65–82. 
https://doi.org/10.1080/19382014.2016.1162367. 
[121] T. van der Meulen, A.M. Mawla, M.R. DiGruccio, M.W. Adams, V. Nies, S. 
Dólleman, S. Liu, A.M. Ackermann, E. Cáceres, A.E. Hunter, K.H. Kaestner, C.J. 
Donaldson, M.O. Huising, Virgin Beta Cells Persist throughout Life at a Neogenic 
Niche within Pancreatic Islets, Cell Metab. 25 (2017) 911-926.e6. 
https://doi.org/10.1016/j.cmet.2017.03.017. 
[122] T. van der Meulen, R. Xie, O.G. Kelly, W.W. Vale, M. Sander, M.O. Huising, 
Urocortin 3 marks mature human primary and embryonic stem cell-derived 
pancreatic alpha and beta cells., PLoS One. 7 (2012) e52181. 
https://doi.org/10.1371/journal.pone.0052181. 
[123] R. Abs, L. Verbist, M. Moeremans, P. Blockx, I. De Leeuw, J. Bekaert, 
Hypoglycemia owing to inappropriate glucagon secretion treated with a 
continuous subcutaneous glucagon infusion system, Acta Endocrinol. (Copenh). 
122 (1990) 319–322. https://doi.org/10.1530/acta.0.1220319. 
[124] A.S. Hancock, A. Du, J. Liu, M. Miller, C.L. May, Glucagon Deficiency Reduces 
Hepatic Glucose Production and Improves Glucose Tolerance In Adult Mice, Mol. 
Endocrinol. 24 (2010) 1605–1614. https://doi.org/10.1210/me.2010-0120. 
[125] P. Collombat, J. Hecksher-Sørensen, J. Krull, J. Berger, D. Riedel, P.L. Herrera, P. 
Serup, A. Mansouri, Embryonic endocrine pancreas and mature beta cells acquire 
alpha and PP cell phenotypes upon Arx misexpression., J. Clin. Invest. 117 (2007) 
961–970. https://doi.org/10.1172/JCI29115. 
[126] P. Collombat, X. Xu, P. Ravassard, B. Sosa-Pineda, S. Dussaud, N. Billestrup, 
 
 
64 
O.D. Madsen, P. Serup, H. Heimberg, A. Mansouri, The Ectopic Expression of 
Pax4 in the Mouse Pancreas Converts Progenitor Cells into α and Subsequently β 
Cells, Cell. 138 (2009) 449–462. https://doi.org/10.1016/J.CELL.2009.05.035. 
[127] M.G. White, H.L. Marshall, R. Rigby, G.C. Huang, A. Amer, T. Booth, S. White, 
J.A.M. Shaw, Expression of mesenchymal and α-cell phenotypic markers in islet 
β-cells in recently diagnosed diabetes., Diabetes Care. 36 (2013) 3818–3820. 
https://doi.org/10.2337/dc13-0705. 
[128] N.C. Bramswig, L.J. Everett, J. Schug, C. Dorrell, C. Liu, Y. Luo, P.R. Streeter, A. 
Naji, M. Grompe, K.H. Kaestner, Epigenomic plasticity enables human pancreatic 
α to β cell reprogramming, J. Clin. Invest. 123 (2013) 1275–1284. 
https://doi.org/10.1172/JCI66514. 
[129] H. Pisharath, J.M. Rhee, M.A. Swanson, S.D. Leach, M.J. Parsons, Targeted 
ablation of beta cells in the embryonic zebrafish pancreas using E. coli 
nitroreductase, Mech. Dev. 124 (2007) 218–229. 
https://doi.org/10.1016/j.mod.2006.11.005. 
[130] M. Courtney, E. Gjernes, N. Druelle, C. Ravaud, A. Vieira, N. Ben-Othman, A. 
Pfeifer, F. Avolio, G. Leuckx, S. Lacas-Gervais, F. Burel-Vandenbos, D. 
Ambrosetti, J. Hecksher-Sorensen, P. Ravassard, H. Heimberg, A. Mansouri, P. 
Collombat, The Inactivation of Arx in Pancreatic α-Cells Triggers Their 
Neogenesis and Conversion into Functional β-Like Cells, PLoS Genet. 9 (2013) 
e1003934. https://doi.org/10.1371/journal.pgen.1003934. 
[131] X. Xiao, P. Guo, C. Shiota, T. Zhang, G.M. Coudriet, S. Fischbach, K. Prasadan, J. 
Fusco, S. Ramachandran, P. Witkowski, J.D. Piganelli, G.K. Gittes, Endogenous 
Reprogramming of Alpha Cells into Beta Cells, Induced by Viral Gene Therapy, 
Reverses Autoimmune Diabetes, Cell Stem Cell. 22 (2018) 78-90.e4. 
https://doi.org/10.1016/j.stem.2017.11.020. 
[132] N. Ben-Othman, A. Vieira, M. Courtney, F. Record, E. Gjernes, F. Avolio, B. 
Hadzic, N. Druelle, T. Napolitano, S. Navarro-Sanz, S. Silvano, K. Al-Hasani, A. 
Pfeifer, S. Lacas-Gervais, G. Leuckx, L. Marroquí, J. Thévenet, O.D. Madsen, 
D.L. Eizirik, H. Heimberg, J. Kerr-Conte, F. Pattou, A. Mansouri, P. Collombat, 
Long-Term GABA Administration Induces Alpha Cell-Mediated Beta-like Cell 
 
 
65 
Neogenesis, Cell. 168 (2017) 73-85.e11.https://doi.org/10.1016/j.cell.2016.11.002. 
[133] Z. Zhang, Y. Hu, N. Xu, W. Zhou, L. Yang, R. Chen, R. Yang, J. Sun, H. Chen, A 
New Way for Beta Cell Neogenesis: Transdifferentiation from Alpha Cells 
Induced by Glucagon-Like Peptide 1., J. Diabetes Res. 2019 (2019) 2583047. 
https://doi.org/10.1155/2019/2583047. 
[134] J. Li, T. Casteels, T. Frogne, C. Ingvorsen, C. Honoré, M. Courtney, K.V.M. 
Huber, N. Schmitner, R.A. Kimmel, R.A. Romanov, C. Sturtzel, C.-H. Lardeau, J. 
Klughammer, M. Farlik, S. Sdelci, A. Vieira, F. Avolio, F. Briand, I. Baburin, P. 
Májek, F.M. Pauler, T. Penz, A. Stukalov, M. Gridling, K. Parapatics, C. Barbieux, 
E. Berishvili, A. Spittler, J. Colinge, K.L. Bennett, S. Hering, T. Sulpice, C. Bock, 
M. Distel, T. Harkany, D. Meyer, G. Superti-Furga, P. Collombat, J. Hecksher-
Sørensen, S. Kubicek, Artemisinins Target GABAA Receptor Signaling and 
Impair α Cell Identity, Cell. 168 (2017) 86-100.e15. 
https://doi.org/10.1016/j.cell.2016.11.010. 
[135] T. van der Meulen, S. Lee, E. Noordeloos, C.J. Donaldson, M.W. Adams, G.M. 
Noguchi, A.M. Mawla, M.O. Huising, Artemether Does Not Turn α Cells into β 
Cells., Cell Metab. 27 (2018) 218-225.e4. 
https://doi.org/10.1016/j.cmet.2017.10.002. 
[136] K. Minami, M. Okuno, K. Miyawaki, A. Okumachi, K. Ishizaki, K. Oyama, M. 
Kawaguchi, N. Ishizuka, T. Iwanaga, S. Seino, Lineage tracing and 
characterization of insulin-secreting cells generated from adult pancreatic acinar 
cells, Proc. Natl. Acad. Sci. 102 (2005) 15116–15121. 
https://doi.org/10.1073/pnas.0507567102. 
[137] L. Baeyens, S. De Breuck, J. Lardon, J.K. Mfopou, I. Rooman, L. Bouwens, In 
vitro generation of insulin-producing beta cells from adult exocrine pancreatic 
cells, Diabetologia. 48 (2005) 49–57. https://doi.org/10.1007/s00125-004-1606-1. 
[138] E. Akinci, A. Banga, L.V. Greder, J.R. Dutton, J.M.W. Slack, Reprogramming of 
pancreatic exocrine cells towards a beta (β) cell character using Pdx1, Ngn3 and 
MafA, Biochem. J. 442 (2012) 539–550. https://doi.org/10.1042/BJ20111678. 
[139] Q. Zhou, J. Brown, A. Kanarek, J. Rajagopal, D.A. Melton, In vivo 
reprogramming of adult pancreatic exocrine cells to β-cells, Nature. 455 (2008) 
 
 
66 
627–632. https://doi.org/10.1038/nature07314. 
[140] W. Li, C. Cavelti-Weder, Y. Zhang, K. Clement, S. Donovan, G. Gonzalez, J. Zhu, 
M. Stemann, K. Xu, T. Hashimoto, T. Yamada, M. Nakanishi, Y. Zhang, S. Zeng, 
D. Gifford, A. Meissner, G. Weir, Q. Zhou, Q. Zhou, Long-term persistence and 
development of induced pancreatic beta cells generated by lineage conversion of 
acinar cells, Nat. Biotechnol. 32 (2014) 1223–1230. 
https://doi.org/10.1038/nbt.3082. 
[141] M.J. Lima, K.R. Muir, H.M. Docherty, R. Drummond, N.W.A. McGowan, S. 
Forbes, Y. Heremans, I. Houbracken, J.A. Ross, S.J. Forbes, P. Ravassard, H. 
Heimberg, J. Casey, K. Docherty, Suppression of epithelial-to-mesenchymal 
transitioning enhances ex vivo reprogramming of human exocrine pancreatic tissue 
toward functional insulin-producing β-like cells., Diabetes. 62 (2013) 2821–2833. 
https://doi.org/10.2337/db12-1256. 
[142] M.J. Lima, K.R. Muir, H.M. Docherty, N.W.A. McGowan, S. Forbes, Y. 
Heremans, H. Heimberg, J. Casey, K. Docherty, Generation of Functional Beta-
Like Cells from Human Exocrine Pancreas, PLoS One. 11 (2016) e0156204. 
https://doi.org/10.1371/journal.pone.0156204. 
[143] B.M. Desai, J. Oliver-Krasinski, D.D. De Leon, C. Farzad, N. Hong, S.D. Leach, 
D.A. Stoffers, Preexisting pancreatic acinar cells contribute to acinar cell, but not 
islet β cell, regeneration, J. Clin. Invest. 117 (2007) 971–977. 
https://doi.org/10.1172/JCI29988. 
[144] M.M. Sachdeva, D.A. Stoffers, Minireview: Meeting the demand for insulin: 
molecular mechanisms of adaptive postnatal beta-cell mass expansion., Mol. 
Endocrinol. 23 (2009) 747–758. https://doi.org/10.1210/me.2008-0400. 
[145] A.E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R.A. Rizza, P.C. Butler, Beta-
Cell Deficit and Increased Beta-Cell Apoptosis in Humans With Type 2 Diabetes, 
Diabetes. 52 (2003) 102–110. https://doi.org/10.2337/diabetes.52.1.102. 
[146] R.F. Ogilvie, The islands of langerhans in 19 cases of obesity, J. Pathol. Bacteriol. 
37 (1933) 473–481. https://doi.org/10.1002/path.1700370314. 
[147] K.H. Yoon, S.H. Ko, J.H. Cho, J.M. Lee, Y.B. Ahn, K.H. Song, S.J. Yoo, M. Il 
Kang, B.Y. Cha, K.W. Lee, H.Y. Son, S.K. Kang, H.S. Kim, I.K. Lee, S. Bonner-
 
 
67 
Weir, Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes 
Mellitus in Korea, J. Clin. Endocrinol. Metab. 88 (2003) 2300–2308. 
https://doi.org/10.1210/jc.2002-020735. 
[148] S.C. Hanley, E. Austin, B. Assouline-Thomas, J. Kapeluto, J. Blaichman, M. 
Moosavi, M. Petropavlovskaia, L. Rosenberg, β-Cell Mass Dynamics and Islet 
Cell Plasticity in Human Type 2 Diabetes, Endocrinology. 151 (2010) 1462–1472. 
https://doi.org/10.1210/en.2009-1277. 
[149] T. Mezza, G. Muscogiuri, G.P. Sorice, G. Clemente, J. Hu, A. Pontecorvi, J.J. 
Holst, A. Giaccari, R.N. Kulkarni, Insulin Resistance Alters Islet Morphology in 
Nondiabetic Humans, Diabetes. 63 (2014) 994–1007. 
https://doi.org/10.2337/db13-1013. 
[150] R.E. Stamateris, R.B. Sharma, D.A. Hollern, L.C. Alonso, Adaptive β-cell 
proliferation increases early in high-fat feeding in mice, concurrent with metabolic 
changes, with induction of islet cyclin D2 expression, Am. J. Physiol. Metab. 305 
(2013) E149–E159. https://doi.org/10.1152/ajpendo.00040.2013. 
[151] A.R. Cox, C.J. Lam, M.M. Rankin, K.A. King, P. Chen, R. Martinez, C. Li, J.A. 
Kushner, Extreme obesity induces massive beta cell expansion in mice through 
self-renewal and does not alter the beta cell lineage, Diabetologia. 59 (2016) 1231–
1241. https://doi.org/10.1007/s00125-016-3922-7. 
[152] J. Yamamoto, J. Imai, T. Izumi, H. Takahashi, Y. Kawana, K. Takahashi, S. 
Kodama, K. Kaneko, J. Gao, K. Uno, S. Sawada, T. Asano, V. V. Kalinichenko, 
E.A. Susaki, M. Kanzaki, H.R. Ueda, Y. Ishigaki, T. Yamada, H. Katagiri, 
Neuronal signals regulate obesity induced β-cell proliferation by FoxM1 
dependent mechanism, Nat. Commun. 8 (2017) 1930. 
https://doi.org/10.1038/s41467-017-01869-7. 
[153] D. Newbern, M. Freemark, Placental hormones and the control of maternal 
metabolism and fetal growth, Curr. Opin. Endocrinol. Diabetes Obes. 18 (2011) 
409–416. https://doi.org/10.1097/MED.0b013e32834c800d. 
[154] L. Baeyens, S. Hindi, R.L. Sorenson, M.S. German, β-Cell adaptation in 
pregnancy., Diabetes. Obes. Metab. 18 Suppl 1 (2016) 63–70. 
https://doi.org/10.1111/dom.12716. 
 
 
68 
[155] J.A. Parsons, T.C. Brelje, R.L. Sorenson, Adaptation of islets of Langerhans to 
pregnancy: increased islet cell proliferation and insulin secretion correlates with 
the onset of placental lactogen secretion., Endocrinology. 130 (1992) 1459–1466. 
https://doi.org/10.1210/endo.130.3.1537300. 
[156] K.Y. Lain, P.M. Catalano, Metabolic Changes in Pregnancy, Clin. Obstet. 
Gynecol. 50 (2007) 938–948. https://doi.org/10.1097/GRF.0b013e31815a5494. 
[157] F.A. Van Assche, L. Aerts, W. Gepts, Morphological changes in the endocrine 
pancreas in pregnant rats with experimental diabetes., J. Endocrinol. 80 (1979) 
175–179. 
[158] R.L. Sorenson, T.C. Brelje, Adaptation of islets of Langerhans to pregnancy: beta-
cell growth, enhanced insulin secretion and the role of lactogenic hormones., 
Horm. Metab. Res. 29 (1997) 301–307. https://doi.org/10.1055/s-2007-979040. 
[159] C.A. Beamish, L. Zhang, S.K. Szlapinski, B.J. Strutt, D.J. Hill, An increase in 
immature β-cells lacking Glut2 precedes the expansion of β-cell mass in the 
pregnant mouse, PLoS One. 12 (2017) e0182256. 
https://doi.org/10.1371/journal.pone.0182256. 
[160] A. Malassine, J.-L. Frendo, D. Evain-Brion, A comparison of placental 
development and endocrine functions between the human and mouse model, Hum. 
Reprod. Update. 9 (2003) 531–539. https://doi.org/10.1093/humupd/dmg043. 
[161] F. Mauvais-Jarvis, Role of Sex Steroids in β Cell Function, Growth, and Survival., 
Trends Endocrinol. Metab. 27 (2016) 844–855. 
https://doi.org/10.1016/j.tem.2016.08.008. 
[162] S.K. Szlapinski, R.T. King, G. Retta, E. Yeo, B.J. Strutt, D.J. Hill, A mouse model 
of gestational glucose intolerance through exposure to a low protein diet during 
fetal and neonatal development, J. Physiol. 597 (2019) 4237–4250. 
https://doi.org/10.1113/JP277884. 
[163] A.J. Bone, K.W. Taylor, Metabolic adaptation to pregnancy shown by increased 
biosynthesis of insulin in islets of Langerhans isolated from pregnant rats, Nature. 
262 (1976) 501–502. https://doi.org/10.1038/262501a0. 
[164] I.C. Green, S.L. Howell, W. Montague, K.W. Taylor, Regulation of insulin release 
from isolated islets of Langerhans of the rat in pregnancy. The role of adenosine 
 
 
69 
3’:5’-cyclic monophosphate., Biochem. J. 134 (1973) 481–487. 
https://doi.org/10.1042/bj1340481. 
[165] L. Scaglia, F.E. Smith, S. Bonner-Weir, Apoptosis contributes to the involution of 
beta cell mass in the post partum rat pancreas., Endocrinology. 136 (1995) 5461–
5468. https://doi.org/10.1210/endo.136.12.7588296. 
[166] F.A. Van Assche, L. Aerts, F. De Prins, A morphological study of the endocrine 
pancreas in human pregnancy., Br. J. Obstet. Gynaecol. 85 (1978) 818–820. 
[167] P. Wang, N.M. Fiaschi-Taesch, R.C. Vasavada, D.K. Scott, A. García-Ocaña, A.F. 
Stewart, Diabetes mellitus—advances and challenges in human β-cell 
proliferation, Nat. Rev. Endocrinol. 11 (2015) 201–212. 
https://doi.org/10.1038/nrendo.2015.9. 
[168] C. Huang, F. Snider, J.C. Cross, Prolactin receptor is required for normal glucose 
homeostasis and modulation of beta-cell mass during pregnancy., Endocrinology. 
150 (2009) 1618–1626. https://doi.org/10.1210/en.2008-1003. 
[169] H. Kim, Y. Toyofuku, F.C. Lynn, E. Chak, T. Uchida, H. Mizukami, Y. Fujitani, 
R. Kawamori, T. Miyatsuka, Y. Kosaka, K. Yang, G. Honig, M. van der Hart, N. 
Kishimoto, J. Wang, S. Yagihashi, L.H. Tecott, H. Watada, M.S. German, 
Serotonin regulates pancreatic beta cell mass during pregnancy., Nat. Med. 16 
(2010) 804–808. https://doi.org/10.1038/nm.2173. 
[170] T.C. Brelje, D.W. Scharp, P.E. Lacy, L. Ogren, F. Talamantes, M. Robertson, H.G. 
Friesen, R.L. Sorenson, Effect of homologous placental lactogens, prolactins, and 
growth hormones on islet B-cell division and insulin secretion in rat, mouse, and 
human islets: implication for placental lactogen regulation of islet function during 
pregnancy., Endocrinology. 132 (1993) 879–887. 
https://doi.org/10.1210/endo.132.2.8425500. 
[171] H. Chen, J.W. Kleinberger, K.K. Takane, F. Salim, N. Fiaschi-Taesch, K. Pappas, 
R. Parsons, J. Jiang, Y. Zhang, H. Liu, P. Wang, A.S. Bender, S.J. Frank, A.F. 
Stewart, Augmented Stat5 Signaling Bypasses Multiple Impediments to Lactogen-
Mediated Proliferation in Human β-Cells., Diabetes. 64 (2015) 3784–3797. 
https://doi.org/10.2337/db15-0083. 
[172] C. Benner, T. van der Meulen, E. Cacéres, K. Tigyi, C.J. Donaldson, M.O. 
 
 
70 
Huising, The transcriptional landscape of mouse beta cells compared to human 
beta cells reveals notable species differences in long non-coding RNA and protein-
coding gene expression., BMC Genomics. 15 (2014) 620. 
https://doi.org/10.1186/1471-2164-15-620. 
[173] S. Abouna, R.W. Old, S. Pelengaris, D. Epstein, V. Ifandi, I. Sweeney, M. Khan, 
Non-β-cell progenitors of β-cells in pregnant mice., Organogenesis. 6 (2010) 125–
133. https://doi.org/10.4161/org.6.2.10374. 
[174] X. Xiao, Z. Chen, C. Shiota, K. Prasadan, P. Guo, Y. El-Gohary, J. Paredes, C. 
Welsh, J. Wiersch, G.K. Gittes, No evidence for β cell neogenesis in murine adult 
pancreas, J. Clin. Invest. 123 (2013) 2207–2217. https://doi.org/10.1172/JCI66323. 
[175] C. Toselli, C.M. Hyslop, M. Hughes, D.R. Natale, P. Santamaria, C.T.L. Huang, 
Contribution of a non-β-cell source to β-cell mass during pregnancy., PLoS One. 9 
(2014) e100398. https://doi.org/10.1371/journal.pone.0100398. 
[176] X. Zhao, Increase of beta cell mass by beta cell replication, but not neogenesis, in 
the maternal pancreas in mice., Endocr. J. 61 (2014) 623–628. 
https://doi.org/10.1507/endocrj.ej14-0040. 
[177] E. Hakonen, J. Ustinov, J. Palgi, P.J. Miettinen, T. Otonkoski, EGFR Signaling 
Promotes β-Cell Proliferation and Survivin Expression during Pregnancy, PLoS 
One. 9 (2014) e93651. https://doi.org/10.1371/journal.pone.0093651. 
[178] C. Quesada-Candela, E. Tudurí, L. Marroquí, P. Alonso-Magdalena, I. Quesada, 
Á. Nadal, Morphological and functional adaptations of pancreatic alpha-cells 
during late pregnancy in the mouse., Metabolism. 102 (2019) 153963. 
https://doi.org/10.1016/j.metabol.2019.153963. 
[179] R.R. Banerjee, H.A. Cyphert, E.M. Walker, H. Chakravarthy, H. Peiris, X. Gu, Y. 
Liu, E. Conrad, L. Goodrich, R.W. Stein, S.K. Kim, Gestational Diabetes Mellitus 
From Inactivation of Prolactin Receptor and MafB in Islet β-Cells, Diabetes. 65 
(2016) 2331–2341. https://doi.org/10.2337/db15-1527. 
[180] R.C. Vasavada, A. Garcia-Ocaña, W.S. Zawalich, R.L. Sorenson, P. Dann, M. 
Syed, L. Ogren, F. Talamantes, A.F. Stewart, Targeted expression of placental 
lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet 
mass augmentation, and hypoglycemia., J. Biol. Chem. 275 (2000) 15399–15406. 
 
 
71 
[181] A. Radhakrishnan, R. Raju, N. Tuladhar, T. Subbannayya, J.K. Thomas, R. Goel, 
D. Telikicherla, S.M. Palapetta, B.A. Rahiman, D.D. Venkatesh, K.-K. Urmila, 
H.C. Harsha, P.P. Mathur, T.S.K. Prasad, A. Pandey, C. Shemanko, A. Chatterjee, 
A pathway map of prolactin signaling., J. Cell Commun. Signal. 6 (2012) 169–
173. https://doi.org/10.1007/s12079-012-0168-0. 
[182] T.C. Brelje, L.E. Stout, N. V. Bhagroo, R.L. Sorenson, Distinctive Roles for 
Prolactin and Growth Hormone in the Activation of Signal Transducer and 
Activator of Transcription 5 in Pancreatic Islets of Langerhans, Endocrinology. 
145 (2004) 4162–4175. https://doi.org/10.1210/en.2004-0201. 
[183] M.E.C. Amaral, D.A. Cunha, G.F. Anhê, M. Ueno, E.M. Carneiro, L.A. Velloso, 
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2.1  Introduction  
Gestational diabetes mellitus (GDM) is a form of diabetes that develops during 
pregnancy and regresses postpartum. Between 3%-20% of women develop GDM, 
depending on their risk factors [1]. GDM increases the risk of the mother developing 
subsequent type 2 diabetes mellitus (T2DM) by up to 7-fold compared to euglycaemic 
pregnancies [2]. For the offspring, exposure to GDM in utero has been linked to an 
increased risk of childhood obesity and development of T2DM [3]. 
GDM develops due to insufficient insulin secretion during the relatively insulin-resistant 
state in pregnancy [4]. The state of peripheral maternal insulin resistance is most 
prominent during the third trimester when placental growth hormone and placental 
lactogen levels are highest [5,6]. This ensures normal fetal development by maintaining 
trans-placental flux of glucose to the fetus. Consequently, maternal euglycaemia is 
normally maintained through adaptations of β-cell mass (BCM) in maternal pancreas. 
Both mouse and human β-cells replicate at a low rate in adulthood (~2% per day) [7,8]. 
However, the rise in circulating placental lactogen and prolactin during mouse pregnancy 
has been shown to trigger proliferation of β-cells around gestational day (GD) 12, which 
increases BCM and enhances insulin secretion [9,10]. In mice, BCM increases via β-cell 
replication and hypertrophy, reaching maximal levels towards late gestation [10,11]. 
Elevated maternal estrogen levels during pregnancy protect β-cells against apoptosis [12]. 
As estrogen levels drop after parturition, β-cell apoptosis increases [13] while β-cell 
proliferation decreases [11,14] returning BCM to pre-pregnancy levels. The 
compensatory changes in human BCM remain controversial as the dynamics of BCM 
expansion are hypothesized to be slightly different than in mouse [15]. Nonetheless, the 
only two human studies conducted to date have both reported an increase in β-cell area in 
pancreata of pregnant women at post-mortem [16,17]. These data suggest that the 
pancreas of humans, like mice, should be able to increase BCM and enhance insulin 
secretion during pregnancy. Consequently, in situations where BCM expansion is 
suboptimal, GDM can arise [18]. Thus, murine GDM models characterized by alterations 
to BCM may relate to the pathology in humans as both animal models and genome-wide 
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association studies in humans implicate β-cell dysfunction as the largest determinant to 
GDM pathogenesis [19].  
There is currently no reproducibly effective prevention or reversal intervention for GDM. 
As rates of GDM are on the rise, this poses a threat to both the long- and short-term 
health of the mother and her offspring. Non-invasive imaging to analyse expansion of 
BCM in human pregnancy has ethical and technical issues making animal models a 
desirable alternative for studying the mechanisms leading to GDM. Although there are 
inevitable differences between mouse and human gestation, these differences are well 
characterized; consequently, mice are considered to be valid models for studies of 
pregnancy pathophysiology. One important similarity between mouse and human 
gestation is the fact that both the extent of β-cell dysfunction and insulin resistance play 
an important role in determining metabolic dysfunction in human and animal models 
[19]. A useful animal model of GDM would not demonstrate pre-gestational diabetes but 
show abnormal glucose tolerance as pregnancy progressed. As there are currently few 
clinically applicable animal models of GDM [20] that meet these criteria, we sought to 
develop a mouse model relevant to the clinical characteristics of GDM through dietary 
insult. 
It has been established that maternal (F0) dietary protein restriction (low protein (LP) 
diet) during early life has long-term effects on the endocrine pancreas of the offspring 
(F1), which contributes to glucose intolerance in adulthood [21]. Offspring born to dams 
fed a LP diet have reduced BCM as neonates resulting from decreased rates of β-cell 
proliferation and increased apoptosis [22]. LP-exposed offspring also have impaired β-
cell insulin release which further contributes to glucose intolerance in adulthood [23]. 
Using this well-characterized model, we examined whether female offspring (F1) of LP 
diet-fed dams (F0) would develop glucose intolerance during pregnancy, and whether this 
was associated with an altered adaptation of BCM in maternal endocrine pancreas and/or 
insulin secretion in isolated islets of Langerhans. We hypothesized that female offspring 
(F1) of LP diet-fed dams would be glucose intolerant during pregnancy as a result of 
impaired β-cell plasticity and reduced insulin secretion. 
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2.2  Methods  
2.2.1.  Ethical Approval  
All animal procedures were approved by the Animal Care Committee of Western 
University in accordance with the guidelines of the Canadian Council for Animal Care 
(Approval #2018-027).  
2.2.2.  Animals  
Adult (6-week-old) C57BL/6 male and female mice were obtained from Charles River 
Laboratories (Wilmington, MA, USA) and housed in a temperature-controlled room with 
12-h light/dark cycle at Lawson Health Research Institute, London, ON, Canada. Water 
and food were given ad libitum. Timed pregnancies were accomplished by establishing 
mouse estrous cycling [24]. Individual female and male mice were housed together for 
mating and separated the following morning. Day zero of pregnancy was determined by 
identification of a vaginal plug. Females were housed individually for the remainder of 
pregnancy. F0-females were randomly allocated to either a control (C, 20% protein, Bio-
Serv, Frenchtown, NJ, USA) or low protein diet (LP, 8%) group (Fig. 2.1A), where an 
increase in carbohydrate in LP diet (Table 2.1) yields an isocaloric diet compared to 
control chow [25]. F0-dams were fed either the LP or C diet throughout gestation and 
lactation. A total of 24 control and 21 LP litters were used for the study. Since the 
primary objective of our study was to produce a novel mouse model of GDM we worked 
only with female offspring. On postnatal day (PND) 21, all female offspring (F1) were 
weaned onto C diet for the remainder of the study while males were euthanized (Fig. 
2.1B). At maturity (PND42), female offspring (F1) born to dams fed either a C or LP diet 
were randomly allocated into 2 subsequent study groups: pregnant (CP, LPP) or non-
pregnant (CNP, LPNP, Fig. 2.1A). All pregnant grouped females were time-mated with C 
diet-fed males, separated the following morning and housed individually for the 
remainder of the experiment. Dams were euthanized by CO2 asphyxia following an intra-
peritoneal glucose tolerance test (IPGTT) on a randomly assigned day of gestation (GD9, 
12, or 18) for comparison to non-pregnant age-matched F1 females. Maternal (F1) blood 
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was collected via cardiac puncture following the IPGTT and serum insulin and glucagon 
quantified using an Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers 
Grove, IL, USA) or Mouse Glucagon ELISA kit (Crystal Chem, Downers Grove, IL, 
USA). Pancreata were removed for fixation in 4% paraformaldehyde and sectioned for 
histology as previously described [26]. At least three 7 μm-thick cryosections (replicates) 
were cut from each pancreas with an interval between each section >100 μm.  
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Table 2.1. Composition (g/100g of diet) of control vs. low protein rodent chow (Bio-
Serv, Frenchtown, NJ, USA) 
 
 
Component Control Low Protein 
Cornstarch 40.0 40.0 
Casein (88% protein) 22.3 8.6 
Maltodextrin 13.2 13.2 
Sucrose 10.0 23.6 
Soybean oil 4.5 4.5 
Cellulose 5.0 5.0 
Mineral mix 3.5 3.5 
Vitamin mix 1.0 1.0 
L-Cystine 0.3 0.3 
Choline Bitartrate 0.25 0.25 
Tert-butyl 
hydroquinone 
 0.0014 0.0014 
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Figure 2.1. Murine model of gestational glucose intolerance 
A) Schematic flow chart of experimental groups. F0 females were allocated to LP and C 
diet groups. F1 female offspring were separated into pregnant, CP and LPP (gestational 
day 9, 12, 18) and non-pregnant groups (CNP and LPNP). B) Timeline for treatment and 
sample collection. The F1 offspring were exposed to the low protein (LP) or control (C) 
diet during gestation and lactation and weaned onto control diet. At maturity, F1 females 
were time-mated with control-fed males. Stars demonstrate timepoints where an intra-
peritoneal glucose tolerance test was performed prior to euthanasia and removal of the 
pancreas for histology (n = 4−7 animals for each group). At each timepoint, serum was 
also collected. 
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2.2.3.  Glucose Tolerance Test  
An intra-peritoneal glucose tolerance test (IPGTT) was performed on all animals in their 
home cage prior to euthanasia as previously described [27]. For the F0 mice, this was one 
month after parturition while the IPGTT’s for the F1 mice were performed at the assigned 
gestational day or age for the age-matched group. Mice were fasted for 4-h with free 
access to water, injected intraperitoneally with 5μl·g-1 body weight of 40% glucose 
solution (2g·kg-1 body weight glucose, Sigma Aldrich, St. Louis, Missouri, USA), and 
blood glucose measured from the tail at 0, 5, 15, 30, 60, 90, and 120 min using a One 
Touch Ultra2 glucometer. Area under the glucose tolerance curve was analysed using 
GraphPad Prism software (Version 5.0, La Jolla, CA, USA). 
2.2.4.  Immunohistochemistry  
Immunofluorescence immunohistochemistry was performed to co-localize insulin and 
Ki-67 as a marker for insulin-immunopositive cells undergoing proliferation as 
previously described [10]. Slides were viewed by a blinded technician using a Zeiss 
fluorescence Axioskop microscope and cell counting analysis was performed using 
Image J [28]. Every insulin-expressing cell was imaged at 20X and counted manually. In 
this study, an “islet” was considered to contain >5 β-cells, and an extra-islet “cluster” as 
containing 1-5 β-cells. 
Immunofluorescence immunohistochemistry was also performed to localize insulin (β-
cells) and glucagon (α-cells) for morphometric analysis. Antibodies against insulin 
(1:2000, anti-mouse, Sigma-Aldrich, St. Louis, MO, USA, Cat. No:I2018, 
RRID:AB_260137) and glucagon (1:200, anti-rabbit, Santa Cruz, Santa Cruz, TX, USA, 
Cat. No:NB110-41547, RRID:AB_805593) were applied to cryosections and incubated 
overnight at 4°C. The following day, secondary antibodies (1:500 ThermoFisher, 
Waltham, MA, USA) were applied against the primary antibody using 555 (Cat. No:A-
31570, RRID:AB_2536180) and 488 fluorophores (Cat. No:A-21206, 
RRID:AB_141708), respectively, along with DAPI (4, 6-diamidino-2 phenylindole, 
dihydrochloride, 1:500, ThermoFisher, Waltham, MA, USA, Cat. No:D3571, 
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RRID:AB_2307445) to counterstain nuclei. Alpha-cell mass (ACM) and BCM were 
calculated from at least 2 sections (replicates) per pancreas (n = 4−7 C and LP animals 
per timepoint) as previously described [10]. β-cell size was calculated by taking the sum 
of the traced insulin-expressing area and dividing by the total number of β-cells counted 
for that section. Islets were counted per tissue section and further separated by size into 
small (less than 5000 μm2), medium (between 5000 and 10,000μm2) and large islets 
(more than 10,000 μm2). Tissue represented both the head and tail of the pancreas [29]. 
2.2.5.  Islet Isolation and Static Insulin Secretion  
Pancreatic islets were isolated from CP (n = 7−9 animals) and LPP (n = 6−8 animals) 
pancreata on GD18 by collagenase V (Sigma-Aldrich, St. Louis, MO, USA) digestion 
using a modified sequential Dextran gradient protocol [30,31]. Islets were incubated 
(37°C) overnight in RPMI media containing 6.5 mmol·L-1 D-glucose, 10% fetal calf 
serum, and 1% Penicillin Streptomycin. The following day, islets were pre-incubated in 
Krebs buffer solution (KRB’s, 119 mmol·L-1 NaCl, 4.7 mmol·L-1 KCl, 25 mmol·L-1 
NaHCO3, 2.5 mmol·L-1 CaCl22H2O, 1.2 mmol·L-1 MgSO47H2O, 1.2 mmol·L-1 
KH2PO4, 1% bovine serum albumin, 10 mmol·L-1 Hepes) containing 2.8 mmol·L-1 
glucose for 1-h at 37°C. Groups of 10 islets of similar size were collected into 1 mL of 
KRB’s containing either 2.8 mmol·L-1 or 16.7 mmol·L-1 glucose (1−3 replicate tubes per 
animal). Insulin release was determined in the supernatant after 90 min at 37°C using an 
Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL, USA). 
2.2.6.  Statistical Analysis  
The sample size of 4−7 animals per variable in either the LP or control groups was 
calculated based on achieving a statistically significant difference with an expected 
standard deviation around mean values for BCM and glucose tolerance of 15% or less 
based on our previous studies [10]. Each animal presented as a single unit of analysis (n) 
for the experiments with the F0 dams and F1 offspring. For comparisons of litters, each n 
represented an average value for each litter. Data are presented as mean±SEM, with 
statistics analysed using GraphPad Prism software (Version 5.0, La Jolla, CA, USA). An 
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unpaired two-tailed Student’s t-test was used to compare treatment groups (LP versus C). 
A two-way ANOVA followed by Bonferroni’s post-hoc test was used for comparison 
between treatment groups (LP versus C) at each timepoint during gestation. A repeated 
measures two-way ANOVA followed by Bonferroni’s post-hoc test was used for 
comparison of IPGTT curves between treatment groups (LP versus C) at each timepoint 
during gestation. Animals with fewer than 2 fetuses or more than 8 were excluded from 
statistical analyses. Statistical significance was determined as P < 0.05. 
 
2.3  Results  
2.3.1.  F0 Animals  
No differences were found between consumption of control or LP diet throughout 
gestation. Maternal weight gain increased steadily in both control and LP diet-fed dams 
throughout gestation (Fig. 2.2A). Furthermore, LP diet consumption had no effect on 
litter size (Fig. 2.2B). There were no differences in the number (Fig. 2.2C) or ratio (Fig. 
2.2D) of males to females born to LP versus C diet-fed dams. To test for a possible 
impact of diet on glucose homeostasis, an IPGTT was performed at 1-month postpartum. 
No differences were found between the IPGTT curves (Fig. 2.2E) or area under the 
glucose tolerance curves (AUC, Fig. 2.2F) of LP diet-fed females compared to control 
diet-fed females.  
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Figure 2.2. Low protein diet during pregnancy does not alter pregnancy 
characteristics of F0 dams 
A–C, low protein (LP) and control (C) diet-fed F0 dams did not statistically differ in 
mean values for maternal weight gain (A) (n = 13−14 animals for each group), litter size 
(B) (n = 24 C litters, 21 LP litters), the number of male and female offspring (C) (n = 19 
C litters, 20 LP litters), or the ratio of male to female offspring (D) (n = 19 C litters, 20 
LP litters). E and F, similarly, glucose tolerance (E) and area under the glucose tolerance 
curve (F) did not differ (n = 8 C and 7 LP animals for each group). 
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2.3.2.  F1 Animals  
Offspring born to dams fed a LP diet weighed less at birth (1.25±0.02g vs. 1.34±0.03g, 
p<0.05, unpaired two-tailed Student’s t-test, Fig. 3A) and at PND7 (3.56±0.11g vs. 
4.03±0.15g, p<0.05, unpaired two-tailed Student’s t-test, Fig. 2.3A). Offspring born to 
dams fed a LP diet continued to weigh less with age, demonstrating significantly reduced 
body weights compared to controls at weaning, PND21, (8.20±0.34g vs. 9.59±0.36g, 
p<0.001, two-way ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.3A), which 
persisted until maturity, PND42, (14.81±0.27g vs. 16.25±0.19g, p<0.001, two-way 
ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.3A). The LPP females continued 
to weigh less than CP females (p<0.001) throughout their own pregnancy (Fig. 2.3B). 
This was especially apparent during late gestation where the LPP females gained 
significantly less weight compared to CP females (12.78±1.22g vs. 15.24±1.44g, 
p<0.001, two-way ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.3C). No 
differences in fetal resorptions were found in LPP females compared to CP females (Fig. 
2.3D).  
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Figure 2.3. Offspring of LP-fed dams show altered pregnancy characteristics 
A, offspring of LP-fed mothers weighed less than controls by weaning (postnatal day 
(PND) 21, n = 13−22 litters for each group). B and C, LPP females weighed less than CP 
females throughout gestation (B) and put on less weight at late gestation (C) compared to 
CP females (n = 25 CP and 24 LPP animals). D, the number of fetuses did not differ 
throughout gestation between CP and LPP females (n = 7−22 animals for each group). 
***P < 0.001, **P < 0.01, *P < 0.05, LP vs. C. 
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2.3.2.1.  Offspring of low protein-fed mothers are glucose-
intolerant during their own gestation  
There were no significant differences in fasting blood glucose levels between LPP and 
CP females at any timepoint during gestation or between non-pregnant females (CNP, 
LPNP). Furthermore, no differences in blood glucose levels or AUC were found for non-
pregnant (Fig. 2.4A), GD9 (Fig. 2.4B) or GD12 (Fig. 2.4C) offspring born to dams fed a 
LP or control diet when subjected to an IPGTT. By GD18, LPP females had significantly 
higher blood glucose levels compared to CP at 5 min (18.88±2.22mmol·L-1 vs. 
10.73±0.97 mmol·L-1, p<0.001, repeated measures two-way ANOVA followed by 
Bonferroni’s post-hoc test) but no significant difference was found in AUC (Fig. 2.4D). 
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Figure 2.4. Offspring of low protein-fed mothers are glucose intolerant during their 
own gestation 
Blood glucose (mmol/L) and area under the glucose tolerance curve (AUC) data from 
intraperitoneal glucose tolerance tests performed on offspring from low protein (LP, 
continuous lines, closed squares) and control-fed (C, dashed lines, open squares) mothers. 
A–C, there were no differences between blood glucose and AUC levels of non-pregnant 
(A) (n = 6 CNP and 5 LPNP animals), gestational day (GD) 9 (B) (n = 4 animals for each 
group), or GD12 (C) (n = 6 animals for each group) LPP and CP females. D, LPP 
females displayed higher blood glucose levels on GD18 when compared to CP females. 
However, no differences were found in AUC values (n = 7 CP and 4 LPP females). ***P 
< 0.001, LP vs. C. 
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2.3.2.2.  Offspring of low protein-fed mothers have altered 
pancreatic morphology during pregnancy compared to 
controls  
We next evaluated whether impairments in endocrine pancreas could be contributing to 
the glucose intolerance that was seen in late gestation of LPP females. Expansion of 
BCM was maximal on GD18 in CP females (Fig. 2.5A). However, BCM was 
significantly lower in LPP females compared to CP females on GD18 (0.93±0.16g vs. 
1.96±0.41g, p<0.01, two-way ANOVA followed by Bonferroni’s post-hoc test). CP 
females also showed a maximal peak of ACM on GD18 (Fig. 2.5B). However, LPP 
females had significantly lower ACM expansion on GD18 compared to CP females 
(0.17±0.05g vs. 0.55±0.17g, p<0.01, two-way ANOVA followed by Bonferroni’s post-
hoc test, Fig. 2.5B).  
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Figure 2.5. Offspring of LP-fed mothers have altered pancreatic morphology during 
pregnancy compared to controls 
β-cell mass expansion (A) and α-cell mass expansion (B) were impaired in LPP females 
compared to CP females on GD18 (n = 4−6 animals for each group, 2−3 replicates for 
each animal). C, total β-cell proliferation was reduced during gestation in LPP females on 
GD12 (n = 4−7 animals for each group, at least 2 replicates for 
each animal). D, β-cell proliferation was reduced in clusters during gestation in LPP 
females on GD12 (n = 4−7 animals for each group, at least 2 replicates for each animal). 
**P < 0.01, *P < 0.05, LP vs. C. 
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2.3.2.3.  Mechanisms of reduced BCM expansion  
To determine whether the reduced BCM was due to decreased β-cell proliferation we 
used immunohistochemistry to identify insulin-containing cells co-localized with the 
DNA synthesis marker, Ki-67. Proliferating, insulin-expressing cells were identified in 
both clusters and islets of C and LP animals. Beta-cell proliferation increased during 
pregnancy in CP females but was significantly reduced in LPP females on GD12 
(2.11±0.31%Ki67+Ins+/Ins+(total) vs. 3.48±0.66%Ki67+Ins+/Ins+(total), p<0.05, two-way 
ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.5C). The reduced β-cell 
proliferation at GD12 was specific to small β-cell clusters 
(3.03±1.14%Ki67+Ins+/Ins+(clusters) vs. 6.47±1.22%Ki67+Ins+/Ins+(clusters), p<0.05, 
two-way ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.5D). Representative 
images of proliferating β-cells (%Ki67+Ins+) in non-pregnant, GD12 and GD18 animals 
are shown in Figure 2.6. We found no evidence of co-localized insulin/TUNEL cells 
during gestation (GD12 and 18) in either the control or LP diet-exposed groups.  
Although there was no effect of treatment on the ratio of α- to β-cells there was a change 
with day of pregnancy (p<0.001, two-way ANOVA, Fig. 2.7A). Mean islet size was 
reduced at GD18 in LPP females (4323±463μm2 vs. 7967±1542μm2, p<0.05, two-way 
ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.7B), however there were no 
differences in β-cell size (Fig. 2.7C). No differences in distribution of islet sizes were 
observed in non-pregnant animals (Fig. 2.7D). Nonetheless, there was a reduction in the 
number of small islets in LPP compared to CP mice at GD9 (3.80±0.93 vs. 12.50±1.43, 
p<0.001, two-way ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.7E), GD12 
(5.92±1.27 vs. 11.33±2.32, p<0.05, two-way ANOVA followed by Bonferroni’s post-hoc 
test, Fig. 2.7F), and GD18 (7.90±1.39) vs. 17.88±2.98, p<0.001, two-way ANOVA 
followed by Bonferroni’s post-hoc test, Fig. 2.7G).  
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Figure 2.6. LPP females show reduced β-cell replication at GD12 compared to CP 
females 
Representative immunofluorescence images demonstrating insulin (red), Ki-67 (yellow) 
and nuclei (DAPI, blue) staining of CNP, LPNP, CP and LPP females (at GD12 and 
GD18). White arrows demonstrate co-localized insulin and Ki-67 cells as an example of 
proliferating β-cells within an islet. Scale bar represents 50 μm. 
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Figure 2.7. LPP females have an altered distribution of islet sizes, contributing to a 
reduced mean islet size and BCM expansion at late gestation 
A, α- to β-cell ratio varies with day of pregnancy but not between dietary groups. B, 
mean islet size was reduced in LPP females compared to CP females on GD18. C, 
however, this was not due to a change in β-cell size. D, the number of small islets did not 
differ in LPNP females. However, the number of small islets was reduced in LPP females 
on GD9 (E), GD12 (F) and GD18 (G) (n = 4−6 animals for each group, 2−3 replicates for 
each animal). ***P < 0.001, *P < 0.05, LP vs. C. 
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2.3.2.4.  Offspring of low protein-fed mothers show 
gestational β-cell dysfunction in vitro and in vivo  
To assess β-cell function, we measured insulin secretion of isolated pancreatic islets from 
GD18 CP and LPP females. Levels of insulin were similar between LPP and CP females 
after 90 min in medium containing 2.8 mmol·L-1 glucose (Fig. 2.8A). However, islets 
from LPP females secreted less insulin in the presence of 16.7 mmol·L-1 glucose than CP 
females (0.22±0.04ng·mL-1·islet-1 vs. 0.49±0.07ng·mL-1·islet-1, p<0.01, two-way 
ANOVA followed by Bonferroni’s post-hoc test, Fig. 2.8A). To confirm these findings in 
vivo, serum insulin was quantified from blood drawn by cardiac puncture following the 
IPGTT. Confirming the in vitro findings, LPP females had lower serum insulin levels 
compared to CP females on GD18 (0.57±0.10ng·mL-1 vs. 1.34±0.25ng·mL-1, p<0.05, 
unpaired two-tailed Student’s t-test, Fig. 2.8B). Although serum glucagon levels appeared 
to be lower in LPP females on GD18, there were no significant differences found when 
compared to CP females (Fig. 2.8C). 
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Figure 2.8. Offspring of low protein-fed mothers show gestational β-cell dysfunction 
in vitro and in vivo 
A, glucose-stimulated insulin secretion was reduced on GD18 from isolated pancreatic 
islets from LPP females (n = 6−9 animals for each group, 1−3 replicates for each animal). 
B, serum insulin levels of LPP females were reduced on GD18 (n = 7 animals for each 
group). C, serum glucagon levels did not differ between CP and LPP females on GD18 (n 
= 5 animals for each group). **P < 0.01, *P < 0.05, LP vs. C. 
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2.4  Discussion  
This study proposes a novel mouse model of gestational glucose intolerance in which 
metabolic impairments are restricted to late gestation, as is seen clinically in human 
GDM. Epidemiological studies in humans have demonstrated strong associations 
between poor fetal growth, for instance as encountered in times of famine, and 
susceptibility to metabolic syndrome in adult life [32,33]. These observations have been 
replicated in maternal malnutrition studies in animals, resulting in permanent changes in 
tissue composition and cell size in the offspring during adulthood, ultimately contributing 
to the metabolic syndrome phenotype [34]. In agreement with the concept of 
developmental origins of health and disease [35], we show in this study that the 
intrauterine environment influences the risk of metabolic disease in offspring later in life. 
We previously showed that offspring of LP-fed mothers had reduced BCM and 
developed glucose intolerance in adulthood [31]. In this study we investigated whether 
offspring of LP-fed mothers would have a predisposition to glycaemic dysfunction during 
pregnancy, and the underlying pancreatic physiology that might contribute towards this 
phenotype. Overall, LP diet did not impact the pregnancy characteristics of F0 dams as 
no differences in maternal weight gain, litter size/sex of offspring or glucose homeostasis 
were found. Furthermore, it has previously been shown that isolated islets from pregnant 
LP-fed rats had a similar response to physiological glucose concentrations compared to 
controls [36], while another study concluded that a short period of LP-diet consumption 
did not alter total area under the glucose and insulin curves during a GTT, or basal serum 
glucose measurements, indicating preservation of pancreatic function [37]. Although this 
is being extrapolated from rats, we would not anticipate that LP-fed dams in our study 
would demonstrate gestational glucose intolerance and provide a model for GDM. 
However, the phenotype was altered in offspring of LP-fed mothers showing a reduced 
body weight at birth and PND7, which persisted with age and throughout their own 
pregnancy. Although we do not have data on visceral adipose tissue in our study, a 
previous study in our laboratory found no differences in visceral adipose tissue between 
offspring of LP and C-fed rats at 130 days of age [27]. Furthermore, because we are using 
young, pre-estropausal mice in our study, we anticipate that there would be no 
differences in visceral adipose tissue present in our model at this age. In humans, 
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postmenopausal women begin to have increased visceral fat accrual [38]. Therefore, 
potential differences in visceral adipose tissue in our model might only be seen at 
estropause which in mice is at 9-12 months of age [39]. 
In addition to the physical differences found between offspring of LP and C-fed mothers, 
we found maternal glucose intolerance when LPP females were subjected to an IPGTT at 
GD18. In comparison to our findings, a similar study using the LP diet model in rats 
stated that their model did not promote the onset of GDM [40]. However, this claim is 
made based on AUC data, for which our data are comparable on GD18. Nevertheless, the 
authors did not include their IPGTT curves, which is where we noted abnormally 
elevated maternal blood glucose levels in the LPP females. Previous studies found no 
differences in fasting blood glucose levels in young offspring (PND1, 7, 14 and 30) of LP 
and C-fed mothers [41]. Furthermore, LPNP female rodents did not demonstrate glucose 
intolerance until later in adulthood [27,41,42] and the onset in young adults in this study 
is likely to have been precipitated by the metabolic stress of pregnancy since there were 
no differences in glucose tolerance between CNP and LPNP. Clinically, since prior GDM 
increases the risk of the mother developing subsequent T2DM [43], it is plausible that the 
LPP females could prematurely develop glucose intolerance following pregnancy 
compared to non-pregnant animals. Future studies investigating metabolic differences 
and pancreas histology postpartum using our animal model of GDM could prove 
insightful. 
Consistent with previous findings [10,44], we observed that CP females were able to 
expand BCM to compensate for insulin resistance in pregnancy. However, BCM 
expansion was impaired in LPP females compared to CP females, as has been postulated 
to occur in human GDM [11,45,46]. In agreement with our previous work, the expansion 
of BCM during pregnancy was associated with increased β-cell proliferation [10], which 
was significantly reduced in LPP females. This was particularly apparent within the small 
extra-islet endocrine clusters which we have previously shown to be a source of β-cell 
progenitors [26]. This suggests that the proliferation of progenitors or their differentiation 
into functional β-cells might be impaired in LPP females. Reduced β-cell proliferation in 
LPP females contributed to a reduced mean islet size at GD18, consequently contributing 
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to reduced BCM expansion. Although there were no differences in β-cell size in LPP 
versus CP females, there were fewer small islets in LPP females at GD9, 12 and 18 
compared to CP females. Since there was a relative increase in large-sized islets of CP 
females at GD18 compared to GD9, we postulate that β-cell replication within small 
islets facilitates islet growth into medium and large sized islets as gestation progresses 
(GD18). This further contributed to increased BCM expansion in CP females at GD18. 
However, since LPP females had fewer small islets, there were fewer available to 
facilitate an adaptive expansion of BCM at GD18. Since there were no differences in islet 
size distribution in the LPNP versus CNP animals, these differences were attributed to the 
metabolic state of pregnancy. Although increased β-cell apoptosis is seen in offspring of 
LP-fed mothers [22], here we found no evidence of apoptosis within β-cells of LPP or CP 
females during a subsequent gestation; thus, excluding the possibility of β-cell apoptosis 
contributing to the reduced capacity for BCM expansion in LPP females. These results 
are in agreement with the findings of another animal model of maternal glucose 
intolerance during gestation in which the authors also reported that β-cell apoptosis did 
not contribute to the impairment of BCM expansion [47]. These results could be 
attributed to the contribution of the protein survivin, which normally becomes 
upregulated during gestation and acts as an inhibitor of apoptosis via epidermal growth 
factor-receptor signalling [48]. In addition to the dynamics of BCM investigated in this 
study, we are the first to report on α-cell dynamics in the pancreas during mouse 
pregnancy. Although there was no effect of treatment on the ratio of α- to β-cells there 
was a change with day of pregnancy. Further to reduced BCM, we found a relative 
decrease in ACM in CP females throughout gestation when compared to CNP. While CP 
females replenished ACM by GD18, this was not found in LPP females. There is 
evidence through lineage tracing of α-cells that they can replenish β-cells following β-cell 
loss or during β-cell stress via transdifferentiation [49,50]. These findings could implicate 
α- to β-cell transdifferentiation as a contributor to expanded BCM during pregnancy, 
which might be impaired in LPP females. 
We also examined β-cell functional capacity in our model, since β-cell dysfunction is a 
key feature of the pathophysiology of GDM [51]. Although insulin release from isolated 
islets harvested in late pregnancy in response to basal glucose concentration did not differ 
 
 
105 
between dietary groups, glucose-stimulated insulin secretion (GSIS) was significantly 
decreased in LPP females. These results are in agreement with other reports in which 
impaired GSIS was found in islets of offspring of LP-fed mothers as a result of 
mitochondrial dysfunction in β-cells [52]. Future studies investigating mitochondrial β-
cell dysfunction in our model would be insightful as women with GDM demonstrate 
increased oxidative stress, which has been suggested to contribute to β-cell dysfunction in 
GDM [53]. We confirmed our in vitro findings in vivo, showing that LPP females had 
reduced serum insulin levels at GD18 compared to CP females. These data supported our 
hypothesis and implicate β-cell dysfunction both in vivo and in vitro at late gestation in 
our model of gestational glucose intolerance. Therefore, in our model a combination of 
reduced BCM and impaired GSIS most likely contributed to the glucose intolerance seen 
in LPP females. Since our study was limited to changes in pancreas histology we cannot 
eliminate the possibility that insulin resistance at the level of target tissues contributed to 
glucose intolerance during pregnancy in offspring of LP-fed mothers. However, this has 
previously been shown to occur only in late adulthood (130 days) and not within the 
young adult mice used in these studies [27]. Indeed, pilot studies from our laboratory 
provide further support for this claim, suggesting no differences in HOMA-IR (a measure 
of insulin resistance) between CP and LPP females at GD18 (Supplemental Fig. 2.1). 
Nevertheless, a major strength of our study was the ability to reproduce gestational 
glucose intolerance during pregnancy complications such as GDM in which glucose 
intolerance is not diagnosed until late gestation. In our study, glucose intolerance was 
restricted to GD18 and was not seen in the non-pregnant state as has been shown in other 
models of gestational glucose intolerance [40]. Furthermore, additional animal models of 
diabetes in pregnancy that demonstrate pre-gestational obesity and diabetes [54,55] 
display glucose intolerance prior to conception, which is not a true diagnosis of clinical 
GDM [56]. Animal models utilizing chemical destruction of β-cells are widely used for 
modelling pre-gestational and gestational diabetes; however, these models more 
accurately resemble pre-gestational type-1 diabetes as opposed to the characteristics of 
insulin resistance seen in conditions such as GDM [57]. Therefore, in comparison to 
other models, our model of fetal programming of gestational glucose intolerance via 
dietary insult more accurately demonstrates the hyperglycaemic state of GDM, which 
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occurs only at late gestation. Although our dietary insult involves protein restriction 
during development, the LP diet is made isocaloric to the control diet through increased 
carbohydrate, which prompts the question of whether our findings are due to the effects 
of reduced protein or increased carbohydrate intake. However, the increase in 
carbohydrate content represents only a 20% increase compared to the more prominent 
40% reduction of protein (20% casein versus 8%) [58], which suggests that the glycaemic 
dysfunction and impairments in pancreas histology and function in our model are more 
likely the result of reduced protein. 
Susceptibility to developing GDM arises from a complex combination of both 
polygenetic and environmental factors. Taking this into account, the developmental 
programming of adult metabolism utilized in this mouse model of glycaemic imbalance 
during pregnancy does not reproduce the predominant predisposing causes of human 
GDM, which include pre-gestational obesity and excessive gestational weight gain 
[2,59]. Nonetheless, there are a number of anatomic and metabolic similarities including 
a failure to adequately increase BCM during pregnancy and impaired GSIS in late 
gestation. Post-mortem studies of human pancreata obtained from pregnant individuals 
confirmed an increase in endocrine mass during healthy pregnancies compared to the 
non-pregnant state [16,17], and it has been suggested that failure to adaptively increase 
BCM might contribute to the risk of GDM in humans [18]. Thus, further research efforts 
should focus on molecular mechanisms (i.e. signalling via prolactin and/or estrogen 
receptors) leading to reduced BCM expansion during gestation so that targeted 
interventions could be implemented. Measurements of serum placental lactogen, 
prolactin and estrogen in our animal model could also prove insightful. In conclusion, the 
model of hyperglycaemia in pregnancy described in this study could prove useful in 
evaluating pharmacological interventions aimed at safely increasing BCM or GSIS 
during pregnancy. 
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2.5  Supplemental Figures  
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Supplemental Figure 2.1. HOMA-IR measurements in control compared to LP mice 
at GD18 
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) values between 
treatment groups at GD18. n = 3 control and 2 LP animals. 
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Chapter 3  
3  Altered Pancreas Remodeling Following Glucose 
Intolerance in Pregnancy in Mouse  
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3.1  Introduction  
Pregnancy presents as a unique situation of endocrine pancreas β-cell adaptation that 
reverses after parturition. Late pregnancy is characterized by a state of peripheral 
maternal insulin resistance mediated by placental hormones [1] which is essential for 
maintaining trans-placental transport of glucose to the fetus for optimal development. To 
compensate for insulin resistance, the maternal pancreas responds by increasing 
endocrine pancreatic β-cell mass (BCM) to help maintain euglycemia. An adaptive 
expansion of BCM has been documented in both mice and humans and is maximal at late 
gestation (around gestational day (GD) 18 in mice) [2–7]. The adaptive mechanisms of 
BCM expansion during mouse pregnancy have been studied extensively and occur, in 
part, due to increased β-cell hypertrophy and proliferation, and the expansion of a β-cell 
precursor pool, all of which peak at mid-gestation [3,6–8]. These changes are mediated 
by increased levels of hormones including placental lactogen, prolactin, and estrogen 
[1,8]. After parturition, progesterone-mediated β-cell apoptosis increases while 
proliferation decreases concomitant with an absence of placental lactogen, returning 
BCM to pre-pregnancy levels [8,9]. If BCM expansion is suboptimal, gestational diabetes 
mellitus (GDM) can arise. 
GDM is described as diabetes that first appears during pregnancy and occurs due to 
insufficient β-cell adaptation to compensate for insulin resistance in pregnancy. The 
incidence of GDM worldwide is around 7-10% of all pregnancies [10,11] although the 
incidence will vary depending on the population characteristics and diagnostic criteria. 
As more women enter pregnancy obese, or at an older age, the incidence of GDM is 
projected to continue to rise [12]. An increased incidence of GDM is associated with 
morbidity due to adverse fetal outcomes [13–15] and adverse long-term maternal 
outcomes including an increased risk of type-2 diabetes mellitus (T2DM) [16] between 
3% to 90% [17]. Clinical studies have shown that glucose intolerance after parturition 
involves β-cell dysfunction [18–21] which can occur, in part, due to inflammation and 
glucotoxicity-induced oxidative stress in β-cells [22]. 
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Pregnancy can be characterized as a low-grade inflammatory state where the placenta is a 
major source of cytokines that can alter β-cell function [23]. For example, studies have 
postulated that 94% of the increased serum levels of tumor necrosis factor (TNF-α) in 
women during pregnancy results from placental production [24]. The first and early 
second trimester is a pro-inflammatory environment characterized by helper T-cell-1 
(Th1) cytokines, such as TNF-α, interleukin-1β, (IL-1β,), and interferon (IFN)-γ, 
resulting from implantation and placentation processes [23]. The second trimester is 
characterized as an anti-inflammatory environment with Th2 cytokines that permit for 
fetal growth and development [25]. Lastly, the third trimester is characterized by the 
recurrence of a pro-inflammatory environment in preparation for parturition, as 
inflammation promotes uterine contractions [26]. Thus, increased cytokine production 
occurs in healthy pregnancies. However, increased activity of the immune-checkpoint 
molecule programmed death-ligand 1 (PD-L1), and its receptor, PD-1, play a role in the 
maintenance of immunological balance between mother and fetus [27] and likely protect 
maternal β-cells from cytotoxic damage. In healthy pregnancies, PD-L1 is expressed by 
syncytiotrophoblast cells of the placenta in response to pro-inflammatory stimuli and is 
increasingly released into the maternal bloodstream as gestation progresses [28]. The 
interaction between PD-L1 and PD-1 reduces clonal expansion of pathogenic 
lymphocytes and their associated cytokine release [29]. Therefore, with decreased 
lymphocyte expansion, cytokine production is decreased, and β-cells are protected 
against cytokine-induced damage. In the context of GDM and persistent glucose 
intolerance at postpartum, it is plausible that insufficient levels of PD-L1 cause maternal 
β-cells to have greater susceptibility to cytotoxic damage, which can contribute to β-cell 
dysfunction. In GDM pregnancies, the low-grade inflammation that normally takes place 
in uncomplicated pregnancies is exacerbated [30]. The overexpression of pro-
inflammatory cytokines contributes to excessive peripheral insulin resistance in the 
mother, necessitating enhanced insulin secretion to maintain euglycemia, which is often 
not met in GDM pregnancies [31]. Thus, it is plausible that a prolonged low-grade 
inflammatory environment persisting after parturition in the absence of the placenta could 
result from cytokines released by other organs, such as adipose tissue, which could 
contribute to β-cell dysfunction postpartum and lead to dysglycemia. Inflammation can 
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contribute to β-cell dysfunction [32] via endoplasmic reticular stress resulting in 
decreased insulin sensitivity, as has been documented in GDM patients [33].  
We investigated the changes that occur in mouse pancreas during pregnancy and found a 
three-fold increase in BCM on GD18, resulting largely from increased β-cell replication 
which peaked at GD12 [6,7]. In our previous experiments, female offspring of mice fed a 
low protein (LP) diet during gestation and lactation were glucose intolerant at GD18 
during their own pregnancy when compared to offspring from control diet-fed mothers 
[6]. Glucose intolerance was associated with reduced β-cell proliferation leading to a 
lower BCM, in addition to reduced glucose-stimulated insulin secretion (GSIS). Since 
GDM increases the risk of the mother developing subsequent T2DM, we have used the 
above mouse model of gestational glucose intolerance to follow animals after parturition 
and determine whether glucose tolerance normalizes postpartum, and what the long-term 
effects of glucose intolerance during pregnancy are on maternal pancreas morphometry. 
The mechanisms contributing to adaptive BCM expansion during pregnancy in mice have 
been extensively studied. However, few studies exist investigating changes that occur 
past 7-10 days postpartum and to our knowledge no data exists comparing pancreas 
morphometry after hyperglycemic and control pregnancy. We aimed to determine: 1) 
what happens to glucose tolerance and islet morphology postpartum after a normal vs. a 
hyperglycemic pregnancy; and 2) the possible involvement of cytokines and PD-L1 in 
long-term changes in islet morphology and glucose tolerance postpartum. 
 
3.2  Methods  
3.2.1.  Animals and Sample Collection  
Adult (6-week-old) C57BL/6 male and female mice were obtained from Charles River 
Laboratories (Wilmington, MA, USA) and housed in a temperature-controlled room with 
12-h light/dark cycle at Lawson Health Research Institute, London, ON, Canada. Water 
and food were given ad libitum. Mice showing gestational glucose intolerance were 
generated using a previously described protocol involving a dietary insult during early 
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life [6, Chapter 2 of this thesis]. Briefly, timed pregnant F0-females were randomly 
allocated to either a control (C, 20% protein, Bio-Serv, Frenchtown, NJ, USA) or low 
protein diet (LP, 8%) group, where an increase in carbohydrate in LP diet yields an 
isocalorific diet compared to control chow. F0-dams were fed either the LP or C diet 
throughout gestation and lactation. A total of 12 LP and 12 C litters were used. On 
postnatal day (PND) 21, female offspring (F1) were weaned onto C diet for the remainder 
of the study (Fig. 3.1). At maturity (PND42), female offspring (F1) of LP and C diet-fed 
mothers were randomly allocated into 2 subsequent study groups: pregnant (LPP, CP) or 
non-pregnant (LPNP, CNP). All pregnant grouped females were mated with C diet-fed 
males, separated upon confirmation of pregnancy by vaginal plug and housed 
individually for the remainder of the experiment. Upon birth of pups, CP and LPP 
females were randomly allocated to one of three timepoints after parturition (postpartum 
day (PPD), PPD7, PPD30, or PPD90). For consistency, pups from all litters were 
euthanized at postnatal day 7. Mothers (F1) were euthanized by CO2 asphyxia following 
an intra-peritoneal glucose tolerance test (IPGTT) on PPD7, PPD30, or PPD90 for 
comparison to non-pregnant age-matched F1 females. Data (histology and IPGTT) for 
non-pregnant and GD18 animals, except for in vivo serum quantification, presented here 
have previously been published and are being used as a comparison to novel postpartum 
data in this study [6]. Following the IPGTT, maternal (F1) blood was collected via 
cardiac puncture in order to quantify serum insulin, glucagon and PD-L1 quantified using 
an Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL, USA), 
Mouse Glucagon ELISA kit (Crystal Chem, Downers Grove, IL, USA) and PD-L1 
ELISA assay (LifeSpan Biosciences, Seattle, WA, USA), respectively. Data were 
collected using a BioRad iMark plate reader and analyzed using Microplate Manager 
Software.   
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Figure 3.1. Experimental timeline for the generation of mice with gestational glucose 
intolerance and timepoints for sample collection 
Female offspring (F1) were exposed to the low protein (LP) or control (C) diet during 
gestation and lactation and weaned onto C diet. At maturity, F1 females were mated with 
C-fed males. Pups (F2) from all litters were euthanized at postnatal day 7. Stars 
demonstrate timepoints where an intraperitoneal glucose tolerance test was performed, 
the pancreas was removed for histology (n = 4–7 animals for each group), and serum was 
collected via cardiac puncture.  
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Pancreata were removed immediately following euthanasia and fixed in 4% 
paraformaldehyde for histology (PFA, Electron Microscopy Sciences, Hatfield, PA, 
USA). Fixed pancreas tissue was prepared and sectioned as previously described [34]. At 
least two 7 μm-thick cryosections (replicates) were cut from each pancreas with an 
interval between each section >100 μm representing at least 2 longitudinal slices through 
the pancreas. Sections included both the head and tail of the pancreas. All animal 
procedures were approved by the Animal Care Committee of Western University in 
accordance with the guidelines of the Canadian Council for Animal Care. 
3.2.2.  Glucose Tolerance Test  
An IPGTT was performed on all animals prior to euthanasia as previously described [35] 
at the assigned day postpartum or age for the age-matched group (n = 4−7 C and LP 
animals per timepoint). Mice were fasted for 4-h with free access to water, injected 
intraperitoneally with 5 μl/g body weight of 40% glucose solution (2g/kg body weight 
glucose, Sigma Aldrich, St. Louis, Missouri, USA), and blood glucose measured from the 
tail at 0, 5, 15, 30, 60, 90, and 120 min using a One Touch Ultra2 glucometer.  
3.2.3.  Immunohistochemistry and Morphometric Analysis  
Fluorescence immunohistochemistry was performed to localize insulin (β-cells) and 
glucagon (α-cells) for morphometric analysis as previously described [6]. Every insulin 
and glucagon-expressing cell was imaged at 20X with the observer being blind to tissue 
identity using a Nikon Eclipse TS2R inverted microscope (Nikon, Tokyo, Japan) with the 
program NIS elements. The microscope was equipped with an LED light source with 
emission bandwidths set to 460/50 nm for blue emission, 535/50 nm for green emission 
and 590/40 nm for red emission. For morphometric analyses, manual tracing of all islets 
for the tissue section was completed using ImageJ to quantitate fractional α- and β-cell 
area (sum of all glucagon or insulin-expressing areas divided by the whole pancreas 
surface area). Fractional areas were calculated from at least 2 sections (replicates) per 
pancreas (n = 4−6 C and LP animals per timepoint). Islets were counted per tissue section 
and further separated by size into small ( 5000 μm2), medium (5000–10,000 μm2) or 
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large (10,000 μm2) islets as previously described [36]. ApopTag Plus In Situ Apoptosis 
Fluorescein Detection Kit (S7111, EMD Millipore, Billerica, MA, USA) was used to 
identify apoptotic β-cells using the terminal deoxynucleotidyl transferase dUTP nick end 
labelling (TUNEL) assay. 
3.2.4.  Protein Extraction and Cytokine Analysis  
Posterior subcutaneous white adipose tissue (27-50 mg) was lysed for 30 min in an ice-
cold buffer as previously described [37]. Cytokine levels in adipose tissue protein 
extracts (n = 3−4 C and LP animals per timepoint, PPD90 C n = 2) were determined by 
multiplexing in a Bioplex system using customized kits from R&D systems (Magnetic 
Luminex assay) for cytokines of interest (TNF-α, IL-6, IL-1, and IFN). Values were 
normalized to weight of sample. 
3.2.5.  Statistical Analysis  
Data are presented as mean ± SEM, with statistics analyzed using GraphPad Prism 
software (Version 5.0, La Jolla, CA, USA). To determine effects of pregnancy on 
pancreas morphometry postpartum (CP), a one-way ANOVA was used followed by 
Bonferroni’s post-hoc test. For comparisons of LPP and CP groups over time, a two-way 
ANOVA followed by Bonferroni’s post-hoc test was used. A repeated measures two-way 
ANOVA followed by Bonferroni’s post-hoc test was used for comparison of the IPGTT 
curves between treatment groups (LP vs. C) at each timepoint after parturition. An 
unpaired two-tailed Student’s t-test was used for comparison of IL-6 levels at PPD7 
between dietary groups. Each animal presented as a single unit of analysis (n). Only the 
postpartum timepoints were included in statistical analyses to present novel data. To 
account for differences in litter sizes, the mean litter size for LPP and CP groups was 
determined. Litter sizes that were more than 2 standard deviations greater than the mean 
were considered outliers.  This did not result in any outliers in the data set. Statistical 
significance was determined as P < 0.05.  
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3.3  Results  
3.3.1.  Mice with gestational glucose intolerance display 
altered pregnancy characteristics  
Offspring born to dams fed a LP diet during gestation and lactation (F1, LPP) weighed 
less than controls (F1, CP) throughout gestation (Fig. 3.2A) and gained significantly less 
weight than CP females at GD17 and 19 (Fig. 3.2B). There were no significant 
differences in body weight between dietary groups after parturition (Fig. 3.2C). Body 
weight differed with time after parturition in both dietary groups (P<0.01, Fig. 3.2C).  
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Figure 3.2. Mice with gestational glucose intolerance display altered pregnancy 
characteristics 
(A) Pregnant female mice born to dams fed a low protein diet (LPP) weighed less and (B) 
gained less weight than pregnant female mice born to dams fed a control diet (CP) 
throughout pregnancy (n = 7 CP females, n = 10 LPP females). (C) No differences in 
body weight were found after parturition between dietary groups (n = 4–6 CP and LPP 
females). ***P < 0.001, **P < 0.01, LPP vs. CP. 
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3.3.2. Mice with gestational glucose intolerance demonstrate 
prolonged glucose intolerance after parturition 
We compared glucose tolerance in LPP vs. CP mice after parturition. LPP females that 
were relatively glucose intolerant at GD18 continued to display glucose intolerance at 
PPD7 with higher blood glucose levels at 15 and 30 min into an IPGTT (Fig. 3.3A). The 
relative glucose intolerance persisted at 1 month postpartum (PPD30, Fig. 3.3B). 
However, by 3 months postpartum (PPD90, Fig. 3.3C) LPP females had a similar 
glycemic profile as that seen in controls. Furthermore, the glycemic profile at PPD90 was 
restored to that of a non-pregnant animal (Fig. 3.3D). There were no significant 
differences in fasting blood glucose levels between dietary groups or with time 
(Supplemental Fig. 3.1A). Additionally, area under the glucose tolerance curve was 
higher in the LPP group at PPD7 compared to controls (Supplemental Fig. 3.1B).  
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Figure 3.3. LPP females show prolonged glucose intolerance after parturition  
Pregnant female mice born to dams fed a low protein diet (LPP) show glucose intolerance 
relative to pregnant female mice born to dams fed a control diet (CP) at (A) postpartum 
day 7 (PPD7, n = 6 CP females, 7 LPP females) and continue to be glucose intolerant at 
(B) 1 month postpartum (PPD30, n = 6 CP females, 5 LPP females). (C) However, by 3 
months postpartum (n = 4 CP females, 4 LPP females) LPP females display a glycemic 
profile similar to that of a control and demonstrate a similar glycemic profile to that of a 
(D) non-pregnant animal (n = 6 C non-pregnant females, 5 LP non-pregnant females). 
***P < 0.001, **P < 0.01, *P < 0.05, LPP vs. CP. 
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3.3.3.  Pregnancy alters pancreas morphology postpartum 
after both control and hyperglycemic pregnancies  
We investigated how endocrine pancreas morphology changed after parturition, both in 
CP and LPP groups. Pancreatic sections were immunostained for insulin (β-cells) and 
glucagon (α-cells) for morphometric analyses (Fig. 3.4). Since pancreas weight was 
relatively higher in the LPP group at PPD30 and PPD90 (Fig. 3.5A), β/α-cell fractional 
areas were used for histological analyses rather than BCM. Beta-cell fractional area was 
lower in LPP animals compared to CP animals at PPD7 (Fig. 3.5B). Notably, relative to 
PPD7, CP females had a ~30% reduction in BCM at PPD30 and a ~40% reduction by 
PPD90 (Fig. 3.5B), the latter resulting in a β-cell fractional area comparable to a non-
pregnant animal. In contrast to CP females, β-cell fractional area did not further decrease 
postpartum in the LPP group; rather the values remained at a similar level from GD18 up 
until PPD90 (Fig. 3.5B). Alpha-cell fractional area was lower in LPP animals compared 
to CP at PPD7 (Fig. 3.5C). Furthermore, α-cell area was lower at PPD30 vs. PPD7 in CP 
females. There were no significant differences in the α- to β-cell ratio (Fig. 3.5D) 
between dietary groups or with time after parturition. No evidence of dual-stained 
insulin/TUNEL cells was found when investigating the contribution of β-cell apoptosis at 
PPD7.  
Islet quantification demonstrated that the number of small, medium and large-sized islets 
varied with time after parturition (Table 3.1). At PPD90, there were significantly more 
small-sized islets in the LPP females compared to controls (Table 3.1). There were no 
significant differences in mean islet size after parturition between dietary groups (Table 
3.1). However, the mean islet size was 1.8-fold higher at PPD90 (6373 ± 2065 m2) 
compared to PPD7 (3599 ± 452 m2) in the LPP group (P = 0.147, Table 3.1). 
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Figure 3.4. Representative immunofluorescent images of islets after parturition 
Representative immunofluorescent images demonstrating β- (insulin, red) and α-cells 
(glucagon, green) in pregnant female mice born to dams fed a control diet (CP) and 
pregnant female mice born to dams fed a low protein diet (LPP) at postpartum days 
(PPD) 7 and PPD90. Nuclei were counterstained with DAPI (blue). Scale bar represents 
25 microns. 
 
 
 
129 
A) B)
C)
G
D
18
PP
D
7
PP
D
30
PP
D
90
N
on
-p
re
gn
an
t
0.0
0.2
0.4
0.6
0.8
1.0
Timepoint
A
lp
h
a
 c
e
ll:
B
e
ta
 c
e
ll
G
D
18
PP
D
7
PP
D
30
PP
D
90
N
on
-p
re
gn
an
t
0.000
0.005
0.010
0.015 *
Timepoint
B
e
ta
 c
e
ll 
fr
a
c
ti
o
n
a
l 
a
re
a
G
D
18
PP
D
7
PP
D
30
PP
D
90
N
on
-p
re
gn
an
t
0.000
0.001
0.002
0.003
0.004
0.005
*
***
Timepoint
A
lp
h
a
 c
e
ll
 f
ra
c
ti
o
n
a
l a
re
a
G
D
18
PP
D
7
PP
D
30
PD
D
90
N
on
-p
re
gn
an
t
0.0
0.1
0.2
0.3
CP
LPP
* *
Timepoint
P
a
n
c
re
a
s
 w
e
ig
h
t 
(g
)
D)
 
Figure 3.5. Pregnancy alters pancreas morphology postpartum after control and 
hyperglycemic pregnancies  
(A) Pancreas weight was higher in pregnant female mice born to dams fed a low protein 
diet (LPP) at postpartum day (PPD) 30 and PPD90 relative to pregnant female mice born 
to dams fed a control diet (CP). Both the fractional (B) β-cell area and (C) α-cell area 
were lower in LPP animals vs controls at PPD7. Furthermore, α-cell area was lower at 
PPD30 vs PPD7 in CP females. (D) Alpha to β-cell ratio did not differ between dietary 
groups or timepoints after parturition (n = 4–6 CP and LPP females). ***P < 0.001, *P < 
0.05, LPP vs. CP. 
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Table 3.1 Islet size distributions are altered postpartum after control and 
hyperglycemic pregnancies in mouse 
The number of small, medium and large-sized islets varied with time after parturition in 
both dietary groups (P<0.05). There were more small islets at postpartum day (PPD) 90 
in pregnant female mice born to dams fed a low protein diet (LPP) compared to pregnant 
female mice born to dams fed a control diet (CP). There were no significant differences 
in mean islet size after parturition between dietary groups.  * P<0.05 LPP vs. CP. 
 
 
Timepoint Treatment Small ( 
5000 μm2) 
Medium 
(5000–
10,000 μm2) 
Large 
(10,000 
μm2) 
Mean islet 
size (um2) 
Non-pregnant Control 9.64 1.79 2.00 4974 
 LP 7.50 1.42 1.33 4076 
GD18 CP 17.88 3.00 5.00 7967 
 LPP 7.90 1.30 1.60 4324 
PPD7 CP 13.92 2.50 3.83 6394 
 LPP 11.80 1.30 1.80 3599 
PPD30 CP 17.20 4.50 6.70 6141 
 LPP 13.73 2.63 4.00 5390 
PPD90 CP 5.29 1.50 2.13 6403 
 LPP 12.29 *  2.00 2.00 6373 
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3.3.4.  Cytokines may contribute to glucose intolerance after 
parturition in mice experiencing hyperglycemic pregnancies  
To investigate a potential contribution to prolonged glucose intolerance after parturition 
in the LPP group, we measured levels of representative cytokines in adipose tissue 
extracts by determining levels of TNF-α, IL-6, IL-1, and IFN. TNF-α levels varied 
with time after parturition in both dietary groups and were 1.4-fold higher in the LPP 
group at PPD7 compared to controls (3.56 ± 1.10 pg/mL/mg tissue vs. 2.55 ± 0.98 
pg/mL/mg tissue, P=0.534, Fig. 3.6A). Levels of IL-6 were higher in the LPP group at 
PPD7 compared to controls (Fig. 3.6B). There were no significant differences in levels of 
IL-1 with time after parturition or between dietary groups (Fig. 3.6C). However, IL-1 
was 1.4-fold higher at PPD7 in LPP compared to controls (698.5 ± 254.7 pg/mL/mg 
tissue vs. 517.8 ± 274.2 pg/mL/mg tissue, P=0.654, Fig. 3.6C). Levels of IFN were 3.1-
fold higher at PPD7 in LPP compared to controls (68.63 ± 24.94 pg/mL/mg tissue vs. 
21.88  ± 4.51 pg/mL/mg tissue, P=0.139, (Fig. 3.6D). 
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Figure 3.6. Altered cytokines may contribute to glucose intolerance in 
hyperglycemic mice after parturition 
Adipose tissue content of: (A) TNF-α, (B) IL-6, (C) IL-1β, and (D) IFNγ for pregnant 
female mice born to dams fed a control diet (CP) and pregnant female mice born to dams 
fed a low protein diet (LPP) at postpartum days (PPD) 7, 30, and 90. (A) TNF-α content 
significantly increased with time postpartum but not between dietary groups. (B) IL-6 
content decreased with time but was significantly higher in LPP animals. (C) IL-1β and 
(D) IFNγ content did not differ with time or between diets. n = 3–4, **P < 0.01, *P < 
0.05, LPP vs. CP. 
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Next, circulating levels of PD-L1, insulin and glucagon in serum were quantified. There 
were no significant differences in levels of PD-L1 between dietary groups. However, 
values differed with time after parturition as levels of PD-L1 were higher at PPD90 
compared to PPD7 in controls, but not in LPP mice (Fig. 3.7A). Of note, there was also a 
2.7-fold higher amount of PD-L1 present in LPP animals at PPD7 compared to controls 
(145 ± 49.54 pg/mL vs. 54.76 ± 28.9 pg/mL, P=0.214, Fig. 3.7A). The ratio of serum 
insulin to glucagon varied with time after parturition in both CP and LPP mice (Fig. 
3.7B) with a trend towards a higher ratio in the LPP group (P=0.071 LP vs. C, Fig. 3.7B). 
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Figure 3.7. Pregnancy results in long-term alterations in serum levels of PD-L1, 
insulin, and glucagon after parturition 
Serum levels of (A) PD-L1 and (B) insulin:glucagon ratio. (A) PD-L1 levels increased 
with time in pregnant female mice born to dams fed a control diet (CP) but not in 
pregnant female mice born to dams fed a low protein diet (LPP). (B) The serum 
insulin:glucagon ratio trended to be higher in LPP animals compared to controls (P = 
0.0705) and varied with time in both groups. n = 3–5, ***P < 0.001, *P < 0.05, LPP vs. 
CP. 
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3.4  Discussion  
GDM increases the subsequent risk of maternal dysglycemia or T2DM by up to 7-fold 
[17], although the relationship of this risk to longstanding changes in β-cell histology 
postpartum is unknown. Using a mouse model of gestational glucose intolerance, we 
addressed this knowledge gap by showing that dams continue to show glucose 
intolerance for at least a month after parturition (PPD30), and glycemic control did not 
normalize until 3 months postpartum (PPD90). This persistent glucose intolerance was 
associated with lower β- and α-cell fractional areas at PPD7 compared with control 
pregnancies representing an extension of the relative differences seen in late pregnancy 
for the glucose-intolerant dams.  
Several studies have reported the presence of β-cell dysfunction postpartum clinically 
after GDM [18–21]. Progressive β-cell dysfunction is likely the predominant factor that 
drives the transition from impaired glucose tolerance to T2DM after GDM [38,39]. In 
this study, LPP animals displayed glucose intolerance at PPD7 and PPD30 relative to 
controls. We have previously shown that LPP animals exhibit β-cell dysfunction at late 
gestation (GD18), resulting in reduced GSIS [6, Chapter 2 of this thesis]. A previous 
clinical study classified β-cell dysfunction as the key factor in the development of 
postpartum dysglycemia amongst non-obese patients [40]; insulin resistance, however, 
was determined to be the driver of postpartum hyperglycemia in obese patients. Our 
animal model of gestational glucose intolerance, which represents the non-obese 
category, therefore accurately reflects the changes that occur during β-cell dysfunction 
after GDM, rather than another underlying cause (such as insulin resistance as seen in 
obese patients). Although pre-gestational obesity is a major driver of GDM, 20-30% of 
women that develop GDM do not fall into this category. Therefore, this implicates 
dysfunction at the level of the β-cell to GDM pathophysiology [12]. This study thus 
proves useful for revealing underlying mechanisms of glucose intolerance postpartum 
characterized by β-cell dysfunction. Since the animal model represents only a mild 
hyperglycemia, the animals in this study were able to normalize blood glucose levels by 
PPD90. Nonetheless, it is plausible that additional metabolic stress such as a second 
pregnancy, or an age-related decline in β-cell function [41], could precipitate T2DM. 
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Human studies of impaired glucose tolerance postpartum do not allow visualization of 
histological changes occurring in endocrine pancreas. Previous studies of healthy mouse 
pregnancy [7,8] report that offspring born to dams fed a control diet (CP) had a ~50% 
reduction in BCM at PPD7 compared to GD18. In this study, CP females had a ~30% 
reduction in β-cell fractional area at PPD30 compared to PPD7 and ~40% by PPD90 
relative to PPD7, reducing β-cell fractional area to a level comparable to a non-pregnant 
animal. These differences could be attributed to the use of fractional area in this study 
instead of BCM. We used fractional area to exclude the effect of changes in exocrine 
tissue mass postpartum. Prolactin can alter exocrine tissue mass during lactation in mice 
[42] and we found differences in pancreatic weight postpartum in LPP mice. Thus, the 
use of fractional area provides a more accurate representation of endocrine changes in 
this study. These data support previous findings that β-cell apoptosis is occurring in 
controls after parturition in order to facilitate normalisation of BCM. This occurs in part 
due to a switch of β-cell serotonin receptor expression from HTR2B to HTR1D, 
mediating an inhibitory signal and promoting regression of BCM via increased β-cell 
apoptosis [9,43], in addition to higher levels of steroid hormones at late gestation which 
block lactogen-induced β-cell replication [44]. Insulin/TUNEL staining was negative 
when investigating the contribution of β-cell apoptosis at PPD7, suggesting that the 
apoptotic processes likely occur earlier postpartum since BCM was already reduced by 
PPD7. Nonetheless, a potential explanation for the retained β-cell fractional area at PPD7 
in controls could be due to persistently higher expression of serotonin synthetic enzyme 
tryptophan hydroxylase-1, Tph1, which normally increases during pregnancy in β-cells in 
order to mediate BCM expansion. A previous study found that Tph1 expression remained 
high at PPD7 until the end of lactation (PPD21) when levels returned to pre-pregnancy 
levels [43]. Further regression of β-cell fractional area at PPD30 and PPD90 could be due 
to regression of β-cell size, which was recently suggested as a contributor to BCM 
regression after pregnancy, prior to subsequently being increased during lactation. 
However, PPD30 and PPD90 mice in our study were not lactating, therefore, it is 
plausible that regression of β-cell fractional at these timepoints does indeed occur due to 
reduced β-cell size [45]. 
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In terms of changes in pancreatic α-cell abundance, fractional area was lower at PPD30 
compared to PPD7 in CP females. Thus, it is evident that there is a prolonged effect of 
pregnancy on the ontogeny of α-cells, as fractional area decreases to a level lower than 
the non-pregnant control at PPD90. These findings prompt interesting questions for 
future studies, especially concerning a second pregnancy and whether the pool of α-cells 
would increase and expand as observed on GD18 in a healthy pregnancy? [6,46]. 
Furthermore, would the pool of α-cells take longer to replenish, or is the α-cell 
complement fully depleted after a first pregnancy?  
In contrast to CP females, β-cell fractional area was not further decreased postpartum in 
LPP mice; the values instead remained at a similar level from GD18 to PPD90. There 
were no differences in β-cell proliferation between dietary groups at PPD7 compared to 
non-pregnant animals (Supplemental Fig. 3.1C). These data confirm previous findings 
that lactogen-induced β-cell proliferation that normally occurs during pregnancy, which 
is also functionally linked to increased levels of progesterone and estradiol as pregnancy 
progresses [44], is arrested by PPD7. However, since levels of β-cell replication were 
comparable in CP and LPP groups postpartum this excludes β-cell replication as a 
mechanism for the sustained elevated fractional β-cell in LPP mice. As previously 
mentioned, we found no evidence of β-cell apoptosis at PPD7. These findings support 
clinical data that markers of β-cell loss were reduced in serum samples from women 
postpartum after GDM and reached levels seen in non-pregnant women [47]. Thus, our 
study is the first to provide histological evidence to support these clinical findings by 
demonstrating that less β-cell loss is occurring postpartum after mild GDM. 
When comparing healthy and hyperglycemic pregnancies, both α- and β-cell fractional 
areas were lower in LPP mice at PPD7; a likely result of the insufficient endocrine 
pancreas adaptation previously found to occur at GD18, appearing to persist at PPD7. 
Importantly, α-cells have been identified as a target for serotonin action as a study in 
human islets showed that β-cell-derived serotonin inhibited glucagon secretion in 
response to high glucose [48]. Due to a reduced fractional β-cell area in LPP animals at 
PPD7 in this study, it is plausible that α-cells receive a reduced serotonergic input from 
β-cells and thus lose their ability to regulate glucagon secretion. This may result in 
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uncontrolled glucagon secretion and could contribute to the hyperglycemia seen in LPP 
animals at PPD7. This was shown to occur in vivo in women with GDM through a lack of 
suppression of plasma glucagon at late pregnancy that persisted postpartum [49]. These 
findings highlight an important role for pancreatic α-cells in pregnancy which has 
previously been overlooked. 
Despite the lack of a placental hormone stimulus to endocrine cell expansion postnatally, 
the β-cell fractional area did not change in LPP mice. This might be a compensatory 
mechanism in attempt to attain euglycemia. Size stratification of islets varied at PPD7 
and PPD30 in both control and LP groups, but there were no differences between dietary 
groups. This suggests that pregnancy itself causes re-modeling of islet populations after 
parturition. Additionally, there were more small islets in LPP females compared to 
controls found at PPD90, contributing to a recovered mean islet size comparable to that 
of a control. Thus, these data support an additional adaptive response in endocrine cells 
postpartum in LPP animals. These data could implicate β-cell neogenesis of small islets 
to facilitate normalization of mean islet size at PPD90 as a compensatory mechanism, 
thereby resulting in a rescue of glucose tolerance relative to controls. The LPP group had 
a higher ratio of insulin relative to glucagon after parturition compared to controls which 
provides further support of such an adaptive response. 
Pro-inflammatory cytokines can modify insulin signaling pathways and can lead to β-cell 
dysfunction [50]. Consequently, overexpression of cytokines can accelerate inflammation 
and exacerbate insulin resistance. Women with GDM have been shown to have increased 
circulating levels of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 all of which 
are associated with β-cell dysfunction [12,51]. Thus, it is plausible that prolonged glucose 
intolerance or T2DM after GDM could involve persistent inflammation postpartum. Both 
mouse and human placenta express multiple cytokines that contribute to the state of 
insulin resistance that occurs during pregnancy; for instance, TNF-α induces IRS-1 serine 
phosphorylation, which contributes to BCM expansion and insulin resistance in 
pregnancy [52,53]. In women with GDM, the decrease in insulin receptor tyrosine kinase 
phosphorylation does not improve postpartum as it does in women following a healthy 
pregnancy [33,54]. In the present model, levels of TNF-α were relatively higher in the 
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LPP animals compared to controls after parturition which could contribute, in part, to the 
glucose intolerance seen at PPD7 and PPD30. TNF-α levels in adipose increased with 
time, as seen in non-obese women in a study investigating longitudinal changes in serum 
pro-inflammatory markers across pregnancy and postpartum [55]. IL-6 has been found to 
be significantly higher in women with GDM, independent of adiposity [56] as observed 
in adipose samples from the non-obese animals used in this study where levels of IL-6 
were higher in LPP mice at PPD7 compared to controls. Interestingly, IL-6 levels were 
reduced in both CP and LPP groups by PPD90 concomitant with the return of glucose 
tolerance to control values. Some studies have found that high concentrations of IL-6 
could promote β-cell apoptosis and contribute to glucose intolerance [57]. However, 
since β-cell area did not change at any timepoint after parturition in LPP mice it is more 
likely that IL-6 is exerting effects on non-islet tissues. IL-6 has been shown to increase 
lipolysis in adipocytes, damage mitochondria and Glut2 function, and as a result decrease 
insulin sensitivity [58]. It is reasonable that higher IL-6 tissue levels contibuted to 
increased insulin resistance postpartum in LPP mice [52]. IL-6 can also induce 
production of IL-1 and TNF-α [59] further intensifying levels of pro-inflammatory 
cytokines postpartum and contributing to β-cell dysfunction and glucose intolerance. 
However, IL-1 levels in adipose tissue did not differ between dietary groups in the 
present studies. Collectively, these findings implicate a potential contribution of 
inflammation to insulin resistance postpartum in LPP mice, resulting in a maintaned β-
cell area resistant to apoptosis postpartum.  
An increase in cytokine production occurs in healthy pregnancies. However, the activity 
of PD-L1 also increases and attenuates the low-grade inflammatory immune response 
[27], potentially protecting maternal β-cells from cytotoxic damage. In the present study, 
levels of PD-L1 were relatively higher in LPP mice at PPD7 compared to controls. This 
may have helped to enhance β-cell survival in the face of a higher cytokine environment, 
as has been observed in autoimmune diabetes in NOD mice [29]. The PD-L1 ligand has 
also been shown to be expressed in β-cells of individuals with type 1 diabetes as a 
possible attempt to attenuate autoimmune attack [60]. However, PD-L1 was absent from 
islets of non-diabetic controls. Furthermore, the same study showed that IFN induced 
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PD-L1 mRNA expression in human pancreatic β-cells in vitro, potentially implicating 
IFN at PPD7 in LPP mice in this study as a mechanism for increasing PD-L1 levels. 
This pathway might also mediate β-cell neogenesis leading to a subsequent increase in 
the number of small islets observed at PPD90. This inflammatory pathway may also 
explain why β-cell fractional area remained elevated in LPP mice postpartum. Follow-up 
experiments treating LPP and CP mice at PPD7/30/90 with a PD-L1 inhibitor would be 
insightful to investigate potential differences in the ratio of serum insulin to glucagon. 
Interestingly, PD-L1 levels increased from PPD7 to PPD90 in controls. As a multitude of 
immunological changes involving both pro- and anti-inflammatory cytokines are 
occurring throughout pregnancy to the postpartum period, it is plausible that serum PD-
L1 levels were elevated in controls in part to suppress maternal immunity, or, to mediate 
a protective effect on β-cells against higher levels of TNF-α at postpartum. Interestingly, 
since PD-L1 levels were ~25% lower in LPP mice at PPD90, perhaps these animals will 
be more prone to cytoxic β-cell damage and could be on the trajectory to dysglycemia or 
T2DM. PD-L1 has also been identified as a biomarker for GDM in humans [61] and our 
findings support a potential role as a marker for prolonged glucose intolerance after 
GDM. 
In summary, we present novel findings of the ontogeny of α- and β-cell fractional areas 
of islet morphology and glucose tolerance postpartum in normal and hyperglycemic 
mouse pregnancies. The results demonstrate long-term pancreatic re-modeling after 
parturition involving both pancreatic α- and β-cells, which was associated with changes 
in the pro-inflammatory environment. These findings are informative in understanding 
the pathophysiology involved in the progression from GDM to glucose intolerance and 
T2DM. 
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3.5  Supplemental Figures  
 
Supplemental Figure 3.1. Metabolic and pancreas histology parameters after a 
GDM and healthy pregnancy 
A) Fasting blood glucose levels did not vary after parturition between dietary groups. 
Values represented are mean ± SEM analyzed by two-way ANOVA, P>0.05. 
 B) Area under the glucose tolerance curve was higher in LPP animals at PPD7 compared 
to controls. Values represented are mean ± SEM analyzed by unpaired two-tailed 
Student’s t-test, ** P<0.01. C) There were no differences in proportion of beta-cell 
proliferation (visualized by cell counting of dual-stained insulin and proliferation marker, 
ki67, positive cells) found relative to all counted beta cells. Values represented are mean 
± SEM analyzed by two-way ANOVA, P>0.05. 
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Chapter 4  
4  The Increased Alpha and Beta Cell Mass during Mouse 
Pregnancy is not Dependent on Transdifferentiation  
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4.1  Introduction  
Pregnancy is a physiological state characterized by relative maternal insulin resistance 
[1]. This has been linked to the presence of placentally-derived hormones and cytokines 
in the maternal circulation in the second half of pregnancy [2]. In preparation for the 
increased demand for insulin, adaptive changes occur in the endocrine pancreas in order 
to maintain euglycemia whilst also supplying the growing fetus with an adequate nutrient 
supply. A reversible expansion of β-cell mass (BCM) has been documented in both mice 
and humans and is maximal at late gestation (around gestational day (GD) 18.5 in mice) 
[3–8]. In situations where BCM expansion is suboptimal, gestational diabetes mellitus 
(GDM) can develop. This has been demonstrated in both clinical studies [9] and animal 
models of GDM [3,8,10–13] implicating β-cell failure as a major driver to metabolic 
pathogenesis. GDM is described as diabetes that first appears during pregnancy, which 
regresses postpartum in most cases. Nonetheless, GDM is associated with adverse short 
and long-term fetal and maternal health outcomes [14–18] necessitating the development 
of effective methods of intervention. Current treatments for GDM, such as lifestyle 
behavioural change or administration of insulin or metformin, aim to decrease 
hyperglycemia but do not treat the underlying causes including a suboptimal BCM. Thus, 
a better understanding of mechanisms of BCM expansion in pregnancy are needed in 
order to effectively target potential therapeutic interventions. 
The adaptive mechanisms of BCM expansion during mouse pregnancy have been shown 
to involve a re-entry of normally quiescent pre-existing β-cells into cell replication, 
mediated in part through prolactin receptor signaling in response to lactogenic hormones 
[12,19,20], in addition to increased β-cell hypertrophy [10]. These processes are maximal 
around mid-gestation in mice to prepare the pancreas for enhanced glucose-stimulated 
insulin release in late pregnancy [7,8]. Additional mechanisms of BCM expansion are 
likely to include the expansion and subsequent differentiation of a multipotent β-cell 
progenitor pool expressing some insulin but low levels of glucose-transporter 2 
(Ins+Glut2LO) [7]. Ins+Glut2LO cells are able to differentiate into mature β-cells under 
metabolic stress [21,22]. Pregnant mice were shown to have a higher proportion of 
proliferating Ins+Glut2LO cells at GD9.5, preceding maximal β-cell proliferation at 
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GD12.5. This was concurrent with increased Pdx1 mRNA expression, marking endocrine 
progenitor and mature β-cells, implicating this progenitor pool to BCM expansion during 
pregnancy. The contribution of non-β-cell progenitors to gestational BCM expansion has 
also been proposed and could contribute up to 25% of new β-cells in pregnancy [23,24]. 
An increase in the number of islets during mouse pregnancy has also been documented, 
providing further support for a contribution of islet neogenesis [7,8,25]. Furthermore, 
there were fewer small-sized islets throughout pregnancy in glucose-intolerant pregnant 
mice, implicating a potential critical role for a deficiency of β-cell neogenesis in the 
development of glucose intolerance [8, Chapter 2 of this thesis]. Although evidence exists 
to support expansion of BCM in pregnant humans, due to the scarcity of human samples, 
the mechanisms involved in BCM expansion remain unclear and controversial [6,26]. As 
such, the scarcity of pregnant human pancreas implicates the reliance on animal models 
of diabetes in pregnancy. 
Although there is evidence that α-cells contribute to hyperglycemia in patients with type 
2 diabetes mellitus (T2DM) via hyperglucagonemia [27–31], the dynamics of pancreatic 
α-cells in pregnancy have only recently been explored [8,32]. The changes in α-cell 
abundance during the endocrine adaptation to pregnancy were described with an 
expansion in α-cell mass (ACM) at GD18.5 in mice [8,32] which was impaired in 
glucose-intolerant pregnancies [8, Chapter 2 of this thesis]. One source of new β-cells 
during pregnancy could derive from a molecular re-programming of glucagon-producing 
α-cells as part of dynamic changes in the α-cell population. Previously it was shown that 
α-cells can replenish β-cells following extreme β-cell loss or during β-cell stress by α- to 
β-cell transdifferentiation [33,34]. Quesada and colleagues suggested that a negligible 
amount of α- to β-cell transdifferentiation was occurring at GD18.5 in normal pregnancy 
compared to non-pregnant mice, however genetic lineage tracing of α-cells was not 
performed to confirm this, and earlier timepoints in pregnancy were not examined [32]. 
As this study was performed in normal pregnancy there remains a lack of information 
about α-cell plasticity in the development of GDM. In this study, we aimed to address 
these knowledge gaps by: (1) documenting changes in the balance of α- and β-cells in 
control compared to glucose-intolerant mouse pregnancy, and (2) elucidating any 
temporal changes in α- to β-cell transdifferentiation in normal mouse pregnancy using 
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genetic lineage tracing. We hypothesized that one of the putative mechanisms related to 
the endocrine adaptational increase in β-cells in pregnancy could be the 
transdifferentiation of α-cells into β-cells and that any disbalance in this process will 
predispose to GDM. 
 
4.2  Methods  
4.2.1.  Animals and Sample Collection  
All animal procedures were approved by the Animal Care Committee of Western 
University in accordance with the guidelines of the Canadian Council for Animal Care. 
Mice were housed in a temperature-controlled room with 12-h light:dark cycle at Lawson 
Health Research Institute, London, ON, Canada. Water and food were given ad libitum. 
Aim 1: Adult (6-week-old) C57BL/6 male and female (F0) mice were obtained from 
Charles River Laboratories (Wilmington, MA, USA). Mice showing gestational glucose 
intolerance at GD18.5 were generated using a previously described protocol involving a 
dietary insult during early life [8, Chapter 2 of this thesis]. Briefly, F0 females underwent 
estrous cycling and were time-mated with males. Dams were randomly assigned to either 
a control (C, 20% protein, Bio-Serv, Frenchtown, NJ, USA) or a low protein (LP, 8%) 
diet similar to that described by Snoeck et al. [35]. The two diets were isocalorific, the 
deficiency in calories in the LP diet being compensated by additional carbohydrate [8]. 
F0 dams were fed either the LP or C diet throughout gestation and lactation, and female 
offspring (F1) were weaned onto C diet. At maturity (postnatal day, PND, 42), female 
offspring (F1) of LP and C diet-fed mothers were randomly allocated into two study 
groups: pregnant or non-pregnant. All pregnant-grouped females were time-mated 
(GD9.5, 12.5, 18.5) with C diet-fed males. Females (F1) were euthanized by CO2 
asphyxia for comparison to non-pregnant age-matched F1 females. The pancreas was 
removed at each assigned day of gestation (n = 4-6 C and LP animals for each timepoint 
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during gestation and for the non-pregnant groups). The pancreas was fixed in 4% 
paraformaldehyde for histology and embedded in optical cutting temperature compound.   
Aim 2: Glucagon-CreiCre mice (stock #030663, Jackson Laboratories, Bar Harbor, Maine, 
USA) that express Cre in 93-95% of α-cells, were crossed with a Rosa26-eYFP reporter 
mouse strain (stock #006148, Jackson Laboratories) to produce double transgenic 
Glucagon-Cre/Rosa26-eYFP (Gcg-Cre/YFP) mice. At maturity, double transgenic female 
offspring were randomly separated into 2 study groups: pregnant and non-pregnant. 
Pregnant-grouped females underwent estrous cycling in order to produce timed 
pregnancies [36]. Individual double transgenic female and wildtype C57BL/6 male mice 
(Charles River Laboratories, Wilmington, MA, USA) were housed together the morning 
of pro-estrous for mating and were separated the following morning. Females in the non-
pregnant group were age-matched to animals in the pregnant group (GD9.5, 12.5, and 
18.5). Animals were euthanized by CO2 asphyxia and the pancreas was removed at each 
assigned day of gestation (n = 4 animals for each timepoint during gestation and n = 8 
animals for the non-pregnant group) and prepared for histology as described above. 
4.2.2.  Immunofluorescence Staining  
Fixed pancreas tissue was prepared and sectioned as previously described [37]. At least 
two 7 μm-thick cryosections (replicates) were cut from each pancreas for 
immunohistochemical analysis. The interval between each section was >100 μm, 
representing at least two longitudinal slices through the pancreas. Sections included both 
the head and tail of the pancreas. For aim 1, immunofluorescence immunohistochemistry 
was performed to localize insulin, glucagon and Ki-67 as described previously [7,8]. 
Antibodies against insulin (1:2000, anti-mouse, Sigma-Aldrich, St. Louis, MO, USA) and 
glucagon (1:200, anti-rabbit, Santa Cruz Biotechnology, Dallas, TX, USA) were applied 
to tissues and incubated overnight at 4°C. To investigate α-cell proliferation, antibodies 
against glucagon (1:200, anti-rabbit, Santa Cruz Biotechnology) and Ki-67 (1:50, anti-
mouse, Biosciences, Mississauga, ON, Canada) were applied to tissues and incubated 
overnight at 4°C. The following day, secondary antibodies (1:500 Thermo Fisher 
Scientific Waltham, MA, USA) were applied against the primary antibody using 555 and 
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488 fluorophores, respectively, along with DAPI (1:500, Thermo Fisher Scientific) to 
counterstain nuclei. ACM data was retrieved from our previous studies [8, Chapter 2 of 
this thesis] and calculated by multiplying the fractional α-cell area (sum of all glucagon-
expressing areas divided by the whole pancreas surface area) by pancreas weight. For aim 
2, fluorescent immunohistochemistry was performed to localize insulin (phenotypic β-
cells), glucagon (phenotypic α-cells) and YFP (α-cell origin) for cell counting analysis. 
Background Sniper (Biocare Medical, Concord, CA, USA) was applied to each tissue 
section for 8 minutes to reduce non-specific background binding. Subsequently, 
antibodies against insulin (1:50, anti-guinea pig, Abcam, Cambridge, UK), glucagon 
(1:2000, anti-mouse, Sigma-Aldrich) and YFP (1:1000, anti-rabbit, Abcam) were applied 
to tissue sections and incubated overnight at 4°C. The following day, secondary 
antibodies (1:400 Thermo Fisher Scientific) were applied against the primary antibody 
using 555, 647, 488 fluorophores, respectively, along with DAPI (4, 6-diamidino-2 
phenylindole, dihydrochloride, 1:500, Thermo Fisher Scientific) to counterstain nuclei. 
4.2.3.  Cell Counting Analysis  
Tissue sections were visualized by a blinded technician at 20x using a Nikon Eclipse 
TS2R inverted microscope (Nikon, Minato, Tokyo, Japan) with the program NIS 
elements (Nikon, Minato, Tokyo, Japan), and images were captured and analyzed using 
cell counter on ImageJ software. Every insulin, glucagon, and YFP expressing cell was 
imaged for each section and for each animal. In this study, an “islet” was considered to 
contain >5 β-cells, and an extra-islet endocrine “cluster” as containing 1-5 β-cells [37].  
For aim 1, manual cell counting analysis determined the percentage of Insulin+Glucagon+ 
(insulin and glucagon double-positive) cells as a marker for α- to β-cell transitional cells 
[32,38–40]. Alpha-cell proliferation was determined by manually counting glucagon and 
Ki-67 double-positive cells. For aim 2, manual cell counting analysis determined the 
percentage of Insulin+YFP+Glucagon+ cells as a marker for a possible intermediate, 
transitional cell type between an α-cell and a β-cell (Fig. 4.1). The percentage of 
Insulin+YFP+Glucagon- cells was also determined to identify phenotypic β-cells arising 
from an α-cell origin. These cells were further localized as either being in the islet core or 
mantle. Co-localized cells that were part of the outermost layer of Insulin+ cells within 
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each islet were classified as being part of the islets’ mantle. Any co-localized cells that 
were closer to the middle of the islet, and therefore surrounded by this outer layer of 
Insulin+ cells, were classified as being part of the islet core. While islets are large enough 
to be able to break down into either core or mantle components, clusters were not. As 
each cluster of cells is only made up of 1 to 5 Insulin+ cells, no definitive outer layer of 
cells exists within this structure. Therefore, the division of co-localized cells into core 
and mantle layers was only feasible in “islets”, which are each composed of 6 or more 
Insulin+ cells. The core and mantle analysis was completed for both 
Insulin+YFP+Glucagon+ cells and Insulin+YFP+Glucagon- cells. For the core and mantle 
calculations, the Insulin+YFP+Glucagon- or Insulin+YFP+Glucagon+ cells that fell within 
either the core or the mantle were divided by the total number of Insulin+YFP+Glucagon+ 
or Insulin+YFP+Glucagon- counted for the tissue section.  
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Figure 4.1. Representative images of islet populations 
Representative images demonstrating staining for insulin (red), glucagon (yellow), YFP 
(green) and nuclei (DAPI, blue) in pancreatic sections from GlucagonCre-YFP transgenic 
female mice. The arrow in the non-pregnant islet represents a β-cell arising from an α-cell 
that no longer expresses glucagon (Insulin+YFP+Glucagon-). The arrow in the GD12.5 
islet represents an Insulin+YFP+Glucagon+ cell. 
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4.2.4.  Serum ELISA Assays  
For aim 1, maternal (F1) blood was collected via cardiac puncture after euthanasia in 
order to quantify serum insulin and glucagon using an Ultra-Sensitive Mouse Insulin 
ELISA kit (Crystal Chem, Downers Grove, IL, USA) or Mouse Glucagon ELISA kit 
(Crystal Chem), respectively. The insulin assay has a sensitivity of 0.05 ng/mL using a 
5uL sample with precision CV ≤ 10.0%. The glucagon assay has a sensitivity of 
1.1pg/mL using a 10uL sample with precision CV ≤ 10%. Samples were run in duplicate. 
Data were collected using a BioRad iMark plate reader and analyzed using Microplate 
Manager Software. Data throughout pregnancy was compared to non-pregnant animals, 
as a previous study [32] found that mice showed hypoglucagonemia as they entered 
pregnancy. Therefore, we compared the data as a percent change to non-pregnant 
animals, to determine how the animals adapt pancreatic α-cells in response to pregnancy. 
4.2.5.  Statistical Analysis  
The sample size of four to six animals per variable in either the LP or C groups was 
calculated based on achieving a statistically significant difference with an expected 
standard deviation around mean values for BCM and glucose tolerance of 15% or less 
based on our previous studies [7]. Data are presented as mean ± SEM, with statistics 
analyzed using GraphPad Prism software (Version 5.0). An unpaired two-tailed Student’s 
t test, one-way ANOVA or two-way ANOVA were applied according to the set of groups 
that were compared. A Tukey’s post-hoc test or a Bonferroni post-hoc test was performed 
after one-way ANOVA or two-way ANOVA analysis, respectively. Non-parametric tests 
were performed when data did not meet the assumption of normality. Significant outliers 
were determined using Grubbs’ test for each parameter. Each animal presented as a single 
unit of analysis (n). Statistical significance was determined as P < 0.05. 
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4.3  Results  
4.3.1.  Glucagon presence and α-cell proliferation in control 
vs. glucose-intolerant pregnancies  
We examined the changes in α-cell presence and function during pregnancy, and 
particularly the cells co-staining for insulin and glucagon, comparing normal pregnancies 
and those previously shown by us to have impaired gestational glucose tolerance with a 
decreased BCM [8, Chapter 2 of this thesis]. During pregnancy, both control and LP mice 
exhibited hypoglucagonemia relative to non-pregnant animals (Fig. 4.2A). However, the 
LP diet group showed a significantly greater serum glucagon presence (Fig. 4.2A) and 
lower serum insulin (Fig. 4.2B) in late gestation compared to control-diet animals when 
expressed relative to the values in treatment-matched non-pregnant animals. Nonetheless, 
the overall serum insulin/glucagon ratio did not change during pregnancy between 
treatment groups, although values were higher throughout pregnancy compared to non-
pregnant animals (Fig. 4.2C). This indicates that an increase in both circulating insulin 
and glucagon occurs during pregnancy but with relatively more insulin.  
When the ontogeny of α-cell proliferation was examined during pregnancy, a significant 
increase was seen at GD9.5 across the whole pancreas compared to pre-pregnancy in 
control animals, although this subsequently declined (Fig. 4.3A). However, proliferating 
α-cells were significantly reduced in extra-islet clusters at GD9.5 in the LP diet group 
relative to controls (Fig. 4.3B). Alpha-cell mass changed across gestation in both control 
and LP groups (P=0.01, Fig. 4.3C). However, ACM was significantly reduced in the LP 
group compared to control animals at GD18.5 (Fig. 4.3C). 
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Figure 4.2. Circulating levels of glucagon and insulin during control and LP 
pregnancies, and changes in ratio of insulin to glucagon  
(A) Serum glucagon and (B) insulin levels are shown as a percentage change relative to 
non-pregnant animals for the gestational days indicated. (C) Serum insulin to glucagon 
ratio throughout pregnancy. Samples were collected after euthanasia via cardiac puncture 
following an intra-peritoneal glucose tolerance test. n = 4-6 C and LP animals, *** 
P<0.001, ** P<0.01, * P<0.05, LP vs. C. 
 
 
 
 
 
 
 
 
 
 
 
 
161 
N
on
-p
re
gn
an
t
G
D
9.
5
G
D
12
.5
G
D
18
.5
0
2
4
6 **
*
* Control
LP
Day of Pregnancy
%
 K
i6
7
+
G
lu
c
+
/G
lu
c
+
 c
e
ll
s
 (
to
ta
l)
N
on
-p
re
gn
an
t
G
D
9.
5
G
D
12
.5
G
D
18
.5
0
2
4
6
8
**
**
*
Day of Pregnancy
%
 K
i6
7
+
G
lu
c
+
/G
lu
c
+
 c
e
ll
s
 (
c
lu
s
te
r
)
N
on
-p
re
gn
an
t
G
D
9.
5
G
D
12
.5
G
D
18
.5
0.0
0.2
0.4
0.6
0.8
**
Day of Pregnancy
A
lp
h
a
 c
e
ll
 m
a
s
s
 (
m
g
)
A B C
 
Figure 4.3 Gestational α-cell proliferation measured by the nuclear presence of Ki67 
in control and glucose-intolerant (LP-treated) mouse pregnancy 
 The percentage of proliferating α-cells in (A) whole pancreas and (B) extra-islet clusters. 
is shown relative to all glucagon immunopositive cells. (C) α-cell mass in control and LP 
pregnancy. n = 4-6 C and 4-5 LP animals, ** P<0.01, * P<0.05, LP vs. C. 
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4.3.2.  The balance of pancreatic α- and β-cells in control vs. 
glucose-intolerant pregnancies  
The frequency of insulin-staining cells that also contained glucagon was approximately 
15% in non-pregnant control diet mice (Fig. 4.4A) but the abundance of such bihormonal 
cells in whole pancreas, islets or extra-islet clusters did not change in control animals 
during pregnancy, and also did not differ in the LP diet group (Fig. 4.4A-C). However, 
the LP mice did enter pregnancy with a pre-existing reduction in the number of such cells 
compared to controls. Furthermore, there was a trend towards fewer dual-stained cells at 
GD12.5 in LP vs. control animals, suggesting that this potential lack of plasticity 
remained throughout pregnancy (Fig. 4.4A, P= 0.087). Notably, there was a transient 
decrease of ~50% of such cells in control pregnancies at GD9.5 (non-pregnant 16 ± 3% 
to GD9.5 7 ± 1%) prior to replenishment of these cells by GD12.5/18.5, potentially 
implicating a burst of α- to β-cell transdifferentiation at GD9.5. This relative decrease in 
dual-stained cells was absent in LP dams at GD9.5 and could implicate α- to β-cell 
transdifferentiation as a mechanism to increased BCM expansion gestation in control 
animals that was impaired in LP females.   
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Figure 4.4. Ontogeny of bihormonal cells containing both glucagon and insulin in 
control and glucose-intolerant (LP-treated) pregnancies  
The percentage of bihormonal cells is shown in (A) whole pancreas, (B) islets, and (C) 
extra-islet clusters relative to the total insulin immunopositive cells. n = 4-6 C and 4-5 LP 
animals, * P<0.05, LP vs. C. 
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4.3.3.  The contribution of α- to β-cell transdifferentiation to 
new β-cells in control pregnancy  
To address this question, we investigated the contribution of α- to β-cell 
transdifferentiation to BCM expansion in the pancreas during pregnancy by 
immunostaining histological sections of Gcg-Cre/YFP mouse pancreata for YFP, 
glucagon and insulin. By using Gcg-Cre/YFP transgenic mice, we were able to accurately 
lineage trace changes in the fate of glucagon-expressing pancreatic α-cells during the 
course of pregnancy to determine if some cells transdifferentiate to express insulin but 
not glucagon. First, co-localization of YFP with insulin in cells that did not contain 
glucagon (Insulin+YFP+Glucagon-) was examined within the pregnant mouse pancreas at 
various timepoints throughout pregnancy. Co-localization was seen in a minority of cells 
in both islets and small extra-islet endocrine clusters. In non-pregnant mice 
approximately 8% of insulin-staining cells also expressed YFP and this did not alter 
significantly throughout pregnancy when examined for the whole pancreas (Fig. 4.5A) or 
considering islets (Fig. 4.5B) or extra-islet clusters alone (Fig. 4.5C). Furthermore, the 
pattern for fold change relative to non-pregnant animals was also negligible in whole 
pancreas (Supplemental Fig. 4.1). Whilst the relative number of insulin-YFP dual stained 
cells in islets did not change during pregnancy the distribution did alter, with a relative 
reduction being seen in late gestation in the outer mantle of the islets relative to the islet 
core (Fig. 4.5D). 
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Figure 4.5. Alpha to β-cell transdifferentiation expressed as the percentage of 
phenotypic β-cells (Insulin+YFP+Glucagon-) 
Alpha to β-cell transdifferentiation in non-pregnant mice and at various gestational ages 
during normal pregnancy as expressed by the percentage of phenotypic β-cells 
(Insulin+YFP+Glucagon-) relative to the total insulin immunoreactive cells. The 
percentage of such cells in (A) the entire pancreas, (B) islets and (C) clusters are shown. 
(D) Localization of Insulin+YFP+Glucagon- cells to the islet mantle vs. the core. n = 8 
non-pregnant and 4 pregnant animals, * P<0.05, core vs. mantle. 
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4.3.4.  Cells in a transitional stage of α- to β-cell 
transdifferentiation increase in the islet mantle at GD18.5 
In addition to insulin-staining cells expressing YFP in the absence of glucagon 
(Insulin+YFP+Glucagon-) an approximately equal number of cells co-stained for insulin, 
YFP and glucagon in non-pregnant animals (Fig. 4.6A). As observed above with the C 
and LP-diet animals, the relative abundance of these cells did not change during 
pregnancy in either islets or extra-islet clusters (Fig. 4.6B-C), but their relative 
anatomical distribution within islets did alter in late gestation with significantly more 
being observed in the islet mantle (Fig. 4.6D).  
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Figure 4.6. Presence of Insulin+YFP+Glucagon+cells in the pancreas of non-pregnant 
and pregnant mice at gestational days 12.5 and 18.5 
The percentage of cells present in (A) whole pancreas, (B) islets and (C) clusters is 
shown relative to all insulin immunoreactive cells. (D) Localization of 
Insulin+YFP+Glucagon+cells to the islet mantle vs. the core. n = 4 non-pregnant and 4 
pregnant animals, ** P<0.01, core vs. mantle. 
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4.4  Discussion  
Pregnancy displays a remarkable reversible adaptation of BCM in order to maintain 
euglycemia, otherwise, pathologies such as GDM can arise. Although β-cells make up the 
majority of the islet, α-cells are the next most abundant cell type in the pancreas. These 
two endocrine cells play a critical role in maintaining glucose homeostasis by functioning 
in an antagonistic manner, whereby the intra-islet hypothesis states that insulin inhibits 
glucagon secretion [41]. The contribution of α-cells to hyperglycemia in patients with 
T2DM via hyperglucagonemia has been well-documented [27–31]. However, much less 
is known regarding the plasticity of pancreatic α-cells in pregnancy and this has yet to be 
investigated in glucose-intolerant pregnancy. Since α-cells can act as a reservoir to 
increase β-cell regeneration via α- to β-cell transdifferentiation in non-pregnant animals 
[42], it was also important to elucidate the role of this transdifferentiation in pregnancy. 
We first investigated changes in pancreatic α-cells in glucose-intolerant pregnancy using 
a previously established mouse model involving a dietary (LP diet) insult [8, Chapter 2 of 
this thesis]. Both dietary groups (LP and C) exhibited hypoglucagonemia during 
pregnancy. This supports findings from a previous study that showed that pregnant mice 
exhibited hypoglucagonemia and impaired glucagon secretion at GD18.5 [32]. This likely 
occurs as a protective effect to prevent hyperglycemia in the presence of insulin 
resistance at late pregnancy. Although, in our study there was less suppression of serum 
glucagon in LP mice at GD18.5, contributing to glucose intolerance in these animals as 
has been shown to occur at late pregnancy in women with GDM [43,44]. Importantly, 
higher glucagon levels persisted after parturition in women with GDM and it has been 
shown that this can contribute to dysglycemia and eventual development of T2DM. 
While treatment for GDM currently focuses on administering blood glucose lowering 
agents, such as insulin, management of uncontrolled glucagon secretion in GDM could 
theoretically also serve as a mechanism to reverse blood glucose levels in hyperglycemic 
women, by means of suppressing these levels. In contrast, levels of insulin were lower in 
LP mice at GD18.5, further contributing to glucose intolerance in these animals, 
occurring due to reduced BCM and insulin secretion [8, Chapter 2 of this thesis]. These 
findings demonstrate the sophisticated integrative islet communication between 
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pancreatic α- and β-cells, functioning to balance levels of insulin and glucagon to 
accommodate metabolic homeostasis in pregnancy, which becomes dysregulated in 
GDM.  
To further elucidate the role of pancreatic α-cells in control and glucose-intolerant (LP-
diet mice) pregnancies, the ontogeny of α-cell proliferation throughout pregnancy was 
assessed. We found that α-cell proliferation was highest at GD9.5 in controls and 
subsequently declined. The decline in α-cell proliferation likely follows similar 
progesterone-mediated inhibition that has been shown to occur in β-cells at late 
pregnancy [32,45]. A previous study determined that α-cell proliferation is mediated by 
placental lactogens and prolactin, similarly to what has been observed in β-cells [32]. 
However, earlier timepoints were not examined in this study [32] which could have 
provided crucial information as pregnancy hormones have been shown to mediate 
changes in pancreatic β-cells at GD9.5 to prepare the pancreas for adaptive BCM 
expansion at GD18.5. Thus, our results demonstrate an earlier onset of α-cell 
proliferation during gestation in control diet animals at GD9.5, which is a significant 
temporal difference that could have important implications for therapeutics. This 
provides histological evidence that α-cells follow similar temporal dynamics to β-cells in 
early pregnancy, which also reach maximal proliferation early in gestation [7,8]. 
Proliferating α-cells were subsequently also localized to islets or clusters within the 
pancreas, as it has been shown that Ins+Glut2LO β-cell progenitors are enriched in clusters 
[37]. In contrast to control-diet animals, glucose-intolerant animals (LP) exhibited less α-
cell proliferation in clusters at GD9.5. These data could implicate a contribution for α-cell 
neogenesis from small endocrine clusters to the adaptive expansion of ACM at GD18.5, 
which has also been shown to be a mechanism of BCM expansion [7,8,25]. However, our 
data suggest that adaptive α-cell mechanisms were impaired in GDM. 
Interestingly, we noted a high percentage of proliferating α-cells at GD9.5 relative to a 
non-pregnant animal (4.15% vs. 0.63%), providing speculation for a process of α- to β-
cell transdifferentiation in pregnancy requiring subsequent α-cell renewal mechanisms. 
This represented a 6.6-fold increase in α-cell proliferation, in comparison to the 3.6-fold 
increase in β-cell proliferation that occurs at the same time during pregnancy in mouse 
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(3.5% vs. 1%) [7,8]. This data brings into question the purpose of such a high level of α-
cell proliferation, which is greater than necessary simply to achieve the ACM expansion 
observed, which is only 2-fold higher at GD18.5 relative to a non-pregnant animal. In 
comparison, a 4-fold increase in BCM is achieved at GD18.5 with less β-cell 
proliferation [8, Chapter 2 of this thesis]. However, studies suggest that α-cells may serve 
as a reservoir for β-cell regeneration [42]. For example, GABA has been shown to cause 
α- to β-cell transdifferentiation and induces replacement of α-cells from duct-lining 
precursor cells that develop an α-cell identity prior to conversion into β-cells [46]. An 
additional study in mice with experimental type 1 diabetes mellitus found an increase in 
the proportion of glucagon+ cells that were positive for insulin or β-cell specific 
transcription factor Pdx1 [39]. Together, these findings suggest that increased pancreatic 
α-cell renewal mechanisms are a strategy to replenish and maintain the α-cell reservoir 
and/or to increase β-cell regeneration via α- to β-cell transdifferentiation.  
Consequently, we co-localized insulin and glucagon double-positive cells whose presence 
outside of pregnancy has been demonstrated previously [32,38–40]. Although insulin and 
glucagon double-positive cells have been suggested to be bihormonal cells in previous 
studies, better characterization of this population of cells would be important for future 
experiments. Data regarding secretion of insulin, glucagon or both by localization of 
hormones to granules using immune transmission electron microscopy would be 
insightful. It would also be interesting to determine if there is heterogeneity of function in 
bihormonal cell populations. Furthermore, additional questions remain, such as whether 
these bihormonal cells are a transitory type of cell, or a dedifferentiated type. A minority 
(~15%) of β-cells were bihormonal in non-pregnant, control-diet females suggesting that 
these cells are present as a normal feature of pancreas morphology and could represent 
functionally immature cell types. However, there was a transient decrease of bihormonal 
cells in controls at GD9.5 that was absent in LP dams, potentially implicating a burst of 
α- to β-cell transdifferentiation as a mechanism to increase BCM expansion during 
gestation in C animals that was impaired in LP females. Transdifferentiation may be 
reduced in these mice due to fewer Insulin+Glucagon+ cells being present in the non-
pregnant LP animal. Therefore, this dietary insult in utero may impair the plasticity of the 
α- and β-cell endocrine lineages and reduce α- to β-cell transdifferentiation [47]. 
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However, there were also fewer Insulin+Glucagon+ cells at GD12.5 in LP animals vs. 
controls, potentially implicating a deficit of α- to β-cell transdifferentiation in glucose-
intolerant pregnancy specifically at this time.  
Accordingly, to elucidate the role of α- to β-cell transdifferentiation to BCM expansion in 
pregnancy, we used transgenic mice to lineage track α-cells. Our data suggested that α- to 
β-cell transdifferentiation does not significantly contribute to BCM expansion in 
pregnancy. Interestingly, a minority (~8%) of β-cells in non-pregnant females expressed 
an α-cell label (Insulin+YFP+) suggesting that these cells are present as a normal feature 
of pancreas morphology. These findings are in contrast to studies that investigated α- to 
β-cell transdifferentiation in unchallenged mice, where baseline values for 
transdifferentiation were only around 1% [33,48,49]. However, it is important to 
acknowledge that these studies used an inducible method for tagging α-cells that was 
initiated after pancreatic development, which would not take into account the significant 
pancreatic remodeling that occurs during postnatal development [50]. Importantly, 
studies suggest that it is possible that some β-cells undergo a bihormonal, glucagon-
expressing progenitor stage during embryonic/postnatal development. One study used 
Gcg-Cre/YFP mice and reported that 10% of β-cells expressed an α-cell label at postnatal 
day 5, and 20% at postnatal day 21, which is comparable to values reported in the present 
study. Likewise, an additional study found comparable values, where 5-10% of β-cells 
were tagged with an α-cell label at postnatal day 1, and 12% at postnatal day 7-14, in a 
similar model using Gcg-Cre/YFP mice where α-cells were also labelled during pancreas 
development [51]. Although direct lineage tracing of transdifferentiated β-cells from an 
α-cell lineage would not be feasible in human samples, clinical data also suggests that it 
is possible that some β-cells undergo a bihormonal, glucagon-expressing progenitor stage 
during embryonic/postnatal development as bihormonal cells were also found in the 
developing human pancreas [52–54]. Since our model is a conditional Cre that is present 
from conception, the higher baseline values in our study compared to what has been 
published in many α- to β-cell transdifferentiation studies could be explained by the 
different lineage tracing models used. One way to address this discrepancy to elucidate 
the effects of the pregnancy time window would be to use an inducible Gcg/CreER model 
[55]. Alternatively, using the model in the present study the fold change can be calculated 
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and compared to baseline in the non-pregnant animals. As we found no temporal 
differences in the percentage of β-cells that underwent transdifferentiation, the pattern for 
fold change was unsurprisingly also negligible. 
Although the relative number of Insulin-YFP dual-stained cells did not change during 
pregnancy, we found that there were fewer of these cells in the islet mantle compared to 
the core at GD18.5. Previous studies have suggested that the mantle of the islet of 
Langerhans (where α-cells predominantly reside in mouse) contains a neogenic niche of 
-cell progenitors [49]. It is suggested that this group of cells is persistent throughout life 
and could represent a transitional cell type between an α-cell and a β-cell phenotype, 
perhaps within a process of α- to β-cell transdifferentiation. If so, then it does not appear 
that the metabolic stress of pregnancy enables a further differentiation of these cells to 
become unihormonal insulin-expressing. Using the lineage tracking molecule YFP, 
subpopulations of cells were also identified within this model that co-expressed both 
insulin and glucagon. While their relative abundance did not change during pregnancy 
their anatomical distribution did. In contrast to phenotypic β-cells 
(Insulin+YFP+Glucagon-) that were predominantly located in the islet core at GD18.5, the 
Insulin+YFP+Glucagon+ cells were found predominantly in the mantle. This supports 
previous findings that lineage-flexible α-cells may be most abundant in the mantle of the 
islets of Langerhans [49], and that they are present during pancreatic remodeling and 
endocrine adaptation in pregnancy. It has been previously reported that β-cell maturation 
begins from the islet mantle and propagates to the islet core, being coordinated by islet 
vascularization [56]. Our data would support the notion that transitional endocrine cell 
types originate at the islet mantle and then likely propagate towards the centre of the islet 
once lineage committed. This process occurs as pregnancy progresses, in order to 
coordinate optimal islet function and facilitate cell-to-cell communication at GD18.5 
when metabolic stress is highest [57]. 
In summary, we present novel data showing that there is an early onset of α-cell 
proliferation during pregnancy in controls, contributing to ACM expansion. This was 
impaired in glucose-intolerant pregnancies (LP) resulting in reduced ACM expansion and 
possibly fewer α-cells for α- to β-cell transdifferentiation to occur. However, using 
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lineage tracing, the process of transdifferentiation did not appear to dynamically alter 
during pregnancy. Nonetheless, both cell phenotypes examined (Insulin+YFP+Glucagon-, 
Insulin+YFP+Glucagon+) underwent anatomical changes in distribution within the islets 
in late gestation and in opposing directions. These data provide support for a potential 
transitional cell type in a pancreatic neogenic niche.   
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4.5  Supplemental Figures  
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Supplemental Figure 4.1. Transdifferentiation expressed as fold change relative to 
baseline 
The fold change of β-cells arising from α-cells that no longer express glucagon 
(Insulin+YFP+Glucagon-) relative to the baseline (non-pregnant animals). n = 8 non-
pregnant and 4 pregnant animals. P>0.05. 
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Chapter 5  
5  Strategies to Improve Glucose Tolerance in Pregnancy  
 
5.1  Introduction  
Pregnancy presents as a physiological state of insulin resistance that requires 
compensatory adaptations in maternal endocrine pancreas to maintain euglycemia [1]. If 
this compensation fails, gestational diabetes mellitus (GDM) can develop, implicating 
pancreatic β-cell failure as a major driver to metabolic pathogenesis. GDM is described 
as diabetes that first appears during pregnancy, which regresses postpartum in most cases. 
Nonetheless, GDM is associated with adverse short and long-term health outcomes to the 
mother (birthing difficulties, T2DM) and offspring (pre-term birth, respiratory distress 
syndrome, obesity, type 2 diabetes mellitus, T2DM) necessitating the development of 
effective methods of intervention [2–6]. Current treatments for GDM, such as lifestyle 
behavioural change or administration of insulin or metformin, aim to decrease 
hyperglycemia but do not treat the underlying causes including a suboptimal β-cell mass 
(BCM). Thus, a better understanding of mechanisms of BCM expansion in pregnancy are 
warranted in order to effectively target potential therapeutic interventions. 
In both mice and humans, a reversible expansion of pancreatic BCM and α-cell mass 
(ACM) has been documented and is maximal at late gestation (gestational day (GD) 18.5 
in mice) [7–13]. In mice, these changes have been shown to be mediated by increased 
levels of placental lactogen and prolactin, initiating proliferation of pre-existing β- and α-
cells [13,14]. Additional placental peptides, such as apelin and apela which signal 
through the apelin receptor (APJ), have been shown to alter β-cell number and function in 
non-pregnant animals and could also influence β-cell adaptations during pregnancy [15]. 
Although evidence exists to support expansion of BCM in pregnant humans, the 
mechanisms involved remain unclear and controversial due to limited samples [10,16]. 
An additional source of new β-cells during pregnancy could derive from 
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transdifferentiation of α-cells. Previous studies in non-pregnant animals reported that α-
cells can replenish β-cells during metabolic stress by α- to β-cell transdifferentiation 
[17,18]. The use of structural analogs of artemisinins, a class of anti-malarial drugs, has 
been shown to stimulate α- to β-cell conversion in vivo and in vitro [19] and improve 
glucose tolerance in non-pregnant animal models of diabetes [20,21]. In rodent and zebra 
fish models, treatment with artemisinins increased GABAA signaling which led to 
transdifferentiation of α-cells into β-cells [19]. The increased BCM resulted in improved 
glucose homeostasis, which suggests a therapeutic effect of treatment with artemisinins in 
animal models of diabetes. Furthermore, based on studies investigating the safety of these 
compounds in pregnancy, the World Health Organization has deemed artemisinins as safe 
to be used during pregnancies complicated by malaria [22,23]. Some data in animals 
suggests that artemisinins are embryotoxic during first trimester and the use is thus 
discouraged in first trimester [23,24]. Nonetheless, recent human studies have found no 
adverse pregnancy outcomes when artemisinins were used in the first trimester [22] and 
additional studies are now recommending re-assessment of this guideline as the benefits 
of artemisinin use in the first trimester exceed any potential risks [25]. 
GDM severely impacts healthcare costs around delivery due to pregnancy complications 
and admission to NICU, as well as long-term health resources due to future T2DM in 
both the mother and offspring. Therefore, a safe method of prevention is needed. 
Replacement of β-cells as a strategy for diabetes treatment is limited by the shortage of 
islet supply from deceased donors, and the use of immune-suppressive drugs would not 
be safe during pregnancy [26]. Current data suggests antidiabetic effects of artemisinins 
in non-pregnant animals, however, no data exists in pregnant animals. In this study, we 
investigated the potential therapeutic effects of artemisinin treatment in an animal model 
of gestational glucose intolerance during and following pregnancy, and elucidated the 
underlying potential mechanisms involved leading to improved glucose tolerance. 
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5.2  Methods  
5.2.1.  Animals, Treatment, and Sample Collection  
All animal procedures were approved by the Animal Care Committee of Western 
University in accordance with the guidelines of the Canadian Council for Animal Care. 
Mice were housed in a temperature-controlled room with 12-h light:dark cycle at Lawson 
Health Research Institute, London, ON, Canada. Water and food were given ad libitum. 
Adult (6-week-old) C57BL/6 male and female (F0) mice were obtained from Charles 
River Laboratories (Wilmington, MA, USA). Mice showing glucose intolerance at 
GD18.5 were generated using a previously described protocol involving a dietary insult 
during early life [12, Chapter 2 of this thesis]. Briefly, F0 females underwent estrous 
cycling and were time-mated with males. Dams were fed a low protein (LP, 8% protein, 
Bio-Serv, Frenchtown, NJ, USA) diet similar to that described by Snoeck et al. [27] 
throughout gestation and lactation. Female offspring (F1) were weaned onto a control 
diet (C, 20% protein) for the remainder of the study. At maturity (postnatal day, PND, 
42), female offspring (F1) of LP diet-fed mothers were randomly allocated into two study 
groups: pregnant (GD18.5 or postpartum day (PPD) 7.5) or non-pregnant. We chose 
GD18.5 based on previous findings that this was the timepoint where glucose intolerance 
and reduced BCM were present. We also investigated mice after parturition at PPD7.5 
due to a previous study showing that glucose intolerance persisted until 1 month 
postpartum [6, Chapter 3 of this thesis]. These animals were subsequently separated into 
an artemisinin-treated group, acetone vehicle group or non-treated group (non-treated 
non-pregnant and GD18.5 data retrieved from [12, Chapter 2 of this thesis], non-treated 
PPD7.5 data retrieved from [6, Chapter 3 of this thesis]). All pregnant-grouped females 
were time-mated with control diet-fed males. Initial experiments followed a protocol 
diluting the artemisinin, artesunate, in dimethyl sulfoxide vehicle (DMSO) [28]. 
However, pregnant mice treated with this mixture presented with pregnancy 
complications including preterm birth and embryolethality (Supplemental Fig. 5.1). 
Therefore, we adapted the protocol from an additional study where mice were treated 
with artesunate in an acetone vehicle diluted in drinking water daily [19]. A stock 
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solution of 250mg/ml artesunate (Cayman Chemicals, Ann Arbor, MI, USA) in acetone 
(Sigma-Aldrich, St. Louis, MO, USA) was prepared daily, 40 l of which was diluted 
daily in 10mL drinking water for a final concentration of 1mg/mL artesunate. An equal 
concentration of acetone was used in the control group, and drinking water was provided 
ad libitum. Water bottles were covered with aluminum foil to prevent light penetration 
[19]. Vehicle or treatment was replaced daily from GD0.5-6.5, after which the solution 
was replaced with tap water for the remainder of the experiment (Fig. 5.1). Females were 
euthanized by CO2 asphyxia at their assigned day for comparison to non-pregnant age-
matched females. Maternal pancreatic samples were fixed in 4% paraformaldehyde for 
histology and embedded in optical cutting temperature compound. Maternal serum 
samples were collected via cardiac puncture. Placenta samples were collected in 1mL of 
RNAlater RNA Stabilization Reagent and frozen at -20°C (Qiagen, Hilden, Germany). 
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Figure 5.1. Animal model of treating glucose intolerance in pregnancy  
F0 dams were fed a LP diet (8% protein) during gestation and lactation. Offspring 
(F1) were weaned onto control diet (C, 20% protein). At maturity, pregnant-grouped 
F1 females were time-mated with C-fed males. Artesunate-grouped pregnant females 
were treated (1mg/mL) via drinking water from gestational day (GD) 0.5-6.5 vs. vehicle-
grouped females which were treated with the acetone vehicle alone, and non-treated 
females which were given regular tap water. The artesunate/acetone treatment group is 
represented by the pink bar, the acetone vehicle alone is represented by the black dashed 
bar. Non-pregnant animals were age-matched to females in the pregnant group. Stars 
indicate timepoints where an intraperitoneal glucose tolerance test was performed prior to 
euthanasia and the pancreas was removed for fluorescence immunohistochemistry. The 
blue box represents the F1 pregnancy experimental timepoints. 
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5.2.2.  Intra-peritoneal Glucose Tolerance Test  
Prior to euthanasia, an intra-peritoneal glucose tolerance test (2g glucose/kg body weight, 
IPGTT) was performed on all animals. Mice were fasted for 4 h. Blood glucose was 
measured from the tail at 0, 5, 15, 30, 60, 90 and 120 minutes using a One Touch Ultra2 
glucometer. 
5.2.3.  Immunohistochemistry and Endocrine Pancreas 
Morphometry  
Fixed pancreas tissue was prepared and sectioned as previously described [29]. At least 
two 7 μm-thick replicate cryosections were cut from each pancreas with an interval 
between each section >100 μm representing at least two longitudinal slices through the 
pancreas. Sections included both the head and tail of the pancreas. Immunofluorescence 
immunohistochemistry was performed to localize insulin and glucagon as described 
previously [12]. Antibodies against insulin (1:2000, anti-mouse, Sigma-Aldrich) and 
glucagon (1:200, anti-rabbit, Santa Cruz Biotechnology, Dallas, TX, USA) were applied 
to tissues and incubated overnight at 4°C. The following day, secondary antibodies 
(1:500 Thermo Fisher Scientific Waltham, MA, USA) were applied against the primary 
antibody using 555 and 488 fluorophores, respectively, along with DAPI (1:500, Thermo 
Fisher Scientific) to counterstain nuclei.   
Tissue sections were visualized at 20x using a Nikon Eclipse TS2R inverted microscope 
(Nikon, Minato, Tokyo, Japan) with the program NIS elements (Nikon, Minato, Tokyo, 
Japan), and images were captured and analyzed using cell counter on ImageJ software. 
Every insulin and glucagon expressing cell was imaged for each section and for each 
animal. Manual cell counting analysis determined the percentage of bihormonal 
Insulin+Glucagon+ cells as a marker for α- to β-cell transitional cells [13,30–32]. 
 To determine BCM and ACM, morphometric analysis was performed by manually 
measuring the total pancreas area for each tissue section, and the relative area of β-cells 
and α-cells [12,33]. BCM and ACM was calculated by multiplying total β or α-cell area 
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(sum of entire β or α-cell area/surface area of entire tissue section) by the pancreas 
weight. Islets were counted per tissue section and further separated by size into small 
(<5000 μm2), medium (5000–10,000 μm2), or large (>10,000 μm2) islets as previously 
described [12,33]. 
5.2.4.  Serum ELISA Assays  
Maternal (F1) blood serum was used to quantify insulin and glucagon using an Ultra-
Sensitive Mouse Insulin ELISA kit (Crystal Chem, Downers Grove, IL, USA) and Mouse 
Glucagon ELISA kit (Crystal Chem), respectively. The insulin assay has a sensitivity of 
0.05 ng/mL using a 5uL sample with precision CV ≤ 10.0%. The glucagon assay has a 
sensitivity of 1.1pg/mL using a 10uL sample with precision CV < 10%. Data were 
collected using a BioRad iMark plate reader and analyzed using Microplate Manager 
Software.  
5.2.5.  Quantitative Polymerase Chain Reaction  
Placenta samples (3-5mg) were minced with scissors in lysis buffer and Qiashredder spin 
columns (Qiagen) prior to total RNA extraction according to the RNeasy Plus Micro kit 
manufacturers’ specifications (Qiagen). Sample yield and purity was quantified by 
absorbance at 260 and 280 nm (value 1.7-2) using a NanoDrop 2000c Spectrophotometer 
(ThermoFisher Scientific, Mississauga, ON). Total RNA (<1 μg) was extracted and 
reverse transcribed to cDNA using iScript Reverse Transcription Supermix (Bio-Rad 
Laboratories, Hercules, CA, USA). Quantitative PCR (qPCR) experiments were 
accomplished using the 2-ΔΔCT method after confirmation of parallel PCR amplification 
efficiencies. The mRNA levels of apelin receptor and apela were quantified using the 
TaqMan gene expression assay and the TaqMan Fast Advanced Master Mix (Invitrogen, 
Carlsbad, CA, USA) with the following Taqman primers: apelin receptor 
(Mm00442191_s1, Applied Biosystems, Forest City, CA, USA), apela 
(Mm04278372_m1, Applied Biosystems), with Cyclophilin A (Mm02342429_g1, 
Applied Biosystems) as the housekeeping gene. qPCR reactions were performed on 
triplicate samples with 20ng cDNA added per reaction using the QuantStudio Design and 
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Analysis Software. QuantStudio 5 Real-Time PCR System (Applied Biosystems) was 
programmed with the following thermal-cycling profile: polymerase activation step at 
95ºC for 20 seconds, followed by 40 cycles of denaturation at 95ºC for 3 seconds, and 
annealing/extension at 60ºC for 30 seconds. Levels of mRNA expression were calculated 
relative to those of the housekeeping gene cyclophilin A. 
5.2.6.  Statistical Analysis  
Data are presented as mean ± SEM, with statistics analyzed using GraphPad Prism 
software (Version 5.0). An unpaired two-tailed Student’s t test, one-way ANOVA or two-
way ANOVA were applied according to the set of groups that were compared. A Tukey’s 
post-hoc test or a Bonferroni post-hoc test was performed after one-way ANOVA or two-
way ANOVA analysis, respectively. Each animal presented as a single unit of analysis 
(n). n = 4 – 7 animals per treatment per timepoint. Statistical significance was determined 
as P < 0.05. 
 
 
5.3  Results  
5.3.1.  Artesunate treatment in mid-gestation and pregnancy 
outcomes  
Our hypothesis was that treatment with artesunate would improve glucose tolerance 
during pregnancy, as was observed in previous studies in non-pregnant diabetic mice 
[34]. We initiated these experiments by treating animals with artesunate in an acetone 
vehicle via drinking water between GD8.5-14.5. Artesunate/acetone treatment caused a 
reduction in weight gain (Supplemental Fig. 5.2A), food consumption (Supplemental Fig. 
5.2B), and altered water consumption (Supplemental Fig. 5.2C) at the onset of treatment 
compared to a non-treated animal. However, fetal resorptions were observed implicating 
substantial embryonic lethality. Similar findings were observed in rats treated with 
artemisinins during organogenesis [23]. Nonetheless, in this study embryolethality was 
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only observed during organogenesis and not when the rats were treated during 
blastogenesis/pre-implantation (GD0.5-6.5) or during the fetal period (GD14.5-20.5). 
Thus, subsequent experiments were modified to treat mice with the artesunate/acetone 
intervention from GD0.5-6.5. 
5.3.2.  Artesunate treatment in early gestation and 
pregnancy outcomes  
Weight gain was significantly reduced in both artesunate/acetone and the acetone vehicle 
group compared to non-treated animals (Fig. 5.2A). However, artesunate/acetone treated 
animals had a higher food consumption relative to non-treated animals (Fig. 5.2B). Both 
treatment groups drank an average of 4mL of solution a day during treatment (Fig. 5.2C), 
which is comparable to values for non-treated mice of 3-4mL depending on body weight 
[35]. There was no difference in the number of fetuses at GD18.5 (Fig. 5.2D). There were 
no significant differences in placental weight (Fig. 5.2E) or fetal weight between 
treatment groups at GD18.5 (Fig. 5.2F). However, artesunate/acetone treated animals 
trended to weigh more compared to non-treated animals (P=0.0618). 
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Figure 5.2. Pregnancy and model characteristics between treatment groups 
A) Both treated groups gained less weight during pregnancy, and B) food consumption 
was higher in artesunate/acetone treated animals. C) Water consumption did not differ 
between treatment groups. There were no differences in (D) number of fetuses at 
GD18.5, E) placental weight, or F) fetal weight between treatment groups. n = 4-6 
animals per treatment group. *** P<0.001, * P<0.05, non-treated vs. treatment group. ## 
P<0.01 non-treated vs. vehicle.  
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5.3.3.  Both artesunate-treated and acetone vehicle-treated 
animals have improved glucose tolerance vs. non-treated 
females  
Animals in both the artesunate/acetone and acetone vehicle group had significantly lower 
blood glucose levels at 5, 15 and 30 minutes during the IPGTT relative to non-treated 
mice at GD18.5 (Fig. 5.3A). At 120 minutes, the acetone vehicle-treated mice had 
significantly higher blood glucose levels compared to non-treated mice. Furthermore, the 
area under the glucose tolerance curve was significantly lower in the acetone vehicle 
group (Fig. 5.3B). IPGTT curves/glycemic curves were similar (as shown for those 
groups at GD18.5), and not significantly different between the artesunate/acetone vehicle 
and acetone vehicle alone for non-pregnant and PPD7.5 animals. This led us to postulate 
that the acetone vehicle was primarily responsible for improved glucose tolerance. 
Therefore, artesunate/acetone and acetone vehicles animals were pooled for further 
analysis. Blood glucose levels were significantly lower in non-pregnant acetone-treated 
animals compared to non-treated animals (Fig. 5.3C/D). Blood glucose levels were also 
lower in acetone-treated animals compared to non-treated animals at PPD7.5 (Fig. 
5.3E/F). 
 
 
 
193 
N
on
-tr
ea
te
d
Ar
te
su
na
te
/A
ce
to
ne
Ac
et
on
e 
V
eh
ic
le
0
200
400
600
800
1000
*
Treatment
A
U
C
 (
m
m
o
l/
L
 *
 m
in
)
N
on
-tr
ea
te
d
A
ce
to
ne
0
200
400
600
800
*
Treatment
A
U
C
 (
m
m
o
l/L
 *
 m
in
)
0 5 15 30 60 90 120
0
10
20
30
Non-treated
Acetone
***
**
***
PPD7.5
Time (minutes)
B
lo
o
d
 g
lu
c
o
s
e
 (
m
m
o
l/
L
)
0 5 15 30 60 90 120
0
5
10
15
20
25
Non-treated
Artesunate/Acetone***
**
**
Acetone Vehicle
GD18.5
#
## #
#
Time (minutes)
B
lo
o
d
 g
lu
c
o
s
e
 (
m
m
o
l/L
)
0 5 15 30 60 90 12
0
0
5
10
15
20
25
Non-treated
Acetone
Non-pregnant
***
**
Time (minutes)
B
lo
o
d
 g
lu
c
o
s
e
 (
m
m
o
l/
L
)
N
on
-tr
ea
te
d
A
ce
to
ne
0
200
400
600
800
*
Treatment
A
U
C
 (
m
m
o
l/
L
 *
 m
in
)
A B
C D
E F
 
Figure 5.3. Artesunate-treated and vehicle animals have improved glucose 
tolerance vs. non-treated females 
 A) Artesunate/acetone and acetone vehicle-treated females had significantly reduced 
blood glucose levels compared to non-treated animals at GD18.5. B) Area under the 
glucose tolerance curve was significantly lower in acetone vehicle-treated animals vs. 
non-treated LP females at GD18.5. Similar trends were observed in non-pregnant (C, D) 
and PPD7.5 (E, F) animals. n = 4 animals at GD18.5 per treatment group, n = 4-7 animals 
per treatment in non-pregnant and PPD7.5 animals. *** P <0.001, ** P<0.01, * P<0.05, 
non-treated vs. treatment group. ## P<0.01, # P<0.05 non-treated vs. vehicle. 
 
 
194 
5.3.4.  Acetone treatment alters pancreas histology during 
and after pregnancy  
Again, there were no differences in BCM between artesunate and vehicle-treated animals, 
thus data was combined. Beta-cell mass was significantly higher in non-pregnant 
acetone-treated animals compared to non-treated animals (Fig. 5.4A). There were no 
significant differences in ACM (Fig. 5.4B) or mean islet size (Fig. 5.4C) between 
treatment groups over time. Islet sizes did not vary between treatment groups in non-
pregnant (Fig. 5.4D) or GD18.5 (Fig. 5.4E) animals. However, acetone-treated animals at 
PPD7.5 had significantly more medium and large-sized islets compared to non-treated 
animals (Fig. 5.4F). 
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Figure 5.4. Acetone treatment alters BCM in non-pregnant animals but not 
during or after pregnancy  
A) BCM, B) ACM, and C) mean islet size. Islet sizes did not differ in D) non-pregnant 
or E) GD18.5 animals. F) However, there were more medium and large islets at PPD7.5 
in treated animals. n = 4-8 animals per treatment group. * P <0.05, acetone-treated vs. 
non-treated. 
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5.3.5.  Acetone treatment causes hyperglucagonemia 
during and after pregnancy  
Serum insulin and glucagon were quantified from blood collected via cardiac puncture at 
the end of the IPGTT (120 mins). There were no significant differences in serum insulin 
between treatment groups over time (Fig. 5.5A). However, serum glucagon levels were 
significantly higher at GD18.5 and PPD7.5 in acetone-treated animals compared to non-
treated animals (Fig. 5.5B). There were no significant differences in serum insulin to 
glucagon ratio between treatment groups over time (Fig. 5.5C).  
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Figure 5.5. Acetone treatment alters glucagon levels during and after pregnancy  
A) Serum insulin, B) serum glucagon, and C) serum insulin to glucagon ratio. n = 3-8 
animals per treatment group. * P <0.05. acetone-treated vs. non-treated. 
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5.3.6.  Acetone treatment increases bihormonal transitional 
cell number in islets  
To investigate a potential mechanism of new β-cells observed in non-pregnant acetone-
treated animals, we quantified the percentage of Insulin+Glucagon+ (insulin and glucagon 
double-positive, Fig. 5.6A/B) cells as a marker for α- to β-cell transitional cells [13,30–
32]. Acetone-treated non-pregnant animals had significantly more bihormonal cells 
compared to non-treated animals (Fig. 5.6C). However, there were no significant 
differences in the percentage of bihormonal cells between treatment groups at GD18.5 or 
PPD7.5. 
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Figure 5.6. Representative micrographs and quantification of bihormonal cells  
A) Bihormonal (Insulin+Glucagon+) cell of a non-treated non-pregnant animal. B) 
Bihormonal cell of an acetone-treated GD18.5 animal. C) Total percentage of 
bihormonal cells relative to all insulin+ cells. n = 5-8 animals per treatment group. ** P 
<0.01, * P <0.05, acetone-treated vs. non-treated. 
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5.3.7.  Acetone treatment leads to increased expression of 
the placental apelinergic system  
To investigate a potential mechanism of improved glucose tolerance in pregnant acetone-
treated animals, we analyzed the placenta, since placental weight was relatively higher in 
acetone-treated animals and body weight was recovered in acetone-treated animals 
despite reduced weight gain during treatment (Fig. 5.2E). Since the placenta secretes 
apelin, and it is known to alter both β-cell number and function we looked at the 
apeligneric system. Both APJ (Fig. 5.7A) and apela (Fig. 5.7B) mRNA levels were 
significantly higher in acetone-treated animals compared to non-treated animals. 
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Figure 5.7. Acetone treatment increases placental apelinergic system 
Placental mRNA expression of both A) apelin receptor, and B) apela were 
significantly higher in acetone-treated vs non-treated animals at GD18.5. The fold 
change in expression was measured relative to housekeeping gene cyclophilin A. n = 5 
non-treated animals and 4 acetone-treated animals. ** P<0.01, * P<0.05, acetone-treated 
vs. non-treated. 
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5.4  Discussion  
GDM is associated with adverse health consequences for both the mother and her child, 
implicating the need for an effective method of treatment. The initial experiments in this 
study sought to treat mice with gestational glucose intolerance with the artemisinin, 
artesunate via drinking water. Artemisinins have been shown to increase BCM via α- to 
β-cell transdifferentiation and improve glucose homeostasis in non-pregnant animal 
models of diabetes [19], although these findings are controversial and have been rebutted 
by some studies [28,36]. Our experiments revealed a high consumption of artesunate 
within drinking water and no indications of fetal resorptions to implicate embryolethality. 
Nonetheless, the initial objective of testing artesunate was negated as we noted that 
multiple parameters investigated in our study demonstrated similar findings between the 
treatment group (artesunate diluted in the acetone vehicle) and the vehicle (acetone 
alone). This led us to conclude that our findings could be primarily due to the use of the 
acetone vehicle. Thus, we rejected our initial hypothesis and suggest that artesunate had 
no effect on multiple parameters in this study, as compared to the vehicle alone. 
Subsequently, we re-adjusted our focus to determine the effects of acetone on glucose 
homeostasis and pancreas histology. 
Weight gain was lower in acetone-treated animals during treatment, although body 
weight recovered by the end of the experiment. Acetone-treated animals consumed a 
comparable amount of food as non-treated animals, bringing into question whether there 
could have been a transient effect of acetone on nutrient uptake via the villi in the small 
intestine, resulting in reduced weight gain in treated animals. Although we did not collect 
gastrointestinal tissues in our studies, other studies have found that acetone abolished 
adhesion of F18-fimbriated (F18R) E. coli to isolated porcine intestinal villi in vitro, 
concluding F18R was a glycolipid [37]. Since glycosphingolipids (GSL) are a major 
component of intestinal enterocytes, it is possible that acetone could be breaking down 
these villi and preventing nutrient absorption. In an animal model with genetic deletion of 
the gene for the enzyme that catalyzes the initial step of GSL biosynthesis (Ugcg), 
newborn mice presented with growth retardation and loss of body fat deposits, due to a 
severe disturbance in uptake of nutrients [38]. The same study showed that adult mice 
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presented with a drastic decrease in body weight, as was observed in animals in our study 
during treatment with acetone. It was concluded that GSLs in the intestinal epithelium are 
essential for intestinal endocytic function to effectively absorb nutrients. These findings 
could provide an explanation for the reduced weight gain observed in acetone-treated 
animals in our study at a time where food consumption was unchanged. It is worth noting 
that reduced nutrient and glucose uptake for the time period of the treatment in our study 
could mimic a situation of fasting, which has been suggested to have protective effects on 
reducing oxidative stress and protects against many diseases in both rodents and humans 
[39,40]. Intermittent or periodic fasting has also been shown to improve glucose tolerance 
in part via adipose tissue remodeling [41,42], which could explain why glucose tolerance 
was improved in non-pregnant, GD18.5 and PPD7.5 acetone-treated animals in our study. 
Thus, acetone abolition of glycolipids on enterocytes could have affected nutrient 
absorption, mimicking a situation of fasting which led to improved glucose tolerance in 
the treated-mice in our study. It is important to note that the data for untreated controls 
used in this chapter were retrieved from chapter 2 and 3. Thus, we acknowledge the use 
of historical controls as a potential weakness in design which could be strengthened with 
an additional group of untreated animals. 
Next, we sought to investigate a mechanism of improved glucose tolerance in acetone-
treated animals and investigated changes in endocrine pancreas. BCM was higher in non-
pregnant acetone-treated animals but this did not correlate with higher serum insulin 
levels. Serum glucagon levels were higher at the end of the IPGTT at both GD18.5 and 
PPD7.5, despite no differences being observed in ACM. The high glucagon levels at 
GD18.5 likely contributed to hyperglycemia in the acetone-treated animals compared to 
non-treated animals at the end of the IPGTT. In contrast, there were no differences in 
serum insulin levels at GD18.5 and PPD7.5. However, with the half-life of insulin being 
relatively short (~4-6 minutes) in comparison to the time span of the IPGTT and blood 
collection via cardiac puncture (~120 minutes), it is possible that there could have been 
differences in serum insulin levels at earlier timepoints (0, 5, and 15 minutes) when 
insulin secretion is highest (i.e. first phase insulin secretion). Indeed, analysis of the 
IPGTT curves of acetone-treated animals might implicate improved insulin secretion, as 
shown by the blunted blood glucose curve in response to the glucose bolus. Furthermore, 
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the L-cells in the distal ileum and colon secrete glucagon-like peptide 1 (GLP-1), an 
incretin hormone that is released in response to nutrient ingestion. GLP-1 increases 
insulin secretion and inhibits glucagon secretion [43]. Thus, a mechanism for improved 
glucose tolerance could also involve a regenerative response of the enteroendocrine cells 
post acetone treatment, resulting in greater GLP-1 production and improved insulin 
secretion. Therefore, acetone could be resulting in increased insulin secretion, although 
improved insulin sensitivity in peripheral tissues also remains to be explored. 
Interestingly, the finding of hyperglucagonemia at the end of the IPGTT at GD18.5 and 
PPD7.5 was not observed in non-pregnant animals which was likely due to BCM being 
higher and maintaining glucose homeostasis. There is much convincing data that α-cells 
play an essential role in regulating insulin secretion from β-cells [44]. For example, one 
study reported that insulin secretion was higher in response to glucose in paired α- and β-
cells compared to single β-cells alone [45]. Furthermore, it was shown that α-cells were a 
target for serotonin in human islets, whereby β-cell-derived serotonin inhibited glucagon 
secretion in high glucose conditions [46]. Since BCM was higher in non-pregnant 
animals in our study, it is plausible that α-cells received an increased serotonergic input 
from β-cells to regulate glucagon secretion. However, BCM did not increase in acetone-
treated animals at GD18.5 and was lower than BCM levels observed in a healthy 
pregnancy (~2mg). Thus, a potential explanation for the hyperglucagonemia observed at 
GD18.5 could be due to decreased serotonergic input from β-cells, resulting in 
hypersecretion of glucagon. Overall, these findings demonstrate the importance of the 
sophisticated integrative islet communication between pancreatic endocrine cells in order 
to effectively manage glucose homeostasis. 
To investigate a potential mechanism for the generation of new β-cells resulting in an 
increased BCM in non-pregnant acetone-treated animals, we quantified bihormonal 
(insulin and glucagon double-positive) cells as a marker for possible α- to β-cell 
transitional cells. There was an increased percentage of bihormonal cells in non-pregnant 
acetone-treated animals compared with non-treated animals. Since the acetone ingestion 
in our study may mimic a situation of short-term fast, these findings agree with those 
observed following transient fasting where a greater number of transitional α- to β-cells 
were observed upon re-feeding [47]. In these non-pregnant mice, transient fasting 
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resulted in β-cell regeneration and rescue from type 1 and type 2 diabetes [47]. In this 
study, non-pregnant animals were fasted for 4 days followed by up to 10 days of re-
feeding. This is comparable to our study where we postulate that the animals are fasted 
for at most 6 days, dependent on the length of time required for acetone to destroy villi 
and impair nutrient uptake.  
In terms of pregnancy and fasting, clinical studies on the effects of fasting on pregnancy 
outcomes are inconsistent. Some studies suggest that fasting during pregnancy results in 
adverse fetal outcomes [48] and a higher incidence of developing GDM [49], while 
others found no differences in pregnancy and fetal outcomes in fasting women [50–52]. 
A number of these studies also reported lower birth weight or intrauterine growth 
restriction. However, in our study there were no indications of growth restriction in 
acetone-treated animals. Therefore, because of the short duration of the treatment during 
the first week of pregnancy it is plausible that deleterious effects would not be observed. 
Nonetheless, to our knowledge, this has not been investigated in pregnancy in mouse and 
we are the first to show a beneficial effect of a likely pathologically-induced functional 
fasting in early gestation to improved glucose tolerance in mice with GDM at GD18.5 
and glucose intolerance at PPD7.5 without adversely affecting fetal parameters. 
Given that there were no differences in bihormonal cells or BCM in pregnant or lactating 
animals to account for the improved glucose tolerance observed, we investigated if a 
placental-specific mechanism might exist. To investigate a mechanism for improved 
glucose tolerance in acetone-treated animals during and after pregnancy, we analyzed the 
placenta for compensatory mechanisms since placental weight was relatively higher in 
acetone-treated compared to non-treated animals. For example, previous studies have 
shown increased deposition of glycogen in GDM placentas with the placenta acting as a 
buffer for excess glucose and thereby lowering blood glucose levels in the mother [53]. 
Interestingly, the apelinergic system was shown to promote transplacental transport of 
glucose from mother to fetus in rat dams injected intravenously with apelin-13 without 
changes to the expression of placental glucose transporters Glut1 and Glut3 [54]. Rather, 
it was reported that at mid to late gestation, apelinergic signaling increased vasodilation 
of fetal arterioles and glucose transport to the fetus. In the present study, acetone-treated 
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animals expressed increased placental apela and APJ at GD18.5 compared to non-treated 
animals. Therefore, transfer of glucose from mother to fetus in our study could be 
increased by the placental apelinergic system, resulting in improved glucose tolerance in 
the mother. The trend of higher fetal weight in acetone-treated animals further supports 
this hypothesis, as excess glucose is transferred to the fetus and subsequently stored in 
fetal tissues. Apelin has been linked to placental growth and efficiency due to 
observations that fetal apelin levels were reduced in studies with maternal food restriction 
during gestation [54]. In the present study, high levels of apelingeric system in the 
placenta could be responsible for the relatively larger placenta observed in acetone 
compared to non-treated animals. Apelin has also been shown to be involved in the 
regulation of food intake [55] and could explain the hyperphagia seen in acetone-treated 
animals at late gestation (GD17.5). Interestingly, apelin is a beneficial adipokine with 
anti-obesity and diabetic effects [55]. Despite reduced weight gain upon acetone 
treatment, the treated animals in this study recover in body weight. The subsequent 
hyperphagia could result in adipogenesis, and thus it could be insightful to determine 
levels of apelin in adipocytes in future studies to investigate if apelin is also secreted 
from adipocytes and causing an anti-diabetic effect in acetone-treated animals.  
In conclusion, artesunate had no effect on multiple parameters investigated in this study. 
However, acetone treatment improved glucose tolerance in non-pregnant, GD18.5 and 
PPD7.5 LP-treated animals. In non-pregnant animals, improvements in glucose tolerance 
were due to an increased BCM, possibly involving α- to β-cell conversion. However, 
pregnant/lactating animals demonstrated overall improved glucose tolerance likely due to 
compensatory mechanisms in the placenta involving upregulation of placental apelinergic 
system, resulting in vasodilation and increased glucose transfer decreasing maternal 
blood glucose levels, and/or better insulin release dynamics during an IPGTT. Our 
findings provide a potential therapeutic glucose-lowering effect of acetone via mimicking 
a situation of short-term fasting to improve glucose tolerance, including a model of 
gestational glucose intolerance. Potential mechanisms include beneficial changes in 
pancreas histology and placental function. 
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5.5  Supplemental Figures  
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Supplemental Figure 5.1. The effects of artesunate intervention in a DMSO vehicle 
on a GD18.5 LP animal treated GD0.5-6.5  
A) Weight gain was reduced in DMSO vehicle animals compared to non-treated animals. 
B) Food consumption during treatment did not vary between treatment groups. C) 
Treatment solution consumption in artesunate/DMSO was lower compared to non-treated 
animals throughout gestation.  
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Supplemental Figure 5.2. The effects of artesunate intervention on a GD18.5 LP 
animal treated GD8.5-14.5 
A) Weight gain, B) food consumption, and C) artesunate/water consumption in an 
artesunate/acetone-treated dam throughout gestation. 
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6  Summary and Perspectives  
6.1  Summary of Major Findings  
GDM is an increasingly prevalent pathology in pregnancy that is associated with adverse 
maternal and fetal health outcomes, necessitating the need for interventional strategies. 
There is currently no reliable method of prevention for GDM. Thus, we sought to better 
understand the mechanisms of impaired endocrine adaptability in GDM by creating a 
mouse model that can be used to establish novel therapeutics.   
We hypothesized that a dietary LP insult during early development in mice would impair 
β-cell adaptability in pregnant offspring, resulting in glucose intolerance during 
pregnancy, which could be reversed with treatment. Within this thesis, we addressed four 
major objectives: first, we established a novel mouse model for study of suboptimal 
endocrine adaptations during pregnancy. Using this model, we then determined the long-
term effects of GDM following parturition and mechanisms of suboptimal endocrine 
mass expansion. Finally, we used this model and our knowledge of impaired mechanisms 
in GDM from our previous work to propose a therapeutic intervention for GDM through 
the manipulation of BCM. 
 
6.1.1  A mouse model of gestational glucose intolerance 
through exposure to a low protein diet during fetal and 
neonatal development  
To implement targeted therapeutics, a better understanding of suboptimal endocrine 
adaptations in GDM is needed. However, as pancreatic samples from GDM patients are 
scarce, and no safe in vivo imaging modalities for endocrine cells in pregnancy exist at 
the present time, initial experiments involved the development of a novel mouse model of 
gestational glucose intolerance. This was accomplished using a dietary insult (LP diet) 
during fetal and neonatal development, previously shown to program impaired endocrine 
pancreas plasticity in offspring [1–3]. This model produced female offspring with glucose 
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intolerance restricted to GD18.5, as is observed in late pregnancy in human GDM. 
Glucose intolerance was attributed to reduced β-cell proliferation, leading to reduced 
BCM expansion and GSIS at GD18.5 relative to a healthy pregnancy. We also presented 
novel findings of reduced ACM at GD18.5 in glucose-intolerant mice, revealing the 
significance of the often overlooked pancreatic α-cell population to glucose homeostasis 
in GDM. A major strength of these findings was the ability to reproduce glucose 
intolerance in pregnancy that was restricted to late gestation, as other animal models of 
diabetes in pregnancy demonstrate pre-gestational obesity and/or diabetes [4–7], which is 
not comparable to a diagnosis of clinical GDM [8]. 
 
6.1.2  Altered pancreas remodeling following glucose 
intolerance in pregnancy in mice  
GDM increases the risk of T2DM after parturition by up to 90% [9], yet no histological 
data existed comparing endocrine pancreata after healthy and GDM pregnancies. Next, 
we sought to use our animal model of gestational glucose intolerance to determine the 
long-term effects of GDM on glucose tolerance and pancreas histology after pregnancy. 
Analysis of pancreata at PPD7.5 revealed suboptimal pancreatic maladaptations in 
glucose-intolerant mice that persisted from GD18.5, resulting in prolonged glucose 
intolerance until 1 month postpartum. By 3 months postpartum, a compensatory increase 
in the number of small islets and a higher insulin to glucagon ratio likely enable 
euglycemia to be attained in the previously glucose-intolerant mice. Our findings 
demonstrated long-term pancreatic re-modeling after parturition involving both α- and β-
cells, which were potentially associated with changes in the pro-inflammatory 
environment. These findings are important to understanding the mechanisms involved in 
the progression from GDM to T2DM after parturition. 
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6.1.3  The increased alpha and beta cell mass during mouse 
pregnancy is not dependent on transdifferentiation 
It was evident that impaired endocrine adaptations during GDM were one of the key 
determinants of glucose intolerance not only during pregnancy, but also after pregnancy, 
resulting in long-term metabolic impairments. In order to prevent these adverse health 
outcomes through therapeutic interventions, it is essential to target the underlying causes 
of a suboptimal BCM in GDM. To provide some mechanistic insights of reduced BCM in 
GDM, we looked at the contribution of α- to β-cell transdifferentiation to BCM in 
pregnancy, and also α-cell plasticity in healthy vs. glucose-intolerant pregnancies. Alpha-
cell proliferation was maximal at GD9.5 and resulted in increased ACM expansion at 
GD18.5 in control animals, but this was reduced in glucose-intolerant (LP) mice. 
However, LP mice displayed hyperglucagonemia at GD18.5 contributing to glucose 
intolerance at late gestation in GDM. Notably, hyperglucagonemia has also been 
observed in women with GDM which persisted after parturition, contributing to glucose 
intolerance [10]. Although there were trends in bihormonal transitional 
(Insulin+Glucagon+) cells in LP vs. control pregnancy, lineage tracing in control 
pregnancy revealed a negligible amount of α- to β-cell transdifferentiation contributing to 
BCM expansion. These findings further emphasized the importance of other islet cell 
types, other than just β-cells, to glucose homeostasis in pregnancy, a subject area that has 
previously been overlooked. Importantly, the dynamic changes in ACM that occurred 
during normal pregnancy were altered in glucose-intolerant pregnancies, providing an 
additional potential avenue for therapeutics by targeting hyperglucagonemia to reduce 
hyperglycemia in pregnancy. 
 
6.1.4  Strategies to improve glucose intolerance in 
pregnancy  
As the development of an effective intervention for GDM is clinically important, we 
sought to explore the use of artemisinins, which have been shown to increase BCM and 
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improve glucose tolerance in non-pregnant animal models of diabetes [11]. Importantly, 
artemisinins are safe for use in pregnancy as they are used to treat women suffering from 
malaria [12]. Glucose-intolerant animals were treated with the artemisinin, artesunate. 
While an improved glucose tolerance was found in non-pregnant, GD18.5 and PPD7.5 
animals, this was shown to primarily result from the use of the acetone vehicle. In non-
pregnant acetone-treated animals, this was attributed to a higher BCM, possibly involving 
α- to β-cell conversion. BCM did not differ between acetone-treated and non-treated 
animals at GD18.5. Instead, glucose tolerance in pregnant animals was improved possibly 
due to an upregulation of the placental apelingeric system [13], and/or improved insulin 
secretion. Additionally, acetone-treated animals in these studies demonstrated reduced 
weight gain during treatment despite unaltered food consumption. These findings could 
implicate a transient state of fasting, which could additionally be contributing to 
improvements in glucose tolerance through glucose uptake mechanisms in peripheral 
tissues. Thus, transient fasting could be particularly beneficial in preventing glucose 
intolerance during pregnancy. 
Collectively, the data presented throughout this thesis implicate the importance of 
endocrine adaptations to successfully counter relative maternal insulin resistance during 
pregnancy. Although most research has focused on the importance of pancreatic β-cell 
adaptation in pregnancy, we presented many findings revealing the role that pancreatic α-
cells simultaneously play in regulating glucose levels during pregnancy and demonstrated 
how this is altered in GDM. Although a therapeutic potential of artemisinins was not 
demonstrated, a mimicked state of fasting induced by dilute acetone treatment yielded a 
potential therapeutic, glucose-lowering effect.  Nonetheless, further research is needed 
before the mechanisms of impaired endocrine adaptability presented in this thesis, and 
therapeutic effects of acetone in GDM, can be transferred to a clinical setting. 
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6.2  Limitations and Future Directions   
The purpose of this section is to discuss some limitations of the experiments presented 
throughout this thesis and discuss potential future experiments that can strengthen our 
findings.  
6.2.1  Use of animal models to study diabetes in pregnancy 
in humans  
The rationale for establishing an animal model of gestational glucose intolerance was due 
to the very limited access to pregnant human pancreas samples, and samples from GDM 
women would be even more scarce. Although having human samples would be preferred, 
if samples were retrieved it would be highly likely that data from multiple gestational 
timepoints would need to be combined which could lead to inaccurate conclusions if 
time-specific physiological changes occur, as has been observed in mice. As such, studies 
thus far have highly relied on animal models of diabetes in pregnancy. Although mice are 
powerful models that recapitulate many aspects of human pregnancy, they are not 
without limitations. For example, it is difficult to directly demonstrate the multi-factorial 
nature of GDM pathogenesis in an animal (i.e. including both polygenetic and 
environmental factors). Of relevance to the findings in this thesis are the differences in 
the context of endocrine adaptations in humans compared to mice. The most 
controversial studied difference between mouse and human pregnancy is in regard to β-
cell neogenesis and proliferation, as human β-cells are thought to rarely divide [14]. The 
role of β-cell proliferation in human pregnancy is unclear, as the only study investigating 
this phenomenon in humans showed a lack of replication from pre-existing β-cells [15]. 
However, these findings need to be taken with extreme caution, as samples were pooled 
over multiple gestational timepoints potentially diluting an effect of proliferation 
occurring in a timing-specific manner. Further contributing to a potential difference 
regarding β-cell replication as a major driver of BCM expansion in mouse pregnancy is 
the influence of lactogenic hormones to this process. In mice, strong evidence supports 
that β-cell replication is driven by PRLR signaling [16]. However, human studies report 
 
 
221 
conflicting results on the influence of lactogen treatment on mitogenic activity of β-cells 
[17,18] which could be due to lower PRLR expression on human β-cells than in mice 
[19]. Although it is premature to confirm that there are species differences in mechanisms 
of pancreas adaptations in pregnancy based on a reliance of in vitro data, it is important 
to acknowledge that studies support the presence of endocrine mass expansion in human 
pregnancy [15,20]. Furthermore, both mouse and human gestation implicate β-cell 
dysfunction and insulin resistance as a key driver to metabolic dysfunction in human and 
animal models of diabetes in pregnancy [21]. Therefore, these findings provide strong 
rationale for continued research efforts in this field. 
An exciting methodology to deciphering these mechanisms would be non-invasive in 
vivo imaging to monitor BCM in humans. Indeed, many sophisticated studies have 
performed in vivo imaging of endogenous β-cells in humans and small and large animals 
using positron emission tomograph (PET), single photo emission computed tomography 
(SPECT) and magnetic resonance imaging (MRI) [22,23]. Each methodology presents 
with both strengths and limitations in terms of resolution and sensitivity, and specificities 
of radiotracers for β-cells. These studies are also limited by the small size and density of 
β-cells relative to the remainder of the exocrine pancreas, and/or potential uptake of 
tracers in peripheral tissues. Undeniably, important additional considerations in the 
context of pregnancy would involve technical issues as pregnancy progresses and the 
abdomen enlarges, as the pancreas is located deep in the abdomen. Furthermore, the 
requirement for non-toxic contrast agents that are safe for the fetus are of paramount 
importance. Thus, these considerations need to be elucidated in non-pregnant humans 
first, before implementation can be safely suggested to pregnant women. 
In conclusion, it remains to be investigated whether the maladaptations in endocrine 
pancreas presented in this thesis occur in human GDM. As such, additional caution must 
be considered before extrapolating data in mice directly to humans. Further studies would 
need to be performed in a clinical setting to elucidate whether these mechanisms could 
provide new therapeutic opportunities to promote generation of new β-cells. 
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6.2.2  Influence of cytokines to β-cell dysfunction after GDM  
Cytokines released from adipose tissue and from placenta influence metabolism during 
pregnancy, which often becomes dysregulated in GDM. GDM is characterized as an 
inflammatory state [24–26] which can impact successful β-cell adaptation during 
pregnancy. Imbalanced levels of cytokines can contribute to glucose intolerance in GDM 
by contributing to β-cell dysfunction [27,28] and insulin resistance via impaired insulin 
receptor signaling [29,30]. We showed that increased levels of the pro-inflammatory 
cytokine, IL-6, in adipose tissue could have contributed to glucose intolerance after 
parturition in GDM mice (Chapter 3). Since cytokines can act in a paracrine/autocrine 
manner, it would have also been valuable to measure levels of cytokines in the pancreas 
in order to elucidate if there was a local effect on the histomorphometric changes 
observed in fixed pancreas sections. Some preliminary qPCR experiments were 
performed in whole pancreas preparations; however, most values were below the levels 
of detection. Cytokines in serum samples were also quantified, but most samples were 
also below the levels of detection. In order to draw more precise conclusions, future 
experiments could quantify cytokines in isolated islets at postpartum, as levels of 
cytokines could be diluted by exocrine pancreas in whole pancreas samples since the 
endocrine portion only compromises 2% of the pancreas. Importantly, IL-6 has been 
shown to be involved in α-cell growth and function in rat neonates during suckling [31]. 
In the context of the LP model, undernourished rat neonates had impaired glucagon 
production and secretion. However, there could be species differences and these findings 
could differ in adult mice, such as the animals used in the present study. Nonetheless, 
these experiments further reinforce the importance of elucidating the impact cytokines, 
and specifically IL-6, on the endocrine pancreas in LP compared to control-diet exposed 
mice. It is also important to consider that the animal model of gestational glucose 
intolerance presented in this thesis presents with only a mild glucose intolerance. Thus, it 
is also plausible that these animals present with a mild pro-inflammatory state and 
therefore we might not anticipate observing elevated levels of pro-inflammatory 
cytokines in the pancreas implicating a potentially negligible effect on pancreatic 
endocrine cells in our model. Therefore, the low cytokine values in both serum and 
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pancreas samples could simply implicate a low level of inflammation in our model of 
GDM. 
6.2.3  Discovering the contribution of non-β-cell endocrine 
cells in pregnancy  
Despite the significant influence that pancreatic α-cells have on regulating glucose 
homeostasis by working antagonistically with β-cells, very little was known about the 
contribution of these cells in pregnancy. We investigated α-cell plasticity in healthy 
pregnancies and concluded that α- to β-cell transdifferentiation was negligible. However, 
it is important to acknowledge that the amount of β-cell loss can influence the extent of 
α- to β-cell transdifferentiation. Previous studies have reported that with mild β-cell 
ablation, less α-cell reprogramming occurred, and near-total β-cell ablation was required 
to trigger reprogramming [32]. In the case of the healthy animals in our study, there was 
no loss of β-cells, rather an adaptive increase in BCM expansion was observed in 
pregnancy. Therefore, the metabolic stress of pregnancy was likely insufficient to trigger 
reprogramming of α-cells and without the stressor of β-cell loss, α- to β-cell 
transdifferentiation will likely not occur. Nevertheless, it is plausible that in a situation of 
higher metabolic stress in pregnancy, such as in GDM, α- to β-cell transdifferentiation 
could occur. In our animal model of gestational glucose intolerance, we observed a ~50% 
reduction of BCM (Chapter 2). These findings provide rationale for genetic tagging of 
α-cells to provide mechanistic insights into whether α- to β-cell transdifferentiation could 
be occurring as a compensatory mechanism in GDM pregnancies with mild 
hyperglycemia. These studies would involve the combination of our established animal 
model of gestational glucose intolerance via dietary LP insult (Chapter 2) and transgenic 
Gcg-Cre/YFP mice (Chapter 4). Although BCM was reduced in GDM compared to a 
control, β-cell proliferation was also reduced. Thus, α- to β-cell transdifferentiation could 
be occurring at a larger scale in GDM mice than in controls to contribute to the 
suboptimal BCM expansion that was still higher than in a non-pregnant animal.  
At the same time, it is important to consider that our animal model of gestational glucose 
intolerance presented with only a mild glucose intolerance, which might not pose a high 
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enough metabolic stress to trigger conversion of α-cells into β-cells. Pregnancies with an 
additional metabolic stress, such as in obese mothers, are an example of where there 
could be a high enough metabolic stress to trigger transdifferentiation. Although, some of 
these models are limited by the presence of pre-gestational glucose intolerance [7]. An 
additional experiment that could be performed in subsequent studies would involve 
treating LP mice with a mild STZ intervention before mating, to only partially reduce 
BCM. This could theoretically ensure that glucose tolerance is maintained before mating 
and in early pregnancy. Additionally, future examination of subsequent pregnancies using 
our model could also provide an additional metabolic stress to trigger α- to β-cell 
transdifferentiation. GDM recurs in an estimated 30-69% of subsequent pregnancies 
following a pregnancy with GDM [33]. In our animal model of gestational glucose 
intolerance, glucose intolerance persisted until 1 month postpartum and normalized by 3 
months postpartum (Chapter 3). Nonetheless, it is plausible that an additional metabolic 
stress such as a second pregnancy, could pose a large enough metabolic demand on the β-
cells, triggering α- to β-cell transdifferentiation. Our findings provide a strong rationale 
for investigating a subsequent pregnancy, as we identified that α-cell fractional area was 
lower at 3 months postpartum in control diet mice relative to a non-pregnant animal. 
These findings prompt interesting considerations as to whether an adaptive expansion of 
ACM would occur in a subsequent pregnancy, or if perhaps the α-cell reservoir would be 
fully depleted after the first pregnancy. The investigation of subsequent pregnancies 
would be an invaluable area of future study. Bihormonal cells (Insulin+Glucagon+) have 
been identified in human pancreas sections, where it was reported that de-differentiation 
of β-cells into α-cells contributed to loss of BCM in patients with T2DM [34]. These 
findings suggest endocrine plasticity is possible in humans, however further studies are 
required to elucidate this in humans, which is limited with lineage tracing technology. 
As our studies showed the critical contribution of pancreatic α-cells to endocrine 
adaptations in pregnancy, especially in the context of maladaptations of α-cells 
contributing to hyperglycemia in GDM, these findings provide a strong rationale to 
investigate additional endocrine islet cell types. An additional mechanism that could be 
contributing to hyperglucagonemia in GDM and would be worth exploring in future 
studies would be to assess -cell function. Eloquent studies have started to reveal the 
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precise mechanisms of somatostatin secretion from -cells, as was previously discussed 
(Chapter 1) [35–37]. It is postulated that defective somatostatin secretion can occur in 
diabetes [36]. Indeed, a recent study showed that reduced -cell function resulted in 
reduced inhibition of insulin and glucagon secretion, contributing to hyperglucagonemia 
in mice fed a high fat diet [38]. In pregnant mice, a novel contribution for -cells in early 
compensatory adaptations during pregnancy was also suggested [39]. Delta-cells were 
shown to reprogram to a β-cell identity, increasing insulin secretion to counter relative 
insulin resistance in pregnancy, mediated via less somatostatin-mediated inhibition. 
Therefore, it would be interesting to investigate whether this process is altered in GDM 
pregnancies using our animal model of gestational glucose intolerance. Maladaptations in 
-cells in GDM could be possible, contributing to reduced GSIS or hyperglucagonemia, 
however further studies are required to elucidate this. Evidently, continued research 
efforts to elucidate the integrative communication between multiple endocrine islet cell 
types in pregnancy are important, as the pathology of hyperglycemia in GDM could be 
much more complex than initially presumed if multiple endocrine cell types are involved. 
 
6.2.4  Reversing glucose intolerance in pregnancy  
Our findings in animals treated with artesunate/acetone present convincing data that the 
acetone vehicle was responsible for improvements in glucose tolerance. Although we 
posit some mechanistic insights to these improvements (Chapter 5), definitive 
mechanisms underlying the improved glucose tolerance remain elusive. As we postulate 
that acetone could be impairing nutrient intake in intestinal villi, subsequent studies 
examining histology or nutrient uptake of enterocytes would be of value to provide more 
precise conclusions about whether nutrient intake is indeed impaired. If proven to be true, 
these findings would provide strong evidence that a transient fast-mimicking situation 
could be contributing to improved glucose tolerance in our study. Because the IPGTT 
curve is drastically improved in acetone-treated animals, as shown by significantly 
reduced areas under the curve (Chapter 5), it would also be important to collect blood 
samples from animals at earlier timepoints during the IPGTT to assess if there is 
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improved insulin secretion. Finally, should acetone impair nutrient intake in enterocytes, 
it would be essential to follow animals to a longer time post-treatment to ensure long-
term safety of this compound. Assessment of peripheral tissues could also prove 
insightful to assess for potential effects of toxicity. Moreover, long-term effects of 
acetone exposure in utero on parameters of health in the offspring, and even 
transgenerational effects, would be of interest to elucidate the safety of this compound in 
pregnancy. 
 
6.3  Concluding Remarks 
β-cell dysfunction has been described as a major driver of GDM, although based on the 
data presented in this thesis, the importance of α-cells has also come to light. Evidently, 
effective regulation of glucose homeostasis relies on sophisticated communication 
amongst both of these endocrine cell types. As such, effective treatments for GDM 
regulating both hormones could be pertinent. In summary, the work presented in this 
thesis advances our understanding of mechanisms involved in suboptimal endocrine 
adaptability and glucose intolerance in pregnancy (Fig. 6.1). While we were limited by 
the lack of GDM human pancreas samples for experimentation, the development of 
sophisticated endocrine pancreas imaging modalities to provide non-invasive monitoring 
of BCM/ACM in GDM would be essential to validate our findings. For the time being, 
the animal model and mechanisms explored in this thesis could lay the groundwork for 
evaluating new therapeutic opportunities to safely prevent and/or treat glucose 
intolerance in GDM. 
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Figure 6.1. Summary of endocrine adaptations in a healthy pregnancy and 
maladaptations in GDM 
A) Healthy Pregnancy: Alpha and BCM expansion occurred in response to increased 
insulin demand during the insulin resistant state of pregnancy. Endocrine mass expansion 
occurred due to increased replication of both α- and β-cells. Euglycemia was maintained 
during insulin resistance due to increased endocrine mass and increased insulin secretion. 
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There was a negligible contribution of α- to β-cell transdifferentiation to BCM expansion 
during pregnancy.  
 
B) GDM Pregnancy: i). Both reduced α- and β-cell replication contributed to reduced 
ACM and BCM expansion. Insufficient compensatory endocrine adaptations, including 
decreased insulin secretion, led to glucose intolerance at late gestation which persisted 
until 1 month postpartum. Hyperglucagonemia also contributed to glucose intolerance at 
late gestation. The role of α- to β-cell transdifferentiation in GDM pregnancy remains to 
be determined via lineage tracing of α-cells during pregnancy.  
ii). Treatment with acetone improved glucose tolerance at late gestation without 
increasing BCM, although these animals presented with hyperglucagonemia. 
Improvements in glucose tolerance persisted until 1 week postpartum. It remains to be 
determined whether nutrient uptake is reduced in intestinal villi, mimicking a transient 
state of fast, and/or whether insulin secretion is increased. 
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Appendix A 2. Animal Use Protocol Ethics Approval: Transgenics and Artemisinin Study 
 
AUP Number: 2018-027  
PI Name: Arany, Edith   
AUP Title: Control of regeneration in the endocrine pancreas  
Approval Date:  12/01/2018  
 
 Official Notice of Animal Care Committee (ACC) Approval:  
Your new Animal Use Protocol (AUP)  2018-027:1:  entitled " Control of 
regeneration in the endocrine pancreas" 
has been APPROVED by the Animal Care Committee of the University Council 
on Animal Care. This approval, although valid for up to four years, is subject 
to annual Protocol Renewal. 
 
Prior to commencing animal work, please review your AUP with your 
research team to ensure full understanding by everyone listed within this 
AUP. 
 
As per your declaration within this approved AUP, you are obligated to 
ensure that: 
        1) Animals used in this research project will be cared for in alignment 
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                      a) Western's Senate MAPPs 7.12, 7.10, and 7.15 
                       
http://www.uwo.ca/univsec/policies_procedures/research.html  
                       
                       b) University Council on Animal Care Policies and related 
Animal Care Committee procedures 
                      
http://uwo.ca/research/services/animalethics/animal_care_and_use_policies
.htm  
   2) As per UCAC's Animal Use Protocols Policy, 
                     a) this AUP accurately represents intended animal use; 
                      b) external approvals associated with this AUP, including 
permits and scientific/departmental peer approvals, are complete and 
accurate; 
                       c) any divergence from this AUP will not be undertaken until 
the related Protocol Modification is approved by the ACC; and 
                      d) AUP form submissions - Annual Protocol Renewals and Full 
AUP Renewals - will be submitted and attended to within timeframes 
outlined by the ACC. 
                    e) 
http://uwo.ca/research/services/animalethics/animal_use_protocols.html  
                        
        3) As per MAPP 7.10 all individuals listed within this AUP as having any 
hands-on animal contact will 
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a) be made familiar with and have direct access to this AUP; 
                 b) complete all required CCAC mandatory training 
(training@uwo.ca); and 
                   c) be overseen by me to ensure appropriate care and use of 
animals. 
 4) As per MAPP 7.15, 
                      a) Practice will align with approved AUP elements; 
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                   c) UCAC policies and related ACC procedures will be followed, 
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                                        iv) Continuing Care Visits 
     5) As per institutional OH&S policies, all individuals listed within this AUP 
who will be using or potentially exposed to 
   hazardous materials will have completed in advance the appropriate 
institutional OH&S training, facility-level training, and reviewed related 
(M)SDS Sheets, 
    http://www.uwo.ca/hr/learning/required/index.html  
      
Submitted by: Copeman, Laura 
on behalf of the Animal Care Committee 
University Council on Animal Care 
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Dr.Timothy Regnault, 
Animal Care Committee Chair 
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